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Background: Patients with neovascular age-related macular degeneration (nAMD) usually attend regular
reviews, even when the disease is quiescent. Reviews are burdensome to health services, patients
and carers.
Objectives: To compare the proportion of correct lesion classifications made by community-based
optometrists and ophthalmologists from vignettes of patients; to estimate the cost-effectiveness of
community follow-up by optometrists compared with follow-up by ophthalmologists in the Hospital Eye
Service (HES); to ascertain views of patients, their representatives, optometrists, ophthalmologists and
clinical commissioners on the proposed shared care model.
Design: Community-based optometrists and ophthalmologists in the HES classified lesions from vignettes
comprising clinical information, colour fundus photographs and optical coherence tomography images.
Participants’ classifications were validated against experts’ classifications (reference standard).
Setting: Internet-based application.
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Participants: Ophthalmologists had to have ≥ 3 years post-registration experience in ophthalmology,
have passed part 1 of the Royal College of Ophthalmologists, Diploma in Ophthalmology or equivalent
examination, and have experience in the age-related macular degeneration service. Optometrists had to be
fully qualified, be registered with the General Optical Council for ≥ 3 years and not be participating in
nAMD shared care.
Interventions: The trial sought to emulate a conventional trial in comparing optometrists’ and
ophthalmologists’ decision-making, but vignettes, not patients, were assessed; therefore, there were no
interventions. Participants received training prior to assessing vignettes.
Main outcome measures: Primary outcome – correct classification of the activity status of a lesion based
on a vignette, compared with a reference standard. Secondary outcomes – frequencies of potentially
sight-threatening errors, participants’ judgements about specific lesion components, participant-rated
confidence in their decisions and cost-effectiveness of follow-up by community-based optometrists
compared with HES ophthalmologists.
Results: In total, 155 participants registered for the trial; 96 (48 in each professional group) completed
training and main assessments and formed the analysis population. Optometrists and ophthalmologists
achieved 1702 out of 2016 (84.4%) and 1722 out of 2016 (85.4%) correct classifications, respectively
[odds ratio (OR) 0.91, 95% confidence interval (CI) 0.66 to 1.25; p = 0.543]. Optometrists’ decision-
making was non-inferior to ophthalmologists’ with respect to the pre-specified limit of 10% absolute
difference (0.298 on the odds scale). Frequencies of sight-threatening errors were similar for optometrists
and ophthalmologists [57/994 (5.7%) vs. 62/994 (6.2%), OR 0.93, 95% CI 0.55 to 1.57; p = 0.789].
Ophthalmologists assessed lesion components as present less often than optometrists and were more
confident about their lesion classifications than optometrists. The mean care-pathway cost for assessment
was very similar by group, namely £397.33 for ophthalmologists and £410.78 for optometrists. The
optometrist-led monitoring reviews were slightly more costly and less effective than ophthalmologist-led
reviews, although the differences were extremely small. There was consensus that optometrist-led
monitoring has the potential to reduce clinical workload and be more patient-centred. However, potential
barriers are ophthalmologists’ perceptions of optometrists’ competence, the need for clinical training, the
ability of the professions to work collaboratively and the financial feasibility of shared care for Clinical
Commissioning Groups.
Conclusions: The ability of optometrists to make nAMD retreatment decisions from vignettes is
non-inferior to that of ophthalmologists. Various barriers to implementing shared cared for nAMD
were identified.
Future work recommendations: The Effectiveness, cost-effectiveness and acceptability of Community
versus Hospital Eye Service follow-up for patients with neovascular age-related macular degeneration with
quiescent disease (ECHoES) study web application was robust and could be used for future training or
research. The benefit of reducing HES workload was not considered in the economic evaluation.
A framework of programme budgeting and marginal analysis could explicitly explore the resource
implications of shifting resources within a given health service area, as the benefit of reducing HES
workload was not considered in the economic evaluation. Future qualitative research could investigate
professional differences of opinion that were identified in multidisciplinary focus groups.
Trial registration: Current Controlled Trials ISRCTN07479761.
Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology
Assessment programme and will be published in full in Health Technology Assessment; Vol. 20, No. 80.
See the NIHR Journals Library website for further project information.
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Plain English summary
Wet age-related macular degeneration (AMD) is common and causes severe sight loss and blindness.Active disease is treated monthly until it becomes inactive; patients are then monitored regularly in
hospital in case the disease reactivates, at which point further treatment is needed. Monitoring is
burdensome to patients, their carers and the NHS. This study investigated whether or not community-based
optometrists, after appropriate training, can make decisions about disease reactivation as accurately as
hospital-based ophthalmologists. We also investigated whether or not monitoring by community-based
optometrists would provide value for money for the NHS.
Profiles were created summarising anonymous information about patients with wet AMD twice during
their treatment: once when the disease was inactive and subsequently when the disease was inactive
or active. Profiles comprised the pictures of the eye used by doctors to make retreatment decisions and
age, gender and other summary patient details. A total of 155 ophthalmologists and optometrists
volunteered. Forty-eight of each profession completed training and studied 42 profiles. By comparing the
two pictures taken, the professionals decided whether or not the disease had reactivated. Optometrists
and ophthalmologists made correct decisions for 84.4% and 85.4% of profiles, respectively. Optometrists were
more cautious than ophthalmologists, correctly identifying more reactivated profiles, but also incorrectly
classifying more inactive profiles as reactivated. Average costs for monitoring were very similar: £397.33 and
£410.78 for ophthalmologists and optometrists, respectively.
We concluded that, with adequate training, optometrists’ retreatment decisions are as good as those of
ophthalmologists. Monitoring by community-based optometrists is likely to be more patient-centred
and reduce NHS workload but may be challenging to implement.
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Scientific summary
Introduction
Neovascular age-related macular degeneration (nAMD) causes severe sight loss and blindness. Anti-vascular
endothelial growth factor (VEGF) drugs (drugs that inhibit VEGF) are used to treat nAMD until the lesion
becomes quiescent; patients are subsequently monitored for lesion reactivation at regular (usually monthly)
Hospital Eye Service (HES) appointments. Regular review, often without treatment, uses clinic space and
other resources and is burdensome to patients and carers. If community-based optometrists were able
to monitor lesion reactivation with similar accuracy to ophthalmologists in the HES, there would be a strong
case for devolving monitoring of patients with quiescent disease to community optometrists. Community
optometrists have the necessary training to recognise nAMD but would need training to acquire and
interpret optical coherence tomography (OCT) images to decide whether or not lesions have reactivated.
Advantages of devolving monitoring to community optometrists could include having clinic capacity freed
up for the overstretched NHS and less travel time for patients.
Objectives
The study had five objectives:
1. to compare the proportion of ophthalmologists’ and optometrists’ lesion classifications scored as
‘correct’ with the reference standard
2. to estimate the agreement, and nature of disagreements, between lesion classifications and between
lesion components identified by optometrists and ophthalmologists
3. to estimate the influence of vignette clinical and demographic information on lesion classifications
4. to estimate the cost-effectiveness of monitoring of patients with quiescent lesions in the community by
optometrists compared with ophthalmologists in the HES
5. to ascertain the views of patients, their representatives, optometrists, ophthalmologists and clinical
commissioners on the proposed shared care model.
Methods
Study design
Vignettes were created which summarised information about participants in a previous study with eyes
affected by nAMD. Vignettes described eyes twice in the course of treatment: once when the disease was
inactive (baseline) and subsequently (index) when the disease was inactive or active. Vignettes included
patients’ demographic details, a summary of their nAMD history, clinical information, colour fundus and
OCT images. Ophthalmologists in the HES and optometrists in the community classified index lesions as
‘reactivated’, ‘suspicious’ or ‘quiescent’. Their classifications were scored as correct or not against a
reference standard. A total of 288 vignettes were created; each participant assessed 42 vignettes, each
vignette being assessed seven times within each professional group in a randomised balanced incomplete
block design. Participants had to attend two webinar training sessions (each lasting approximately 1 hour)
and correctly classify the lesion status of at least 75% of 24 training vignettes before they could enter the
main phase of the trial.
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Settings and participants
We recruited ophthalmologists and optometrists working in the UK through information circulated to
members of the UK and Welsh medical retina groups and through optometry journals and forums.
Ophthalmologists had to have 3 years’ post-registration experience in ophthalmology, have passed part 1
of the Royal College of Ophthalmologists examination or hold the Diploma in Ophthalmology or
equivalent and have experience within the age-related macular degeneration (AMD) service. Optometrists
had to be fully qualified, be registered with the General Optical Council for ≥ 3 years, and not be
participating in any AMD shared care scheme.
Interventions
The trial sought to emulate a conventional trial, comparing optometrists’ and ophthalmologists’
decision-making, except that vignettes, not patients, were assessed; therefore, there were no interventions.
Participants received training before assessing vignettes.
Reference standard
Three medical retina experts independently assessed all 288 vignettes, scoring lesion components and
classifying the activity status of the index images in the same way as participants. Rules for classifying a
lesion as reactivated or quiescent from the assessment of lesion components were pre-specified. The
experts collectively reviewed the subset of vignettes for which their classifications disagreed and reached
consensus. This consensus classification (‘reactivated’, ‘suspicious’ or ‘quiescent’ lesion) formed the
reference standard for determining which of the participants’ lesion classifications were ‘correct.’
Outcomes
The primary outcome was correct classification of the lesion status in a vignette by a participant, based on
assessing the index images in a vignette, compared with the reference standard. Activity status could be
classified as ‘reactivated’, ‘suspicious’ or ‘quiescent’. A lesion classification was scored as ‘correct’ if both
participant and reference standard lesion classifications were ‘reactivated’ or if both participant and
reference standard lesion classifications were ‘suspicious’/’quiescent’ (i.e. suspicious and quiescent
classifications were grouped, making the primary outcome binary).
Secondary outcomes were the frequency of potentially sight-threatening errors (if the reference standard
was ‘reactivated’ and participant classification was ‘quiescent’); participants’ judgements about the
presence or absence, and increase from baseline, of lesion components [subretinal fluid (SRF), intraretinal
cysts (IRCs), diffuse retinal thickening (DRT), pigment epithelial detachment (PED), blood and exudates];
participant-rated confidence in their decisions about the primary outcome on a five-point scale; and
cost-effectiveness of monitoring patients with quiescent lesions by optometrists in the community
compared with ophthalmologists in the HES.
Sample size
A sample of 288 vignettes was chosen to have at least 90% power to test the hypothesis that the
proportion of lesions correctly classified by the optometrist group was no more than 10% lower than the
proportion correctly classified by the ophthalmologist group, assuming that the proportion of lesions
correctly classified by the ophthalmologist group was at least 95%. The trial, in fact, had 90% power to
detect non-inferiority for lower proportions of vignettes correctly classified by the ophthalmologist group,
since each vignette was assessed seven times by each group.
Statistical analyses
All primary and secondary outcomes were analysed using mixed-effects regression models, adjusting for
the order in which vignettes were viewed as a fixed effect (tertiles: 1–14, 15–28, 29–42) and, for
participant and vignette, as random effects. All outcomes were binary and analysed using logistic
regression with group estimates presented as odds ratios (ORs) with 95% confidence intervals (CIs).
Hypotheses were tested with likelihood ratio tests; two-tailed p-values < 0.05 were considered to be
statistically significant.
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Economic evaluation
A within-trial cost-effectiveness analysis compared optometrist-led with ophthalmologist-led reviews of the
need for retreatment for patients with quiescent nAMD from the perspective of the UK NHS, Personal
Social Services and private practice optometrists. The main outcome measure was a cost per ‘correct’ lesion
classification. Costs of reviews by optometrists were collected using a bespoke resource-use questionnaire
developed for trial participants; costs for ophthalmologists were taken from those calculated in the IVAN
trial (a randomised controlled trial to assess the effectiveness and cost-effectiveness of alternative
treatments to Inhibit VEGF in Age-related choroidal Neovascularisation). Decision trees were used to model
alternative cost care pathways based on the optometrists’ and ophthalmologists’ lesion classifications for
the trial vignettes. The optometrists were considered cost-effective if the incremental cost-effectiveness
ratio fell below £20,000.
Qualitative research
Focus groups and interviews were conducted with HES users, eye specialists and other health professionals
involved in caring for patients with eye conditions in the UK to explore their views on shared care for
nAMD. Participants were recruited through various sources using maximum variation sampling. Discussions
were audio-recorded, transcribed verbatim and analysed thematically until the point of data saturation.
Results
Trial cohort
Between 1 June 2013 and 6 March 2014, 155 participants registered their interest and, of these,
62 ophthalmologists and 67 optometrists consented to take part. Participants could withdraw or be
withdrawn throughout the trial for various reasons: not completing webinar training; not attaining the
required performance level in their training vignettes; no longer wanting to take part; no longer being
required to reach the target sample size. Ninety-six participants, 48 from each profession, completed the
main trial assessments and formed the analysis population.
Reference standard classifications
The reference standard classified 142 (49.3%) of the 288 vignettes as reactivated, five (1.7%) as suspicious
and 141 (49.0%) as quiescent.
Participant characteristics
The average age and proportion of women among optometrists and ophthalmologists were similar {mean
age 43.1 years [standard deviation (SD) 10.1 years] and 42.2 years (SD 8.0 years), respectively (50.0% vs.
43.8%)}. Optometrists had, on average, more years of qualified experience than ophthalmologists {median
17.4 years [interquartile range (IQR) 10.1–28.4 years] and 11.4 years (IQR 4.8–16.9 years), respectively}.
Primary outcome
Ophthalmologists and optometrists correctly classified 1722 out of 2016 (85.4%) and 1702 out of 2016
(84.4%) of vignettes. The difference was not statistically significant (OR 0.91, 95% CI 0.66 to 1.25;
p = 0.543) and showed optometrists to be non-inferior to ophthalmologists with respect to lesion
classification according to the pre-specified limit of 10% absolute difference (0.298 on the odds scale).
Secondary outcomes
Serious sight-threatening errors (which could occur only for the vignettes classified as ‘reactivated’ by the
reference standard) occurred in 62 out of 994 (6.2%) of ophthalmologists’ classifications and 57 out of
994 (5.7%) of optometrists’ classifications. This difference was not statistically significant (OR, 0.93, 95%
CI 0.55 to 1.57; p = 0.789). Ophthalmologists judged lesion components to be present less often than
optometrists for all components except PED; the differences between groups were statistically significant
for SRF (25.5% vs. 31.1%, OR 1.73, 95% CI 1.21 to 2.48), DRT (23.9% vs. 41.0%, OR 3.46, 95% CI 2.09
to 5.71), blood (7.4% vs. 9.6%, OR 1.56, 95% CI 1.00 to 2.44) and exudates (7.5% vs. 18.8%, OR 3.10,
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95% CI 1.58 to 6.08), but not for IRC (39.6% vs. 40.1%, OR 1.00, 95% CI 0.61 to 1.65) or PED
(41.9% vs. 41.8%, OR 0.91, 95% CI 0.47 to 1.79). Ophthalmologists were significantly more likely
to be ‘very confident’ about their lesion classifications than optometrists (58.3% vs. 28.5%, OR 0.15,
95% CI 0.07 to 0.32).
Economic evaluation
The mean cost for an optometrist-led monitoring review in the community was £51.82 per review,
compared with £75.60 for an ophthalmologist-led review in hospital. However, once information on
retreatment decisions was considered (e.g. follow-up consultations and anti-VEGF injections), the average
cost per care pathway was very similar between the two professional groups. The cost for optometrist-led
monitoring was £410.78 compared with £397.33 for ophthalmologist-led monitoring (difference
of £13.45).
Acceptability of the shared care model to patients and health professionals
Findings from the focus groups and interviews found consensus that optometrist-led monitoring of
patients with quiescent nAMD in the community has the potential to reduce clinical workload and could
represent a more patient-centred option for patients. However, potential barriers were identified which
could limit the feasibility of a shared care scheme, including ophthalmologists’ perceptions of optometrists’
competence, the need for clinical training, whether or not optometry and ophthalmology could work
more collaboratively and whether or not shared care was a financially efficient option for clinical
commissioning groups.
Discussion
Main findings: study conduct
The virtual trial design required each participant to assess a specific set of vignettes, which made
recruitment and conduct of the trial challenging in a short time frame. Fewer suitable images were
available to create vignettes than anticipated, requiring changes to the methods. Some images used to
create vignettes were suboptimal and paired viewing of baseline and index images was not possible. The
reference standard was not available to assess performance after training but this did not disadvantage
any participant.
Main findings: study results
Optometrists were non-inferior to ophthalmologists with respect to the overall proportion of lesions
correctly classified, but they made different kinds of error. Compared with ophthalmologists, they were
less likely to classify a reactivated lesion as quiescent or suspicious and more likely to classify a quiescent or
suspicious lesion as reactivated. These findings suggested optometrists adopted a more cautious decision
criterion. Such caution may be desirable, although it limits the potential for community monitoring to
reduce the HES workload and be cost-effective. No harms could arise in the trial because decisions were
being made on the basis of vignettes.
The economic evaluation showed that monitoring by optometrists had slightly higher costs and resulted in
slightly fewer correct retreatment decisions compared with ophthalmologists. However, the differences
were very small (an incremental cost of £13 per consultation and one additional incorrect decision per
101 reviews conducted).
Focus group participants and interviewees agreed that monitoring by community-based optometrists may
reduce HES workload and could represent a more patient-centred option for patients. However, potential
barriers to implementation include ophthalmologists’ perceptions of optometrists’ competence and the
need for training and for optometrists and ophthalmologists to work more collaboratively.
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Strengths and limitations
The Effectiveness, cost-effectiveness and acceptability of Community versus Hospital Eye Service follow-up
for patients with neovascular age-related macular degeneration with quiescent disease (ECHoES) study was
done rapidly at low cost and was feasible when a conventional trial may not have been. The virtual nature
of the trial and the adequacy of training are important potential limitations. However, ‘two-stop clinics’
in the HES are common and often depend on ‘virtual’ lesion assessment in the absence of the patient;
the trial results suggest training was satisfactory. The absence of an existing shared care pathway required
optometrists to identify hypothetical resources and costs. It also contributed to uncertainty about the
cost-effectiveness estimates, highlighted by a sensitivity analysis which excluded rereview in the HES of a
patient rapidly referred by an optometrist.
Lessons for the future (if applicable)
We applied methods planned at the time of trial conception with few modifications and recommend
further trials of this nature to address research questions when appropriate data repositories are available.
The study required participating optometrists and service users interviewed about the proposed shared
model to consider a hypothetical scenario. This is not intrinsic to a virtual trial but is a probable feature, as
the design has most to offer when a particular service is not yet established. This constraint imposes some
limitations and uncertainties. Conversely, the qualitative research highlighted the importance of exploring
views of relevant stakeholders alongside a virtual trial; key concerns were identified that would need to be
addressed in formulating a concrete shared care model.
Conclusion
Optometrists were as good as ophthalmologists at classifying the activity status of a lesion in vignettes,
but made different types of error. Optometrists adopted a more cautious decision criterion, making them
less likely to misclassify reactivated lesions, which is potentially a desirable attribute. The economic
evaluation showed small differences in the costs and effects of monitoring by optometrists and
ophthalmologists for patients with quiescent nAMD. Patients and professionals were enthusiastic about
the possibilities of a shared care model for nAMD but had concerns about implementation.
Future research
The ECHoES study web application was robust and could be used for future training or research.
Improvements in technology, and increasing expertise of OCT technicians in capturing OCT images, may
make the vignettes based on the IVAN trial image repository irrelevant. Creating new vignettes based on
up-to-date images for patients managed in the HES would be easy to do but would require investment.
The web application could be modified to allow automatic image importation from imaging equipment
and viewing by multiple users across a local area network. Wider integration with the HES could allow for
telemedicine-style shared care, including interaction with HES ophthalmologists in scheduled virtual clinics,
providing training and potentially improving trust between professions.
The benefit of reducing HES workload was not considered in the economic evaluation. A framework of
programme budgeting and marginal analysis could explicitly explore the resource implications of shifting
resources within a given health service area.
Future qualitative research could investigate professional differences of opinion that were identified in
multidisciplinary focus groups.
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Chapter 1 Introduction
Background
Wet, or neovascular, age-related macular degeneration (nAMD) is a common condition which can cause
severe sight loss and blindness. It occurs as a result of a pathological process in which new blood vessels
arising from the choroid breach the normal tissue barriers and come to lie within the subpigment epithelial
and subretinal spaces. These new blood vessels leak fluid and, because they are fragile, they can bleed
easily. The collection of fluid or blood between the tissue layers and within the neural retina is incompatible
with normal eyesight. Other variants of nAMD which are usually treated as nAMD include (1) an abnormal
vascular complex arising de novo from the retinal circulation, known as retinal angiomatous proliferation,
and (2) intrachoroidal aneurysmal dilatation(s) of the vasculature, known as polypoidal choroidopathy.
Currently, patients with nAMD (or nAMD variants) are treated with intravitreal injections of anti-vascular
endothelial growth factor (VEGF) drugs1 (drugs that inhibit VEGF). The most commonly used drugs are
ranibizumab (Lucentis®, Novartis Pharmaceuticals UK), bevacizumab (Avastin®, Roche Products Limited) and
aflibercept (Eylea®, Bayer). Ranibizumab prevents sight loss in over 90% of eyes with nAMD when given as
monthly intravitreal injections for up to 2 years.2,3 Bevacizumab (unlicensed for nAMD) and aflibercept are
non-inferior to ranibizumab in maintaining visual acuity after 1 year of treatment,4–6 and bevacizumab is
also non-inferior to ranibizumab after 2 years of treatment.7–9
Anti-VEGF drugs render the nAMD lesion quiescent by making the leaky vessels competent. However,
adequate concentrations of the drug need to be present in order to maintain the neovascular complexes in
a quiescent non-leaky state and to ameliorate the exudative manifestations. Once the macula has been
rendered fluid free, cessation of treatment is the norm and patients are monitored for relapse at regular
clinic visits, which are usually monthly. Monitoring involves visual acuity checks, clinical examination and
optical coherence tomography (OCT), with treatment being restarted if required. There is now evidence that
intensive regular monthly review to detect recurrence, restarting treatment when necessary, can result in
functional outcomes similar to those observed in industry-sponsored trials of ranibizumab in which patients
received monthly treatment over 2 years.1,3,8 However, regular monthly review in the Hospital Eye Services
(HESs), even without treatment, blocks clinic space, uses valuable resources, is expensive and is also
burdensome to the patients and their carers. Ophthalmologists have also investigated giving ‘prophylactic’
treatment to quiescent eyes, extending the interval between clinic visits providing the disease remains
quiescent, in order to lessen the burden of regular visits to patients and to the NHS. A disadvantage of this
method of treatment is that it can lead to unnecessary overtreatment.
Existing evidence
There is currently no evidence about the effectiveness of community follow-up by optometrists for nAMD.
On the other hand, there is evidence about the effectiveness of optometrists providing ‘shared care’ with
the HESs for glaucoma and diabetic eye disease and the training programmes that have been used to
achieve them. Evaluations comparing management by optometrists and ophthalmologists have shown
acceptable levels of agreement between the decisions made in the context of glaucoma and accident and
emergency services.10,11 Thus, there are existing models of shared care management which are well
established through formal evaluation. A recent review has outlined different approaches used to increase
the capacity in nAMD services across the UK.12 The case studies in this review show a variety of scenarios,
with many involving extended roles for optometrists and nurse practitioners, but these occur within the HES.
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Some studies have also evaluated the potential of remote care, but these approaches involve assessments
by an ophthalmologist specialising in medical retina working in the HES of OCTs captured by
outreach services.13,14
Taking and interpreting retinal images are skills that can be easily taught (the former is usually carried
out by technicians in the HES) and, therefore, the final evaluation in a telemedicine scenario need not
always involve an ophthalmologist. Many of the hospital-based scenarios involve specialist optometrists
and nurse practitioners making clinical decisions, although the effectiveness of these management
pathways has not yet been formally evaluated. The transfer of the care of patients who are not receiving
active treatment for nAMD requires the ability to interpret signs in the fundus of the eye (through either
clinical examination or fundus photography) combined with an examination of OCT images of the macula,
as well as the facility for patients to be returned seamlessly and expediently to the HESs when there
is reactivation of disease. Optometrists represent a highly skilled and motivated workforce in the UK and
the vast majority of optometric practitioners are based in the community. A number of UK community
optometric practices have already invested in the technology for performing digital fundus photography
and OCT and use these technologies to make decisions about diagnosis and the need to refer a patient to
the HES. However, the skill and ability of optometrists to differentiate quiescent nAMD from active nAMD
have not been evaluated. In addition, to the best of our knowledge, no shared care management scheme
for nAMD has been formally evaluated.
Relevance to the NHS/health policy
Even when nAMD has been successfully controlled by treatment with an anti-VEGF drug, clinicians
continue to review patients regularly because there is a very high risk of relapse, evidenced by the
proportion of patients who remain in follow-up for many years after initiation of therapy.15 One of two
strategies is typically used: (1) monthly review until active disease recurs, termed the ‘pro re nata regimen’,
or (2) the ‘treat and extend regimen’. The latter method requires that treatment is administered even if
there is no fluid at the macula, but the subsequent review interval is extended by approximately 2 weeks.
The pro re nata regimen is very burdensome for patients and for the NHS, and the treat and extend
regimen leads to overtreatment, with its attendant risks and additional expense.
If monitoring of the need for retreatment by community optometrists could be shown to have similar
accuracy to the monitoring of the need for retreatment by ophthalmologists in the HES, there would be a
strong impetus to devolve monitoring of patients whose disease is quiescent to the community setting.
Community optometrists have the necessary training to recognise nAMD (they are responsible for the
majority of referrals to the HES) but would need to be trained to acquire OCT images and to interpret
them in order to assess the need for retreatment. If optometrists can be trained to perform these tasks and
make the correct clinical decision, they could manage patients with quiescent disease effectively in the
community until reactivation occurs, at which point rapid referral to the HES could be initiated.
The advantages of devolving monitoring to community optometrists include having clinic capacity freed up
for the overstretched NHS and less travel time for patients.
Aims and objectives
The aim of the ECHoES (Effectiveness, cost-effectiveness and acceptability of Community versus Hospital
Eye Service for follow-up) trial was to test the hypothesis that, compared with conventional HES follow-up,
community follow-up by optometrists (after appropriate training) is not inferior for patients with nAMD
with stable vision.
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This hypothesis was tested by comparing decisions made by samples of ophthalmologists working in the
HES and optometrists working in the community about the need for retreatment using clinical vignettes
and images generated in the IVAN (a randomised controlled trial to assess the effectiveness and
cost-effectiveness of alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation)
clinical trial [Health Technology Assessment (HTA) programme reference: 07/36/01; International Standard
Randomised Controlled Trial Number (ISRCTN) 921665609]. Retreatment decisions made by participants in
both groups were validated against a reference standard (see Chapter 2, Reference standard).
The trial had five specific objectives:
1. to compare the proportion of retreatment decisions classified as ‘correct’ (against the reference
standard, ‘active’ vs. ‘suspicious’ or ‘inactive lesion’) made by optometrists and ophthalmologists
2. to estimate the agreement, and nature of disagreements, between retreatment decisions made by
optometrists and ophthalmologists
3. to estimate the influence of vignette clinical and demographic information on retreatment decisions
4. to estimate the cost-effectiveness of follow-up in the community by optometrists compared with
follow-up by ophthalmologists in the HES
5. to ascertain the views of patient representatives, optometrists, ophthalmologists and clinical
commissioners on the proposed shared care model.
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Chapter 2 Methods
The results of the cost-effectiveness analysis have been published open access in BMJ Open.16
Study design
The ECHoES study is a non-inferiority trial designed to emulate a parallel-group design (Table 1). However,
as all vignettes were reviewed by both optometrists and ophthalmologists in a randomised, balanced,
incomplete block design,17,18 the ECHoES trial is more analogous to a crossover trial than to a parallel-group
trial. This trial is registered as ISRCTN07479761.
The trial aimed to quantify and compare the diagnostic accuracy of ophthalmologists and optometrists in
assessing reactivation of quiescent nAMD lesions, compared with the reference standard (see Reference
standard). This type of design was possible only with limited permutations of the total number of vignettes,
participants and number of vignettes per participant. For the ECHoES trial, a total of 288 vignettes were created.
Forty-eight ophthalmologists and 48 optometrists each assessed a sample of 42 vignettes. Each vignette was
assessed by seven ophthalmologists and seven optometrists. Each sample of 42 vignettes was assessed in the
same order by one optometrist and one ophthalmologist, both selected randomly from their cohorts.
Vignettes
A database of vignettes was created for the ECHoES trial using images collected in the IVAN trial
(HTA reference: 07/36/01; ISRCTN 921665609), which included a large repository of fundus images and
OCT images from eyes with varying levels of lesion activity. In the IVAN trial, OCT and fundus images were
captured from 610 participants every 3 months for up to 2 years, generating a repository of almost 5000
sets of images, with associated clinical data. However, only a subset (estimated to be about 25% of all of
the available OCT images) was captured using the newer-generation Fourier domain technology (now the
TABLE 1 Research question components tested in the ECHoES trial compared with the hypothetical parallel-group
trial that it aimed to emulate
Research question
component ECHoES (crossover) trial Conventional (parallel-group) trial
Population Vignettes representing the clinical features of
patients with quiescent nAMD being monitored
for reactivation of disease
Patients with quiescent nAMD being
monitored for nAMD reactivation
Intervention Assessment of vignettes by a traineda
optometrist to identify nAMD reactivation
Monthly review by a community optometrist,
after training,b to detect nAMD reactivation
Comparator Assessment of vignettes by a traineda
ophthalmologist to identify nAMD reactivation
Monthly review by an ophthalmologist in the
HESb to detect nAMD reactivation
Outcome Correct identification of reactivated nAMD
(presumed to lead to appropriate treatment to
preserve visual acuity)
Visual acuity
a In the ECHoES trial, both professional groups were required to undergo identical training.
b In the parallel-group trial, optometrists would be required to undergo training (not defined here, but which could be
similar to the training provided in the ECHoES trial). In a pragmatic design, ophthalmologists in the HES might be
assumed to be adequately trained already, since both trials would recruit from ophthalmologists who already make such
decisions in the HES.
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5
clinical standard), which provides optimal images of the posterior ocular findings. The vignettes in the
ECHoES trial were populated only with OCT images captured on spectral/Fourier domain systems.
Each vignette consisted of sets of retinal images (colour and OCT) at two time points (baseline and index),
with accompanying clinical information (gender, age, smoking status and cardiac history) and best
corrected visual acuity (BCVA) measurements obtained at both time points. The ‘baseline’ set were images
from a study visit when the nAMD was deemed quiescent (i.e. all macular tissue compartments were
fluid free) and the ‘index’ set consisted of images from another study visit. Considering both baseline
and index images, and taking into account the available clinical and BCVA information, participants
reviewed these vignettes and made classification decisions about whether the index lesion was believed to
be reactivated, suspicious or quiescent. Further details are published elsewhere.19 A reference standard
lesion classification was assigned to each vignette on the basis of independent assessment by three retinal
experts (see Reference standard).
Participants
Recruitment
The ECHoES trial was publicised in optometry journals and forums to attract optometrists, and circulated to
ophthalmologists who were members of the UK and Welsh medical retinal groups. Potential participants
were directed to the ECHoES trial website, where they could read the information sheet and register their
interest in the trial.
Eligibility criteria
Participants had to meet the following inclusion/exclusion criteria.
Ophthalmologists:
l have 3 years’ post-registration experience in ophthalmology
l have passed part 1 of the Royal College of Ophthalmologists examination or hold the Diploma in
Ophthalmology or equivalent qualification
l working in the NHS at the time of participation in the ECHoES trial
l have experience within an age-related macular degeneration (AMD) service.
Optometrists:
l be fully qualified and registered with the General Optical Council for at least 3 years
l be practising within the General Optical Service at the time of participation in the ECHoES trial
l must not be working within AMD shared care schemes or undertaking OCT interpretation within AMD
care pathways.
There were also some practical circumstances in which a potential participant was not accepted to assess
the main study vignette set:
l unable to attend any of the webinar training sessions
l unable to achieve an adequate standard (75%) with respect to the assessment of lesion activity status
(i.e. reactivated, suspicious or quiescent) on the training set of vignettes.
Training participants
Both ophthalmologists and optometrists are qualified to detect retinal pathology, but optometrists (and
some ophthalmologists) may not have the skills to assess fundus and OCT images for reactivation of
nAMD. Therefore, the training was designed to provide the key information necessary to perform this task
METHODS
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successfully, so that all participants had a similar level of background knowledge when starting their main
trial vignette assessments. The training included two parts.
Webinar lectures
All participants were required to attend two mandatory webinar lectures. The first webinar covered the
objectives of the EcHoES trial, its design, eligibility criteria for participation, outcomes of interest, and the
background to detection and management of nAMD. The second webinar covered the detailed clinical
features of active and inactive nAMD, the imaging modalities used to determine activity of the lesion
and interpretation of the images. Each webinar lecture lasted approximately 1 hour, with an additional
15 minutes for questions.
Test of competence
After confirmation of attendance at the webinars, participants were allocated 24 training vignettes. In
order to qualify for the main trial, participants had to assign the ‘correct’ activity status to at least 75%
(18 of 24) of their allocated training vignettes, according to expert assessments (see Reference standard).
If participants failed to reach this threshold, they were allocated a further 24 vignettes (second training set)
to complete. If participants failed to reach the performance threshold for progressing to the main trial on
their second set of training vignettes, they were withdrawn from the trial. Participants who successfully
passed the training phase (after either one or two attempts) were allocated 42 vignettes for assessment in
the main phase of the trial.
Training vignettes were randomly sampled from the same pool of 288 vignettes as those used in the main
study. However, the sampling method ensured that participants assessed different vignettes in their main study
phase from those assessed during their training phase; the samples for assessment in the main trial were
allocated to participant IDs in advance (as part of the trial design) and training sets of vignettes were sampled
randomly from the 246 remaining vignettes.
Reference standard
The reference standard was established based on the judgements of three medical retina experts. Using
the web-based application (see Implementation/management/data collection), these experts independently
assessed the vignette features and made lesion classification decisions for all 288 index images. As the
judgements of experts did not always agree, a consensus meeting was held to review the subset of
vignettes for which experts’ classifications of lesion status disagreed. The experts reviewed these vignettes
together without reference to their previous assessments and reached a consensus agreement. This
consensus decision (‘reactivated’, ‘suspicious’ or ‘quiescent’ lesion) for all 288 vignettes made up the
reference standard and was used to determine ‘correct’ participant lesion classification decisions.
As described in the protocol,20 the classification of a lesion as reactivated or quiescent depended on the
presence or absence of predefined lesion components and whether or not the lesion component had
increased from baseline. Two imaging modalities were used. These were colour fundus (CF) photographs
and OCT images. Lesion components in colour photographs that were prespecified comprised haemorrhage
and exudate. Tomographic components comprised subretinal fluid (SRF), diffuse retinal thickening (DRT),
localised intraretinal cysts (IRCs) and pigment epithelial detachment (PED). Experts indicated whether each
lesion component was present or absent. Rules for the classification of a lesion as reactivated or quiescent
from the assessment of lesion components were prespecified (Table 2). Experts could disagree about the
presence or absence of a specific lesion component and whether or not these components had increased
from the baseline; however, they had to follow the rules when classifying a lesion as reactivated or
quiescent (note that the PED lesion component did not inform lesion classification as active or quiescent).
Validation prompts reflecting these rules were added to the web application after the training phase to
prevent data entry or keystroke errors; the validation rules did not assist participants in making the overall
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assessment because they had to enter their assessments of the relevant image features present in each
vignette before classifying the lesion status.
Owing to the short duration of the trial, participant training and assessments were undertaken
concurrently with the independent experts’ assessments of the vignettes. Therefore, training sets of
vignettes were scored against experts’ assessments that were complete at the time. Subsequently, checks
were instituted to ensure that no participant was excluded from the main trial who might have passed the
threshold performance score had the consensus reference standard been available at the time.
Outcomes
Primary outcome
The primary outcome was correct classification of the activity status of the lesion by a participant, based on
assessing the index images in a vignette, compared with the reference standard (see Reference standard).
Activity status could be classified as ‘reactivated’, ‘suspicious’ or ‘quiescent’. For the primary outcome,
a participant’s classification was scored as ‘correct’ if:
l both the participant and the reference standard lesion classification were reactivated
l both the participant and the reference standard lesion classification were quiescent
l both the participant and the reference standard lesion classification were suspicious
l either the participant or the reference standard lesion classification was suspicious, and the other
classification (reference standard or participant) was quiescent.
In effect, for the primary outcome, suspicious and quiescent classifications were grouped, making the
primary outcome binary (Table 3).
TABLE 2 Framework for reference classifications
Feature Lesion reactivated Lesion quiescent
SRF on OCT Yes No
Or And
IRC on OCT Yes, and increased from baseline No/not increased from baseline
Or And
DRT on OCT Yes, and increased from baseline No/not increased from baseline
Or And
Blood on CF Yes, and increased from baseline No/not increased from baseline
Or And
Exudates on CF Yes, and increased from baseline No/not increased from baseline
TABLE 3 Definition of primary outcome
Participant classification
Reference standard classification
Reactivated Suspicious Quiescent
Reactivated ✓ ✗ ✗
Suspicious ✗ ✓ ✓
Quiescent ✗ ✓ ✓
METHODS
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Secondary outcomes
1. The frequency of potentially sight-threatening ‘serious’ errors. An error of this kind was considered to have
occurred when a participant’s classification of a vignette was ‘lesion quiescent’ and the reference standard
classification was ‘lesion reactivated’; that is, a definitive false-negative classification by the participant.
Definitive false positives were not considered sight-threatening, but were tabulated. Misclassifications
involving classifications of ‘lesion suspicious’ were also not considered sight-threatening.
2. Judgements about the presence or absence of specific lesion components, for example blood and
exudates in the fundus colour images, SRF, IRC, DRT and PED in the OCT images and, if present,
whether or not these features had increased since baseline.
3. Participant-rated confidence in their decisions about the primary outcome, on a 5-point scale.
Adverse events
This study does not involve any risks to the participants; therefore, it was not possible for clinical adverse
events to be attributed to study-specific procedures.
Implementation/management/data collection
A secure web-based application was developed to allow participants to take part in the trial remotely (see
example screenshots Appendix 2). The website www.echoestrial.org/demo shows how assessors carried
out assessments in the trial. Participants registered interest, entered their details, completed questionnaires
(regarding opinions on ECHoES trial training and shared care), and assessed their training and main study
vignettes through this application. The webinar material was also available in the web application for
participants to consult if they needed to revisit it.
Additionally, the web application had tools accessible only to the trial team to help manage and monitor
the conduct and progression of the trial. Further details are published elsewhere.19
Sample size
With respect to the primary outcome, the trial was designed to answer the non-inferiority question ‘Is the
performance of optometrists as good as that of ophthalmologists?’. A sample of 288 vignettes was chosen
to have at least 90% power to test the hypothesis that the proportion of vignettes for which lesion status
was correctly classified by the optometrist group. We assumed that the proportion of vignettes for which
lesion status was correctly classified by the ophthalmologist group was at least 95% and that each
vignette would be assessed by only one ophthalmologist and one optometrist. However, as each vignette
was assessed seven times by each group, the trial in fact had 90% power to detect non-inferiority for
lower proportions of vignettes correctly classified by the ophthalmologist group.
Statistical methods
The analysis population consisted of the 96 participants who completed the assessments of their training
and main study samples of vignettes. Continuous variables were summarised by means and standard
deviations (SDs), or by medians and interquartile ranges (IQRs) if distributions were skewed. Categorical
data were summarised as a number and percentage. Baseline participant characteristics were described
and groups formally compared using t-tests, Mann–Whitney U-tests, chi-squared tests or Fisher’s exact
tests as appropriate.
Group comparisons
All primary and secondary outcomes were analysed using mixed-effects regression models, adjusting for
the order the vignettes were viewed as a fixed effect (tertiles: 1–14, 15–28, 29–42) and participant and
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vignette as random effects. All outcomes were binary and as such were analysed using logistic regression,
with group estimates presented as odds ratios (ORs) with 95% confidence intervals (CIs).
In addition to the group comparisons, the influence of key vignette features [age, gender, smoking status,
cardiac history (including angina, myocardial infarction and/or heart disease), and baseline and index
BCVA (modelled as the sum and difference of BCVA at the two time points)] on the number of incorrect
vignette classifications were investigated, adjusting for the reference standard classification (reactivated vs.
quiescent/suspicious). This additional analysis was carried out using fixed-effects Poisson regression with
the outcome of the number of incorrect classifications. The prior hypothesis was that this information
would not influence the number of correct (or incorrect) classifications.
The sensitivity and specificity of the primary outcome are also presented. For these performance measures,
the sensitivity is the proportion of lesions for which the reference standard is ‘reactivated’ and participants
correctly classified the lesion. The specificity is the proportion of lesions for which the reference standard
is either ‘suspicious’ or ‘quiescent’ and the participant’s classification is also ‘suspicious’ or ‘quiescent’.
Non-inferiority limit
For the sample size calculation, it was agreed that an absolute difference of 10% would be the maximum
acceptable difference between the two groups, assuming that ophthalmologists would correctly assess
95% of their vignettes. As the group comparison of the primary outcome was analysed using logistic
regression and presented as an OR, this non-inferiority margin was converted to the odds scale. Therefore,
this limit was expressed as an OR of 0.298 [i.e. the odds correct for the worst acceptable performance by
optometrists (85%) divided by the odds correct for worst assumed performance of ophthalmologists
(95%): (0.85/0.15)/(0.95/0.05)].
Sensitivity analysis
A sensitivity analysis of the primary outcome, regrouping vignettes graded as suspicious into the ‘lesion
reactivated’ group rather than ‘quiescent lesion’ group, was undertaken to assess the sensitivity of the
conclusions to the classification of the vignettes graded as suspicious. This analysis was prespecified in the
analysis plan but not in the trial protocol.
Post-hoc analysis
The following post-hoc analyses were prespecified in the analysis plan, but not in the trial protocol.
l Lesion classification decisions were tabulated against referral decisions for both groups.
l A descriptive analysis of the time taken to complete each vignette and how the duration of this time
changed with experience in the trial (learning curve) was performed. The relationship between the
duration of this time and participants’ ‘success’ in correctly classifying vignettes was also explored.
l Cross-tabulations and kappa statistics were used to compare experts’ initial classifications with the final
reference standard. Similarly, cross-tabulations and kappa statistics were used to compare lesion
component classifications between the three experts.
In addition, a descriptive analysis of the participants’ opinions about the training provided in the ECHoES
trial, as well as their perceptions of shared care, was carried out (see ECHoES participants’ perspectives of
training and shared care).
Missing data
By design, there were no missing data for the primary and secondary outcomes. However, time taken to
complete vignettes was calculated as the time between when each vignette was saved on the database.
It was, therefore, not possible to calculate this for the first vignette of each session. Additionally, it was
assumed that times longer than 20 minutes (database timeout time) were due to interruptions, so these
were set to missing. As the analysis using these times was descriptive and was not specified in the
protocol, complete case analysis was performed and missing/available data described.
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Statistical significance
For hypothesis tests, two-tailed p-values of < 0.05 were considered statistically significant. Likelihood ratio
tests were used in preference to Wald tests for hypothesis testing.
All data management and all analyses carried out by the Clinical Trials and Evaluation Unit, Bristol, were
performed in SAS version 9.3 (SAS Institute Inc., Cary, NC, USA) or Stata version 13.1 (StataCorp LP,
College Station, TX, USA).
Changes since commencement of study
At the end of their participation in the trial, all participants were asked to complete a questionnaire
regarding their opinions about the training provided in the ECHoES trial and their attitudes towards a
shared care model. This was made available to all ECHoES trial participants.
In addition, the reference standard was originally planned to include only two categories, namely lesion
reactivated or lesion quiescent. However, after a concordance exercise was carried out by the three retinal
experts on the ECHoES trial team, a third category of suspicious lesion was added. This change occurred
before any experts’ or participants’ lesion classifications were made.
Finally, after much consideration, it was agreed the primary analysis would be carried out using logistic
regression rather than Poisson regression in order to fully account for the incomplete block design. Fitting
a Poisson model would not have allowed us to include both vignette and participant as random effects in
the model.
Health economics
Aims and research questions
The economic evaluation component of the ECHoES trial aimed to estimate the incremental cost and
incremental cost-effectiveness of community optometrists compared with hospital-based ophthalmologists
performing retreatment assessments for patients with quiescent nAMD. This would enable us to determine
which professional group represents the best use of scarce NHS resources in this context. The main
outcome measure was a cost per correct retreatment decision, with correct meaning that both experts
and trial participants judge the vignettes to be lesion reactivated, lesion quiescent or lesion suspicious.
Analysis perspective
The economic evaluation took the cost perspective of the UK NHS, personal social services and private
practice optometrists, and was performed in accordance with established guidelines and recent
publications.21–23 Although it is possible that any incorrect retreatment decisions (false positives) could lead
to costs being incurred by patients, their families or employers because of time away from usual activities,
these wider societal costs were felt to be small compared with the implications for the NHS. Therefore,
in line with the IVAN trial9, we decided not to adopt a societal perspective in the ECHoES trial.
Economic evaluation methods
The methods used in the economic evaluation are summarised in Table 4. Data on resource use and costs
were collected using bespoke costing questionnaires for community optometrists. With the help of the
ECHoES trial team (clinicians and optometrists), we first identified the typical components/tasks which are
included in a monitoring review for nAMD and then subcategorized these tasks into resource groups such
as staffing, equipment and building space. As some optometrist practices are likely to incur set-up costs
associated with assessing the need for retreatment, we compiled a list of items of equipment necessary for
performing each task within a monitoring review. The resource-use and cost questionnaire asked each
participant which items of equipment from this list their practice currently owned and how much they
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had paid for the items. The questionnaire was piloted with a handful of optometrists and ophthalmologists
who were able to advise on whether or not our questionnaire was straightforward to comprehend and
complete. For any items which would be necessary for the review, but which the practice did not already
own, we inferred that these items would have to be purchased ‘ex novo’. Once the total costs of equipment
were identified, along with their predicted life span as suggested by study clinicians, we created an
equivalent annual cost for all of the equipment using a 3.5% discount rate,24 and divided this cost by the
number of potential patients who could undergo the monitoring reviews in the community practices.
See Appendix 3 for a copy of the bespoke costing questionnaires for the optometrists in the ECHoES trial.
We estimated the costs associated with training optometrists to perform the assessments. The costs were
estimated for the 2-hour duration webinar, plus time spent to revisit the webinar and time spent in
checking other resources. Finally, the amount of time the ECHoES study clinicians spent preparing and
delivering the webinars was also estimated.
For information on the costs of ophthalmologists performing the monitoring assessments, we used cost
data from the IVAN trial, in which we had undertaken a very detailed micro-costing study.25
In the economic evaluation, it is advised that value-added tax (VAT) should be excluded from the analysis.21
Where possible, we used costs without VAT for our base-case analysis.
Missing data
Only 40 of the 61 optometrists who were initially invited to complete the health economics questionnaire
(those who completed webinar training) actually submitted the questionnaire; 34 of the 40 completed their
main assessments for the trial. Fifty-five of the 61 optometrists who were invited to complete the health
economics questionnaire replied to the feedback questionnaire, which also contained information on the
time spent on training by the optometrist. This training time was costed and contributes to the calculation
of the cost per monitoring review for optometrists. Therefore, in order to maximise the use of questionnaire
replies, a cost per monitoring review was estimated using all available information as reported by all
optometrists rather than focusing only on the 48 that subsequently completed the main assessments.
For consistency with the procedure adopted in the IVAN trial costing, mean values of the relevant variables
were imputed to the 21 optometrists who did not submit the cost questionnaire and to the six who did
not complete the feedback questionnaire. The estimated costs from the 61 practices were randomly
assigned (see Cost model: random, allocation) to each of the 2016 vignettes assessed by the
48 optometrists who completed the main assignment.
TABLE 4 Summary of methods used in the economic evaluation
Aspect of method Strategy used in base-case analysis
Form of economic evaluation Cost-effectiveness analysis for comparison between optometrists and ophthalmologists
Perspective NHS, Personal Social Services and private practice optometrists’ costs
Data set Optometrist and ophthalmologists enrolled in the ECHoES trial
Missing data Imputation
Costs included in analysis Equipment, staff, building, training for webinars
Effectiveness measurement Correct retreatment decisions
Sensitivity analysis Three injections of Lucentis and consultations instead of one, using Eylea instead of
Lucentis and using Avastin instead of Lucentis
Time horizon A within-trial analysis, taking an average of 2 weeks (maximum of 4 weeks)
METHODS
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Cost model: random, allocation
From the IVAN trial, we had estimates of the cost of clinician-led monitoring reviews from 28 eye hospitals.
Using a random allocation procedure similar to the one used in the IVAN trial,9 these estimates were
allocated to each of the 2016 vignettes assessments carried out by the 48 ophthalmologists in the ECHoES
trial. From the data collected for the ECHoES trial, we had estimates of the cost of the monitoring review
from 61 (after imputation) optometric practices, which varied across practices. Although it would have
been possible to link each vignette to the cost derived for the optometry practice in which the optometrist
assessing the vignette worked, this would have ignored the heterogeneity between practices and the
uncertainty around the estimates of the mean cost of the monitoring review. Therefore, we adopted the
same approach as used for the IVAN trial, which was to randomly allocate costs. We randomly sampled
from the distribution of costs from different optometrist practices using the procedure described below.
Each of the 61 practices (for which the cost of a monitoring review had been estimated) reported the
monthly number of nAMD patients that they could accommodate after all required changes in the practice
(purchase of necessary equipment, changes to the structure/size of the practice, new staff, etc.) would
have been implemented. These numbers were used to calculate weights; that is, each weight was the
number of nAMD patients that the practice could accommodate per month divided by the summation of
all patients with quiescent nAMD who could theoretically be accommodated by all of the practices per
month after implementing changes. Cumulative weights were then calculated and assigned to each
optometric practice. For each vignette (potential patient) a random number was generated. This random
number determined which of the monitoring review costs each vignette was randomly assigned to.
For each vignette assessed by a community optometrist, we randomly drew a value for the cost of the
community optometry review from the distribution of the ECHoES trial monitoring review costs; for each
vignette assessed by an ophthalmologist, we randomly drew a value for the cost of a hospital review from
the cost distribution used in IVAN. For those vignettes where an incorrect treatment decision resulted in an
additional hospital monitoring consultation or an unnecessary injection, we drew additional random
numbers to sample those consultation costs from the distribution of costs as reported for the IVAN trial.
Care cost pathway decision tree
In order to generate an estimate for a cost for a correct retreatment decision, we first mapped the various
care pathways that would possibly happen from the treatment assessments in the study, by comparing the
reference lesion classification for each vignette to the actual classification made by the study participants
(48 ophthalmologists and 48 optometrists). This gave rise to two versions of a simple decision tree: one for
ophthalmologists (Figure 1) and one for optometrists (Figure 2). The starting point for the decision trees
was the ‘actual’ truth. The three main branches of the trees were true active, true quiescent and true
suspicious. Participants’ main trial assessments provided information about the number of participants who
made correct and incorrect decisions on treatment compared with the reference standard decisions.
The decisions that both groups made about the vignettes were then placed into the decision trees and the
associated costs for the different pathways were calculated. This process generated an average cost for
each of the alternative care pathways. Any ‘incorrect’ decisions implied that patients would have had
unnecessary repeat monitoring visits at the optometrist practice or at the hospital and maybe unnecessary
anti-VEGF injections if they misclassified patients as requiring treatment. All costs are reported in 2013/14
prices unless specified otherwise.
Our baseline analysis calculated the average cost and outcome on a per patient basis. From these
estimates, the incremental cost-effectiveness ratios (ICERs) for the different assessment options were
derived, producing an incremental cost per accurate retreatment decision. Sensitivity analyses were carried
out to demonstrate the impact of variation around the key parameters in the analysis on the baseline
cost-effectiveness results. The four sensitivity analyses which we conducted were:
l Sensitivity analysis 1: all patients initiating treatment were assumed to have a course of three
ranibizumab given at three subsequent injection consultations, with no additional monitoring reviews.
This matched the way in which discontinuous treatment was administered in the IVAN trial.
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l Sensitivity analysis 2: treatment was assumed to be one aflibercept injection given during an
injection consultation.
l Sensitivity analysis 3: treatment consisted of one bevacizumab injection given during an
injection consultation.
l Sensitivity analysis 4: only considered the cost of a monitoring review rather than considering the cost
of the whole pathway.
The economic evaluation results were expressed in terms of a cost-effectiveness acceptability curve (CEAC).
This indicates the likelihood that the results fall below a given cost-effectiveness ceiling and could help
decision makers to assess whether optometrists are likely to represent value for money for the NHS when
compared with ophthalmologists in making decisions about retreatment in nAMD patients and also
completely disparate health-care interventions. All health economics analyses were conducted in Stata
version 12.1 (StataCorp LP, College Station, TX, USA), except the budget impact analysis.
Optometrist
Ophthalmologist
True active
Ophthalmologist
judgement = reactivation
Appropriate intravitreal injection
Appropriate cost of one injection consultation and one dose of Lucentis
Patient gets prompt, appropriate treatment
Additional hospital monitoring review
Additional cost of one hospital monitoring consultation
2-week delay before starting treatment
Hospital review in 4 weeks
Delay before starting treatment, during which eyesight might
deteriorate and condition may progress
Unnecessary intravitreal injection
Additional cost of one injection consultation and one dose of Lucentis
Assume to be no other costs or health consequences at this stage
Hospital review in 4 weeks
Hospital review in 4 weeks
Delay before reassessing eligibility for treatment, during which
eyesight might deteriorate and condition may progress
Unnecessary intravitreal injection
Additional cost of one injection consultation and one dose of Lucentis
No health implications besides unnecessary worry (or drug side effects)
Additional hospital monitoring consultation
Unnecessary cost of one hospital monitoring visit
No health implications besides unnecessary worry
Hospital review in 4 weeks
No cost or health implications
Ophthalmologist
judgement = reactivation
Ophthalmologist
judgement = suspicious
Ophthalmologist
judgement = inactive
Ophthalmologist
judgement = reactivation
Ophthalmologist
judgement = suspicious
Ophthalmologist
judgement = inactive
Ophthalmologist
judgement = inactive
Ophthalmologist
judgement = suspicious
True
suspicious
True
quiescent
FIGURE 1 Decision tree for hospital ophthalmologist review. Reproduced open access from Violato et al.16 under
the terms of the Creative Commons Attribution (CC BY 4.0) licence.
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Budget impact
Freeing up HES clinic time could lead to an increase in the overall capacity of the NHS both to manage the
nAMD population more effectively and to manage non-nAMD eye patients (more time for ophthalmologists
to spend with non-nAMD patients if they are seeing fewer nAMD patients for monitoring). Therefore, we
attempted to estimate the potential time and costs that could be saved by HES clinics if some of the
management of nAMD patients could be undertaken in the community. This was done by using the
resource-use information collected during the IVAN trial as a basis on which to consider what proportion
of an ophthalmologist’s time is spent on retreatment decisions for this group of patients relative to
other aspects of their care. We brought together data from the IVAN trial (average number of patients
attending a clinic) and information from the literature, and used expert opinion from the ECHoES study
ophthalmologists and optometrists to try to estimate the total number of patients with quiescent or no
lesion in both eyes who would be eligible for monitoring by a community optometrist in a given month
and the total number of monitoring visits that could be transferred from a hospital to the community
per year. We then replaced the costs of the ophthalmologist’s time with the cost of the optometrist’s time
and examined the difference. The Microsoft Excel® spreadsheet (Microsoft Corporation, Redmond, WA,
USA) calculations for the budget impact are reported in Appendix 3.
Ophthalmologist
Optometrist
True active
Optometrist
judgement = reactivation
Refer to hospital eye clinic
Appropriate cost of one hospital monitoring visit and
one Lucentis injection and one injection consultation
Patient gets prompt, appropriate treatment
Optometry review in 2 weeks
Additional cost of one optometry review
2-week delay before starting treatment
Optometry review in 4 weeks
Delay before starting treatment, during which eyesight
might deteriorate and condition may progress
Refer to hospital eye clinic
Unnecessary cost of one hospital monitoring visit
Not enough information to identify further costs at this stage
Optomerty review in 2 weeks
Optomerty review in 4 weeks
Delay before reassessing eligibility for treatment, during
which eyesight might deteriorate and condition may progress
Refer to hospital eye clinic
Unnecessary cost of one hospital monitoring visit
No health implications besides unnecessary worry
Optometry review in 2 weeks
Unnecessary cost of 0.5 optometry visits
No health implications besides unnecessary worry
Optometry review in 4 weeks
No cost or health implications
Optometrist
judgement = suspicious
Optometrist
judgement = inactive
Optometrist
judgement = reactivation
Optometrist
judgement = suspicious
Optometrist
judgement = inactive
Optometrist
judgement = reactivation
Optometrist
judgement = suspicious
Optometrist
judgement = inactive
True
suspicious
True
quiescent
FIGURE 2 Decision tree for community optometrist review. Reproduced open access from Violato et al.16 under the
terms of the Creative Commons Attribution (CC BY 4.0) licence.
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Qualitative research
Focus groups were conducted with ophthalmologists, optometrists and eye service users separately, and
one-to-one interviews were conducted with other health professionals involved in the care and services of
those with eye conditions.
Recruitment
Focus groups with optometrists and ophthalmologists
Two focus groups were conducted with ophthalmologists and optometrists separately, held at specialist
conferences (the National Optical Conference for Optometrists in Birmingham, November 2013, and the
Elizabeth Thomas Seminar for Ophthalmologists in Nottingham, December 2013). For the optometrist
focus groups, information about the study was placed in specialist press and the ECHoES study website.
Focus group participants were also recruited by the snowball technique, with health-care professionals
informing other potentially interested colleagues. For the ophthalmologist focus groups, conference
organisers emailed information about the study to delegates. Interested participants were asked to contact
the qualitative researcher for more information.
Interviews with commissioners, clinical advisors to clinical commissioning
groups and public health representatives
Clinical commissioning groups (CCGs) in England were contacted by an e-mail which contained
information about the study, asking it to be forwarded on to general practitioners (GPs)/commissioners in
each CCG who were responsible for commissioning ophthalmology care. Those who were interested were
asked to contact the qualitative researcher for more information. Subsequent selection of clinical advisors
and public health representatives was guided via the snowball technique. Interviews were mostly
conducted in person (n = 6) although, when it was not practicable to do so, a telephone interview was
conducted (n = 4). Interviews were conducted between March and June 2014.
Focus groups with service users
Participants with nAMD were recruited from local support groups organised by the Macular Society,
formerly known as the Macular Disease Society, a UK-based charity for anyone affected by central vision
loss with over 15,000 members and 270 local support groups around the UK (www.macularsociety.org).
Three support groups in the south-west of England were initially selected, one based in a major city,
one in a large town and one in a rural village. Service users with any history of nAMD were invited to
join the study (regardless of whether they had nAMD in one eye or both, dry AMD in their other eye,
were currently receiving or had had any treatment in the past).The researcher attended the local support
meetings to explain about the research and provide attendees with a participant information leaflet to take
home. Contact details of those potentially interested at this stage were obtained. Those who expressed an
interest were telephoned by the researcher a week later to discuss the study further and to answer any
questions to help them decide whether or not to take part.
Sampling
Basic demographic, health and professional information was collected from those who agreed to be
contacted for sampling purposes. A purposeful sampling strategy was used to ensure that the feasibility
and acceptability of the proposed shared model of care for nAMD was captured from a range of
perspectives. Within this sampling approach, maximum variation was sought in relation to profession, age,
gender and geographic location (for health professionals) and gender, age, type of AMD and time since
diagnosis (for service users). Participant characteristics were assessed as the study progressed, and
individuals or groups that were under-represented were targeted (i.e. commissioners or clinical advisors).
Where it was felt that variation had been achieved, potential participants were thanked for their interest
and informed that sufficient numbers had been recruited (i.e. optometrists).
METHODS
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Data collection
A favourable ethical approval for this study was granted by a UK NHS Research Ethics Committee.
Written consent was obtained from participants at the start of each focus group or interview. Separate
topic guides were developed for service users, optometrists/ophthalmologists (with additional questions
for each professional group) and all other health professionals, to ensure that discussions within each
group covered the same basic issues but with sufficient flexibility to allow new issues of importance
to the informants to emerge. These were based on the study aims, relevant literature and feedback from
eye-health professionals in the ECHoES study team, and consisted of open-ended questions about the
current model of care for nAMD and perspectives of stable patients being monitored in the community
by optometrists. They were adapted as analysis progressed to enable exploration of emerging themes.
All of the focus groups and interviews were conducted by DT; these were predominantly led by the
participants themselves, with DT flexibly guiding the discussion by occasionally probing for more
information, clarifying any ambiguous statements, encouraging the discussion to stay on track, and, in the
focus groups, providing an opportunity for all participants to contribute to the discussion. All participants
were offered a £20 gift voucher to thank them for their time (two commissioners declined the voucher).
Data analysis
Focus groups and interviews were transcribed verbatim and checked against the audio-recording for
accuracy. Transcripts were imported into NVivo version 10 (QSR International, Warrington, UK), where data
were systematically assigned codes and analysed thematically using constant comparison methods derived
from grounded theory methodology.26 Transcripts were repeatedly read and ongoing potential ideas and
coding schemes were noted at every stage of analysis. To ensure each transcript was given equal attention
in the coding process, data were analysed sentence by sentence and interesting features were coded.
Clusters of related codes were then organised into potential themes, and emerging themes and codes
within transcripts and across the data set were then compared with explore shared or disparate views
among participants. The transcripts were reread to ensure the proposed themes adequately covered the
coded extracts, and the themes were refined accordingly. Emerging themes were discussed with a second
experienced social scientist (NM) with reference to the raw data. Data collection and analysis proceeded in
parallel, with emerging findings informing further sampling and data collection. Data collection and
analysis continued until the point of data saturation, that is, the point at which no new themes emerged.
The ECHoES trial participants’ perspectives of training and shared care
In addition to the information collected during focus groups and interviews, the opinions of all
optometrists and ophthalmologists who had taken part in the ECHoES trial were sought in a short online
questionnaire. The survey related to participants’ experiences of the training and their attitudes towards
shared care for nAMD. Questions required a binary, a Likert scale or a free-text response.
Quantitative data were analysed in Microsoft Excel and presented as proportions. Free-text responses were
imported into NVivo and coded into categories, which were derived from the main survey questions,
relating to feedback on the training programme (experiences of using the web application, ease of training
and additional resources used) and attitudes towards shared care (general perspectives of the proposed
model, and perceived facilitators and barriers to implementation). Data were analysed thematically using
the constant comparative techniques of grounded theory, whereby codes within and across the data set
were compared to look for shared or disparate views among optometrists and ophthalmologists.
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Chapter 3 Results: classification of lesion and
lesion components (objectives 1 to 3)
Registered participants
A total of 155 health-care professionals (72 ophthalmologists and 83 optometrists) registered their interest
in the ECHoES trial. Of these, 62 ophthalmologists and 67 optometrists consented to take part. Everyone
who registered an interest was eligible for the trial; those who did not consent either did not return their
consent forms or were no longer required for the trial. See Figure 3 for details.
Recruitment
Participants were initially recruited between 1 June and 9 October 2013. However, as participants progressed
through the training stages, it became apparent that the withdrawal rate of optometrists was higher than
expected and that more would be required if the planned sample size were to be met. Recruitment was
therefore reopened between 13 February and 6 March 2014, when a further seven optometrists consented
to take part. A number of participants withdrew or were withdrawn by co-ordinating staff throughout the
trial, mostly because they missed webinars or failed their assessment of training vignettes (see Figure 3
and Withdrawals for details). The final participant completed the main study vignettes on 21 April 2014. As
planned, 48 ophthalmologists and 48 optometrists completed the full trial.
At the start of the trial we were unsure how many participants we would need to recruit in order to meet
our target of 48 participants in each group. Therefore, we over-recruited at the consent stage and asked a
number of participants to complete the webinar and then ‘wait and see’ whether or not we needed them
to participate in the main trial. We also slightly over-recruited at each stage of the trial to account for
dropouts. This resulted in a small number of participants being withdrawn at various stages of the trial
because they were no longer required.
Withdrawals
During the ECHoES trial, withdrawals could occur for a number of reasons. First, participants could withdraw
or be withdrawn between consenting and receiving their training vignettes if the mandatory webinar training
was not completed, they no longer wanted to take part or they were no longer needed for the trial. This
occurred for six ophthalmologists and six optometrists (see Figure 3 for details). Second, participants could
be withdrawn if the threshold performance score for the assessments of their training vignettes was not
attained. Of the 54 ophthalmologists who completed their vignette training, 48 (88.9%) passed first time,
two (3.7%) passed on their second attempt and four (7.4%) failed their second attempt so were withdrawn.
Of the 57 optometrists who completed their vignette training, 38 (66.7%) passed first time, 11 (19.3%)
passed on their second attempt and eight (14.0%) failed their second attempt and were withdrawn from the
trial. Two ophthalmologists and one optometrist who passed their training vignettes were withdrawn from
the trial as the target sample size (48 in each group completing main assessments) had already been reached.
Numbers analysed
Ninety-six participants, 48 ophthalmologists and 48 optometrists, were included in the analysis population. For
the primary and secondary outcomes, all participants were included as by design there were no missing data.
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Reference standard classifications
The reference standard classified 142 (49.3%) of the 288 vignettes as reactivated, 5 (1.7%) as suspicious
and 141 (49.0%) as quiescent.
Participant characteristics
The characteristics of participants collected for the trial included only age, gender and date of qualification
for the participant’s profession. As participants were not randomised to the two comparison groups,
Registered health-care professionals
(n = 155)
Ophthalmologist
(n = 72)
Optometrist
(n = 83)
Withdrawals (N = 6)
• Target reached so not required, n = 3
• Did not attend webinar 1, n = 3
Completed webinars and allocated their
training vignettes
(n = 56)
Passed training
first attempt
(n = 48)
Passed training
second attempt
(n = 2)
Passed training
first attempt
(n = 38)
Passed training
second attempt
(n = 11)
Completed main trial and included in
analysis data set
(n = 48)
Completed main trial and included in
analysis data set
(n = 48)
Excluded (N = 10)
• Not invited to consent, n = 1
• Did not return consent form, n = 9
Excluded (N = 16)
• Did not return consent form, n = 16
Consented
(n = 62)
Consented
(n = 67)
Withdrawals (N = 6)
• Target reached so not required, n = 1
• Did not want to ‘wait and see’, n = 1
• Did not attend webinar 1, n = 3
• Did not attend webinar 2, n = 1
Withdrawals (N = 6)
• Did not complete vignette training, n = 2
• Failed training, n = 4
Withdrawals (N = 1)
• Target reached so not required, n = 1
Withdrawals (N = 12)
• Did not complete vignette training, n = 3
• Failed training, n = 8
• Target reached so not required, n = 1
Completed webinars and allocated their
training vignettes
(n = 61)
Withdrawals (N = 2)
• Target reached so not required, n = 2
FIGURE 3 Flow of participants.
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baseline characteristics were presented descriptively and formally compared. Table 5 shows that the
gender balance and average ages were similar among optometrists and ophthalmologists [mean 43.1 years
(SD 10.1 years) and 42.2 years (SD 8.0 years), respectively; 50.0% vs. 43.8% women]. Optometrists had
on average significantly more years of qualified experience than ophthalmologists [median 17.4 years
(IQR 10.1–28.4 years) and 11.4 years (IQR 4.8–16.9 years), respectively].
Primary outcome
The primary outcome (correct lesion classification by a participant compared with the reference standard: 2.5.1)
was achieved by the ophthalmologists for 1722 out of 2016 (85.4%) vignettes and by the optometrists for 1702
out of 2016 (84.4%) vignettes (Table 6). The odds of an optometrist being correct were not statistically different
from the odds of an ophthalmologist being correct (OR 0.91, 95% CI 0.66 to 1.25; p= 0.543). The ability of
optometrists to assess vignettes is non-inferior (both clinically and statistically) to the ability of ophthalmologists,
according to the prespecified limit of 10% absolute difference (0.298 on the odds scale; illustrated by the
dashed black line on Figure 4). In this primary outcome model, the variance attributed to the participant random
effect was far smaller than that of the vignette random effect (0.360 and 2.062, respectively).
The median number of correct lesion classifications (compared with the reference standard) by individual
participants was 37 (IQR 35.0–38.5) in the ophthalmologist group compared with 36 (IQR 33.0–38.0)
in the optometrist group. The lowest number of correct lesion classifications was 26 out of 42 in the
ophthalmologist group and 24 out of 42 in the optometrist group; the highest number of correct lesion
reactivation decisions was 41 out of 42, achieved by one ophthalmologist and three optometrists. It was
recommended by a reviewer that the relationship between years of experience and the number of correct
responses of ophthalmologists should be explored. Appendix 4, Figure 27 suggested no clear relationship.
Appendix 4, Figure 28 shows a plot of individual optometrist participant scores against their paired
ophthalmologist counterparts for the 48 different sets of vignettes. The sensitivity and specificity (see Table 6;
described in Chapter 2, Group comparisons) and detailed breakdown of the participants’ classifications (Table 7
and Figure 5) show the agreement between participants and the reference standard in more detail. Figure 5
shows that optometrists were more likely than ophthalmologists to correctly classify a vignette as reactivated
(80% vs. 74.0%), but were less likely to correctly classify a vignette as quiescent (65.7% vs. 81.7%).
A post-hoc analysis to look at this subgroup effect was undertaken. The interaction between participant
group and reference standard vignette classification (reactivated vs. quiescent/suspicious) was statistically
significant (interaction p < 0.001); the odds of an optometrist being correct were about 50% higher than
those of an ophthalmologist if the reference standard classification was reactivated (OR 1.52, 95% CI 1.08
to 2.15; p = 0.018) but about 70% lower if the reference standard classification was quiescent/suspicious
(OR 0.27, 95% CI 0.17 to 0.44; p < 0.001).
Secondary outcomes
Serious sight-threatening errors
Serious sight-threatening errors could occur only for the vignettes which were classified as ‘reactivated’ by
the reference standard. These errors occurred in 62 out of 994 (6.2%) of ophthalmologists’ classifications
TABLE 5 Characteristics of participants
Characteristic Ophthalmologists (n= 48) Optometrists (n= 48) p-value
Age (years), mean (SD) 42.2 (8.0) 43.1 (10.1) 0.616
Gender (female), n/N (%) 21/48 (43.8) 24/48 (50.0) 0.539
Years since qualification, median (IQR) 11.4 (4.8–16.9) 17.4 (10.1–28.4) < 0.001
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TABLE 6 Correct lesion classification (primary outcome), sensitivity and specificity
Primary outcome
Ophthalmologists
(n= 48)
Optometrists
(n= 48) OR (95% CI) p-value
Lesions correctly classified
(overall), n/N (%)
1722/2016 (85.4) 1702/2016 (84.4) 0.91 (0.66 to 1.25) 0.543
Sensitivity (overall), n/N (%) 736/994 (74.0) 795/994 (80.0) 1.52 (1.08 to 2.15) 0.018
Specificity (overall), n/N (%) 986/1022 (96.5) 907/1022 (88.7) 0.27 (0.17 to 0.44) < 0.001
Median correct participant
score (IQR)
37.0 (35.0–38.5) 36.0 (33.0–38.0) – –
Median sensitivity,
participant level (IQR)
76.5 (64.9–87.1) 83.7 (71.6–94.1) – –
Median specificity,
participant level (IQR)
100.0 (94.6–100.0) 94.7 (79.2–100.0) – –
The number of vignettes classified correctly and the sensitivity and specificity are shown summed across all participants
within each professional group (‘overall’, first three rows) and at the level of participants (‘participant level’, last three rows).
The first row of the table represents the primary analysis.
OR 0.91 (0.66 to 1.25); p = 0.54
0.25 0.50 1.00 2.00 4.00
OR (95% CI)
Favours ophthalmologists Favours optometrists
FIGURE 4 Comparison between optometrists and ophthalmologists for the primary outcome. Black dashed line
represents the non-inferiority limit of 0.298. Effect size point estimate is shown as the OR and the error bar
represents the 95% CI. The solid vertical line illustrates line of no difference at 1.
TABLE 7 Participants’ lesion classifications compared with the reference standard
Participants’ lesion
classifications by reference
standard classification
Ophthalmologists Optometrists Overall
n/N (observations) % n/N (observations) % n/N (observations) %
Reactivated (n = 142)
Reactivated 736/994 74.0 795/994 80.0 1531/1988 77.0
Suspicious 196/994 19.7 142/994 14.3 338/1988 17.0
Quiescent 62/994 6.2 57/994 5.7 119/1988 6.0
Suspicious (n = 5)
Reactivated 1/35 2.9 10/35 28.6 11/70 15.7
Suspicious 17/35 48.6 11/35 31.4 28/70 40.0
Quiescent 17/35 48.6 14/35 40.0 31/70 44.3
Quiescent (n = 141)
Reactivated 35/987 3.5 105/987 10.6 140/1974 7.1
Suspicious 146/987 14.8 234/987 23.7 380/1974 19.3
Quiescent 806/987 81.7 648/987 65.7 1454/1974 73.7
RESULTS: CLASSIFICATION OF LESION AND LESION COMPONENTS (OBJECTIVES 1 TO 3)
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and 57 out of 994 (5.7%) of optometrists’ classifications; this difference was not statistically significant
(OR 0.93, 95% CI 0.55 to 1.57; p = 0.789).
Each participant viewed between 15 and 27 ‘reactivated’ vignettes and the most sight-threatening errors
made by a single participant was eight (out of 25) in the ophthalmologists group and five (out of 19)
in the optometrists group (Table 8). Table 8 also shows the number of non-sight-threatening errors,
that is, participants classifying vignettes as reactivated when the reference standard was quiescent.
This type of error occurred more frequently in the optometrists group (105 out of 987; 10.6%) than in
the ophthalmologists group (35 out of 987; 3.5%); this difference was not formally compared.
Lesion components
We did not attempt to achieve a consensus among the three experts for the individual features of the
vignettes. Therefore, responses given by the professional groups for these individual features were
formally compared with each other rather than with any reference standard. Optometrists judged lesion
components to be present for all components except PED more often than ophthalmologists (Table 9
and Figure 6). This difference was particularly evident for DRT and exudates; the odds of identifying
these components as present were more than three times higher in the optometrist group than in
ophthalmologist group [OR 3.46, 95% CI 2.09 to 5.71 (p < 0.001), and OR 3.10, 95% CI 1.58 to
6.08 (p < 0.001), respectively]. SRF was also reported significantly more often by optometrists than
ophthalmologists (OR 1.73, 95% CI 1.21 to 2.48; p = 0.002). The difference between the groups was of
borderline statistical significance for blood (OR 1.56, 95% CI 1.00 to 2.44; p = 0.048). The differences
between the groups for IRC and PED did not differ statistically [OR 1.00, 95% CI 0.61 to 1.65 (p = 0.985)
and OR 0.91, 95% CI 0.47 to 1.79 (p = 0.786), respectively].
74.0
19.7
6.2
80.0
14.3
5.7
14.8
81.7
10.6
23.7
65.7
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(994 observations on
142 vignettes)
Reference standard = quiescent
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FIGURE 5 Participants’ lesion classifications for vignettes classified as reactivated or quiescent by the reference
standard. The 35 observations in each group for the five vignettes classified by the reference standard as suspicious
are not shown in this graph. [The data are ophthalmologists: 1, reactivated (2.9%); 17, suspicious (48.6%); 17,
quiescent (48.6%); optometrists: 10, reactivated (28.6%); 11, suspicious (31.4%); and 14, quiescent (40.0%). These
data are consistent with a more cautious approach to decision-making about retreatment by optometrists
than ophthalmologists.]
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TABLE 8 Sight-threatening and non-sight-threatening serious errors
Type of serious error
Ophthalmologists (n= 48)
Optometrists
(n= 48)
OR (95% CI) p-valuen/N % n/N %
Sight-threatening 62/994 6.2 57/994 5.7 0.93 (0.55 to 1.57) 0.789
Non-sight-threatening 35/987 3.5 105/987 10.6 – –
Number of participants making different numbers of sight-threatening serious errorsa
0 errors 17/48 35.4 19/48 39.6 – –
1 error 13/48 27.1 13/48 27.1 – –
2 errors 11/48 22.9 8/48 16.7 – –
3 errors 5/48 10.4 5/48 10.4 – –
4 errors 1/48 2.1 2/48 4.2 – –
5 errors 0/48 0.0 1/48 2.1 – –
8 errors 1/48 2.1 0/48 0.0 – –
Number of participants making different numbers of non-sight-threatening serious errorsa
0 errors 27/48 56.3 19/48 39.6 – –
1 error 11/48 22.9 6/48 12.5 – –
2 errors 7/48 14.6 7/48 14.6 – –
3 errors 2/48 4.2 4/48 8.3 – –
4 errors 1/48 2.1 3/48 6.3 – –
5 errors 0/48 0.0 5/48 10.4 – –
7 errors 0/48 0.0 3/48 6.3 – –
15 errors 0/48 0.0 1/48 2.1 – –
a A participant could make only one such error per vignette, i.e. only one ophthalmologist (of 48) made eight
sight-threatening errors and only one optometrist (of 48) made 15 non-sight-threatening errors.
TABLE 9 Identification of lesion components by professional groupa
Secondary outcomes
Ophthalmologists
(n= 48)
Optometrists
(n= 48)
OR (95% CI) p-valuen/N % n/N %
Is there SRF? 515/2016 25.5 627/2016 31.1 1.73 (1.21 to 2.48) 0.002
Has it increased since baseline? 498/515 96.7 541/627 86.3 – –
Are there IRC? 799/2016 39.6 808/2016 40.1 1.00 (0.61 to 1.65) 0.985
Has it increased since baseline? 667/799 83.5 683/808 84.5 – –
Is there DRT? 482/2016 23.9 826/2016 41.0 3.46 (2.09 to 5.71) < 0.001
Has it increased since baseline? 381/482 79.0 597/826 72.3 – –
Is there any PED? 845/2016 41.9 842/2016 41.8 0.91 (0.47 to 1.79) 0.786
Has it increased since baseline? 311/845 36.8 392/842 46.6 – –
Is there blood? 150/2016 7.4 194/2016 9.6 1.56 (1.00 to 2.44) 0.048
New or increased since baseline? 126/150 84.0 146/194 75.3 – –
Are there exudates? 152/2016 7.5 380/2016 18.8 3.10 (1.58 to 6.08) < 0.001
New or increased since baseline? 38/152 25.0 87/380 22.9 – –
a Table 13 shows the frequencies with which lesions components were identified by the experts.
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Confidence ratings
The confidence ratings displayed in Table 10 show that ophthalmologists were clearly more confident in
their decisions than optometrists. Ophthalmologists stated that they were very confident (5 on the rating
scale) in their judgements for 1175 out of 2016 (58.3%) vignettes, whereas optometrists reporting the
same level of confidence in their judgements for only 575 out of 2016 (28.5%) vignettes (OR 0.15,
95% CI 0.07 to 0.32; p < 0.001). For both groups, a confidence rating of 5 resulted in a correct answer
over 90% of the time, but there did not appear to be any clear relationship between confidence and
correctness for lower confident ratings, especially for optometrists (see Table 10).
3.10 (1.58 to 6.08)
1.56 (1.00 to 2.44)
0.91 (0.47 to 1.79)
3.46 (2.09 to 5.71)
1.00 (0.61 to 1.65)
1.73 (1.21 to 2.48)
p = 0.001
p = 0.048
p = 0.786
p < 0.001
p = 0.984
p = 0.002
Exudates
Blood
PED
DRT
IRC
SRF
0.06 0.12 0.25 0.5 1 2 4 8 16
OR (95% CI)
reported lesion component present
More ophthalmologists More optometrists
FIGURE 6 Lesion components. Point estimates for different lesion components are ORs and error bars are 95% CIs.
The vertical dashed line illustrates line of no difference at 1.
TABLE 10 Confidence in classification of activity status of lesions by professional group
Secondary outcomes
Ophthalmologists (n= 48) Optometrists (n= 48)
OR (95% CI) p-valuen/N (observations) % n/N (observations) %
Confidence rating
1 7/2016 0.3 52/2016 2.6 0.15 (0.07 to 0.32)a < 0.001
2 26/2016 1.3 140/2016 6.9
3 220/2016 10.9 496/2016 24.6
4 588/2016 29.2 753/2016 37.4
5 1175/2016 58.3 575/2016 28.5
Correct lesion classifications for each confidence ratingb
1 3/7 42.9 42/52 80.8 – –
2 21/26 80.8 114/140 81.4 – –
3 147/220 66.8 362/496 73.0 – –
4 474/588 80.6 634/753 84.2 – –
5 1077/1175 91.7 550/575 95.7 – –
a Comparison of optometrists vs. ophthalmologists, odds of a confidence rating of 5 vs. a rating of 1–4.
b For example, of the seven vignettes which ophthalmologists gave a confidence rating of 1, three were correct with
respect to the primary outcome.
DOI: 10.3310/hta20800 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 80
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Reeves et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
25
Key vignette information
It was stated in the protocol that the effect of key vignette features on correct reactivation decisions would
be assessed. For interpretability we modelled the effect of these features on the number of incorrect
classifications.
The influence of vignette features was investigated using Poisson regression, adjusting for the reference
standard classification. Interactions between these vignette characteristics and professional group were
tested but were not retained as they were not statistically significant at the 5% level. The outcome of this
analysis can be seen in Figure 7: professional group, gender, cardiac history and age did not significantly
influence the number of incorrect classifications. In contrast, the reference standard classification, smoking
status and BCVA sum and difference were all statistically significant (p < 0.001, p = 0.005, p = 0.001 and
p = 0.004, respectively). Vignettes of current smokers were more likely to be incorrectly classified than
non-smokers, but differences between ex-smoker and non-smoker vignettes were not found [incidence
rate ratio (IRR) 1.33, 95% CI 1.05 to 1.70, and IRR 0.91, 95% CI 0.76 to 1.10, respectively]. Vignettes
with better BCVA (larger average BCVA over the two visits) were less likely to be incorrectly classified
(IRR 0.996, 95% CI 0.993 to 0.998), while vignettes with a greater increase in BCVA from baseline to
index visit were more likely to be incorrectly classified (IRR 1.017, 95% CI 1.005 to 1.028). Vignettes
classified as reactivated by the reference standard were more likely to be incorrectly classified (IRR 3.16,
95% CI 2.62 to 3.81); this finding was in agreement with the raw data displayed in Figure 5 (noting that,
in the two right-hand columns, classifications of quiescent and suspicious should be pooled for the total
percentage correct).
Sensitivity analysis
For the primary outcome, a vignette classification was defined as ‘correct’ if both the reference standard
and the participant classified the vignette as ‘reactivated’ or if both classified a vignette as ‘suspicious’/
1.017 (1.005 to 1.028); p = 0.004
0.996 (0.993 to 0.998); p = 0.001
1.000 (0.987 to 1.014); p = 0.964
0.897 (0.721 to 1.116); p = 0.325
1.334 (1.048 to 1.699)
0.913 (0.757 to 1.101); p = 0.005
0.915 (0.766 to 1.092); p = 0.327
3.160 (2.618 to 3.814); p < 0.001
1.081 (0.920 to 1.271); p = 0.342
BCVA difference
BCVA sum
Age (years)
Cardiac history
No cardiac history
Current smoker
Ex-smoker
Never smoked
Female
Male
RS reactivated
RS Quiescent/suspicious
Optometrists
Ophthalmologists
0.5 1 2 4
IRR (95% CI)
Less incorrect
 responses
More incorrect
 responses
FIGURE 7 Influence of key vignette information. Cardiac history included angina, myocardial infarction and/or
heart failure. Point estimates show IRRs and error bars are 95% CIs. Line of no difference is illustrated by the
vertical dashed line at 1. For items of information with multiple categories, p-values are for tests across all
categories. RS, reference standard.
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’quiescent’. A sensitivity analysis of the primary outcome was performed in which suspicious classifications
were grouped with reactivated classifications instead of quiescent classifications. In this analysis,
ophthalmologists correctly classified 1756 out of 2016 (87.1%) vignettes and optometrists correctly
classified 1606 out of 2016 (79.7%). This difference was statistically significant (OR 0.51, 95% CI 0.38 to
0.67; p < 0.001), but the lower end of the CI did not cross the non-inferiority margin (0.298). Therefore,
when correct classifications were redefined in this way, optometrists were statistically inferior but clinically
non-inferior to ophthalmologists.
Additional (post-hoc) analyses
Vignette classifications compared with referral recommendations
It was of interest to see how lesion classification decisions related to referral decisions. These should be
congruent (as referral decisions should be made based on classification decisions) but no such rules were
imposed in this trial. Table 11 illustrates that, as expected, lesions classified as reactivated were usually
paired with a recommendation for rapid referral to hospital (1679/1682, 99.9%) and lesions classified
as quiescent were usually paired with a recommendation for review in 4 weeks (1526/1604, 95.1%).
There was very little difference between the two professional groups in the extent to which lesion
classifications and referral decisions were paired. Lesions classified as suspicious were often paired with
a recommendation for review in 2 weeks (605/746, 81.1%), but rapid referral to hospital was not
uncommon (131/746, 17.6%). Optometrists more often than ophthalmologists tended to pair suspicious
classifications with review in 2 weeks (87.3% vs. 74.4%), whereas ophthalmologists tended to pair
suspicious classifications with rapid referral to hospital more often than optometrists (24.8% vs. 10.9%).
Duration of vignette assessment
The assessment durations were calculated for each participant as the difference between the time an
assessment was saved and the time the previous assessment was saved. Therefore, this information was
not available for all 4032 assessments because many participants took breaks between assessments
(see Chapter 2, Missing data). The median durations of vignette assessment for all main study assessments
were 2 minutes 21 seconds (IQR 1 minute 39 seconds to 3 minutes 27 seconds; n= 1835) for ophthalmologists
and 3 minutes 2 seconds (IQR 2 minutes 5 seconds to 4 minutes 57 seconds; n= 1758) for optometrists.
TABLE 11 Referral recommendation by lesion classification decision
Referral decisions by
lesion classification
Ophthalmologists (n= 48) Optometrists (n= 48) Overall (n= 96)
n/N (observations) % n/N (observations) % n/N (observations) %
Reactivated
Refer to hospital 771/772 99.9 908/910 99.8 1679/1682 99.8
Review in 2 weeks 0/772 0.0 2/910 0.2 2/1682 0.1
Review in 4 weeks 1/772 0.1 0/910 0.0 1/1682 0.1
Suspicious
Refer to hospital 89/359 24.8 42/387 10.9 131/746 17.6
Review in 2 weeks 267/359 74.4 338/387 87.3 605/746 81.1
Review in 4 weeks 3/359 0.8 7/387 1.8 10/746 1.3
Quiescent
Refer to hospital 1/885 0.1 1/719 0.1 2/1604 0.1
Review in 2 weeks 44/885 5.0 32/719 4.5 76/1604 4.7
Review in 4 weeks 840/885 94.9 686/719 95.4 1526/1604 95.1
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Assessment time, on average, reduced as experience increased, especially in the optometrists group; for
ophthalmologists and optometrists respectively, the median assessment durations were 2 minutes 44 seconds
(IQR 2 minutes 3 seconds to 4 minutes 40 seconds; n= 45) and 5 minutes 23 seconds (IQR 3 minutes 18 seconds
to 10 minutes 3 seconds; n= 41) for the second main study vignette, and 1 minute 55 seconds (IQR 1 minute
19 seconds to 2 minutes 49 seconds; n= 48) and 2 minutes 31 seconds (IQR 1 minute 52 seconds to 4 minutes
26 seconds; n= 48) for the 42nd (final) main study vignette. Figure 8 shows this relationship.
Among vignette assessments for which duration was not missing, there were 1570 out of 1835 (85.6%)
correct responses by ophthalmologists and 1492 out of 1758 (84.9%) correct responses by optometrists.
Figure 9 illustrates the relationship between assessment duration and the percentage of correct responses;
broadly speaking, shorter assessment durations were more likely to result in correct lesion assessments
than longer assessment durations. This relationship was similar for both professional groups.
Expert classifications for derivation of the reference standard
Each expert individually assessed the vignettes in order to develop the reference standard (see Chapter 2,
Reference standard). The lesion classifications of the three experts were congruent for these assessments
for 219 out of 288 (76.0%) vignettes (comprising 103 out of 219 classifications of reactivated and 116 out
of 219 classifications of quiescent). The three experts then held a consensus meeting and jointly assessed
the vignettes for which there was disagreement about the lesion classification. The presence or absence of
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FIGURE 8 Duration of vignette assessment. Point estimates show median assessment durations and error bars
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FIGURE 9 Correct responses by vignette assessment duration. Point estimates show the percentage of correct
assessments and errors bars show exact 95% CIs.
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lesion components in index images of these vignettes, and their change from baseline, were discussed in
detail. Consensus lesion classifications were agreed which, together with the congruent classifications,
made up the final reference standard. Experts did not attempt to reach consensus about specific lesion
components. A few specific vignettes were reassessed by experts who felt that they had made errors about
the lesion components in their original assessments. When carrying out these reassessments, data were
collected only for assessments of the lesion components.
Table 12 shows the reference standard classification against each expert’s initial individual classification;
774 out of 864 (89.6%) of the individual classifications remained unchanged, with the rest (10.4%)
being amended after group discussions. The responses that did not change are shaded green. The majority
of the changed classifications involved an initial classification of suspicious by one expert.
Comparing lesion component classifications across experts
Although a reference standard was established for the overall lesion classification, no such standard was
established for the lesion component classifications. Therefore, it was of interest to compare lesion
component classifications across experts for the six lesion components. The experts could classify each
lesion component as absent, present but not increased since baseline, or present and increased since baseline.
The frequencies with which each expert identified different lesion components across all vignettes are shown
in Table 13. Agreement between experts with respect to lesion components is shown in Table 14. Table 14
shows that agreement was best for blood and exudates; the three experts agreed about blood classification
for 266 out of 288 (92.4%) vignettes and for exudate classification for 260 out of 288 (90.3%) vignettes.
Table 13 shows that experts observed no blood or exudates on the about colour images of > 90% of the
vignettes. Agreement for SRF and IRC was also high, with total agreement for 259 out of 288 (89.9%)
and 243 out of 288 (84.4%) of the vignettes, respectively (see Table 14). Interestingly, for both these
components, expert 2 disagreed with the other two experts slightly more often than experts 1 and 3 did
with each other; Table 13 shows that expert 2 identified SRF to be present more often than experts 1 and 3,
and identified IRC to be present less often than experts 1 and 3. Agreement between experts was lower for
DRT and PED than for the other components, suggesting that classification of these components was
potentially more difficult or less clear-cut. In addition, Table 14 shows the agreement between the experts
about the overall lesion classification, prior to any discussions to agree the reference standard.
TABLE 12 Reference standard compared with initial expert classification
Individual experts
Reference standard
Agreement (%)Reactivated (n= 142) Suspicious (n= 5) Quiescent (n= 141)
Expert 1
Reactivated 131 1 4 89.9
Suspicious 6 4 13
Quiescent 5 0 124
Expert 2
Reactivated 110 0 0 86.1
Suspicious 14 0 3
Quiescent 18 5 138
Expert 3
Reactivated 134 1 5 92.7
Suspicious 3 3 6
Quiescent 5 1 130
Responses that did not change are shaded green.
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TABLE 13 Lesion component classifications of individual experts
Lesion component Absent, n (%)
Present but not
increased, n (%)
Present and increased
since baseline, n (%)
SRF
Expert 1 222 (77.1) 0 (0.0) 66 (22.9)
Expert 2 197 (68.4) 3 (1.0) 88 (30.6)
Expert 3 220 (76.4) 0 (0.0) 68 (23.6)
IRC
Expert 1 193 (67.0) 9 (3.1) 86 (29.9)
Expert 2 206 (71.5) 12 (4.2) 70 (24.3)
Expert 3 190 (66.0) 6 (2.1) 92 (31.9)
DRT
Expert 1 189 (65.6) 6 (2.1) 93 (32.3)
Expert 2 237 (82.3) 5 (1.7) 46 (16.0)
Expert 3 252 (87.5) 6 (2.1) 30 (10.4)
PED
Expert 1 129 (44.8) 95 (33.0) 64 (22.2)
Expert 2 53 (18.4) 185 (64.2) 50 (17.4)
Expert 3 93 (32.3) 127 (44.1) 68 (23.6)
Blood
Expert 1 267 (92.7) 2 (0.7) 19 (6.6)
Expert 2 266 (92.4) 2 (0.7) 20 (6.9)
Expert 3 261 (90.6) 2 (0.7) 25 (8.7)
Exudates
Expert 1 266 (92.4) 13 (4.5) 9 (3.1)
Expert 2 279 (96.9) 7 (2.4) 2 (0.7)
Expert 3 283 (98.3) 1 (0.3) 4 (1.4)
TABLE 14 Comparison of lesion component classifications across experts
Lesion
component
All experts
agree, n (%)
Experts 1 and 2
agree (expert 3
differs), n (%)
Experts 1 and 3
agree (expert 2
differs), n (%)
Experts 2 and 3
agree (expert 1
differs), n (%)
None agree,
n (%)
Kappa
statistic, n
Overall lesion
classification
219 (76.0) 16 (5.6) 31 (10.8) 15 (5.2) 7 (2.4) 0.697
SRF 259 (89.9) 4 (1.4) 21 (7.3) 4 (1.4) 0 (0.0) 0.827
IRC 243 (84.4) 8 (2.8) 22 (7.6) 11 (3.8) 4 (1.4) 0.759
DRT 189 (65.6) 36 (12.5) 17 (5.9) 43 (14.9) 3 (1.0) 0.327
PED 134 (46.5) 23 (8.0) 55 (19.1) 67 (23.3) 9 (3.1) 0.420
Blood 266 (92.4) 7 (2.4) 6 (2.1) 9 (3.1) 0 (0.0) 0.660
Exudates 260 (90.3) 4 (1.4) 4 (1.4) 19 (6.6) 1 (0.3) 0.183
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Participants’ views on the ECHoES trial training
This section includes information provided by all participants who completed the questionnaire on
their opinions of the ECHoES trial training, regardless of whether or not they completed the study and
were included in the analysis population. A total of 102 participants completed the questionnaire:
47 ophthalmologists (44 of whom passed training and became main study participants) and 55 optometrists
(47 of whom passed training and became main study participants).
Overall, participants gave positive feedback about the training. In particular, both the ophthalmologists and
the optometrists commented on the thorough nature of the webinars and how helpful the trial staff were,
particularly the trial co-ordinator. Many optometrists were pleased to have taken part, finding the training
to be ‘very useful’ and noting that the training had improved their confidence.
Well designed, a lot of thought and hard work to set and to run.
Optom262
Extremely useful and well structured.
Ophthalm131
I learnt a lot and am pleased I took the opportunity to take part.
Optom269
Table 15 shows that more ophthalmologists than optometrists found the web application harder to use.
Of those who provided free-text responses, the majority (both ophthalmologists and optometrists)
commented on the content of the training. Specifically, 10 participants felt that the quality of the OCT
images was poor. Eight participants (five of whom were optometrists) also commented that it would have
been helpful to have a side-by-side comparison of baseline and index images on the same screen, as it was
difficult and time-consuming to have to change back and forth between images. Three participants
commented that they used two different screens alongside each other to overcome this.
Some of the images were difficult to view as they were of poor quality.
Optom254
I found it time-consuming changing between the baseline and index scans. I speeded up once I solved
this by having one set on my iPad® and one set on my monitor.
Optom268
Only issue I had was that we were unable to compare the baseline and index images side by side
which made assessing more difficult.
Optom225
Table 15 shows that 78% of optometrists felt that additional training may be required, compared with
only 30% of ophthalmologists. One ophthalmologist and five optometrists elaborated on this, stating that
they had found the content of the webinars to be confusing (particularly in terms of the questions about
lesion components), and one ophthalmologist and three optometrists said they had found the
training challenging.
Uncertainty about the some of the decisions I was making – not good for the nerves!
Optom256
Questions sometimes were confusing.
Ophthalm102
DOI: 10.3310/hta20800 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 80
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Reeves et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
31
It was really challenging . . . you really had to think.
Ophthalm107
Years of ophthalmic experience did not appear to influence how well the training was received;
ophthalmologist participants who felt that additional training was required had a median of 9.6 years of
experience (IQR 4.6–15.3 years of experience), whereas ophthalmologist participants who felt training
was completely sufficient had a median of 11.0 years of experience (IQR 5.6–16.1 years of experience).
Almost all optometrists (96%) stated that they had revisited the webinar content, compared with half of
ophthalmologists (49%; see Table 15). On average, the optometrists also spent over 1 hour longer
revisiting the material than the ophthalmologists. Only 11% of ophthalmologists said that they had used
other resources, compared with 67% of optometrists. Most participants used websites (25%) or a
textbook (20%), had discussions with colleagues (6%) or looked through previous conference notes (3%).
With respect to textbooks, the majority of participants had used Clinical Ophthalmology by Kanski
and Bowling.27
TABLE 15 Participants’ opinions on the ECHoES trial training
ECHoES trial training feedback Ophthalmologists (n= 47) Optometrists (n= 55)
What did you think of the training?
Excellent, n/N (%) 11/47 (23.4) 4/55 (7.3)
Very good, n/N (%) 17/47 (36.2) 17/55 (30.9)
Good, n/N (%) 15/47 (31.9) 18/55 (32.7)
Fair, n/N (%) 4/47 (8.5) 11/55 (20.0)
Poor, n/N (%) 0/47 (0.0) 5/55 (9.1)
Very poor, n/N (%) 0/47 (0.0) 0/55 (0.0)
How easy did you find the web application to use?
Very easy, n/N (%) 23/47 (48.9) 22/55 (40.0)
Easy, n/N (%) 20/47 (42.6) 23/55 (41.8)
Neutral, n/N (%) 2/47 (4.3) 7/55 (12.7)
Difficult, n/N (%) 2/47 (4.3) 2/55 (3.6)
Very difficult, n/N (%) 0/47 (0.0) 1/55 (1.8)
Was the training sufficient?
Completely sufficient, n/N (%) 33/47 (70.2) 6/55 (10.9)
Additional training required, n/N (%) 14/47 (29.8) 43/55 (78.2)
Completely different training required, n/N (%) 0/47 (0.0) 6/55 (10.9)
Did you revisit webinars?
Did not revisit, n/N (%) 24/47 (51.1) 2/55 (3.6)
Did revisit, n/N (%) 23/47 (48.9) 53/55 (96.4)
If revisited, how long for? (hours), median (IQR) 1 (1, 2) 3 (2, 3)
Did you use other resources?
Did not use other resources, n/N (%) 42/47 (89.4) 18/55 (32.7)
Did use other resources, n/N (%) 5/47 (10.6) 37/55 (67.3)
If other resources used, how long for (hours)?, median (IQR) 3 (1–3) 3 (2–4)
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Chapter 4 Results: health economics (objective 4)
Resource use and unit costs
Tables 16–22 present the main results of the analysis of resource use and costs. In summary, Tables 16 to
19 present resource-use results, with Table 20 providing information on most of the unit costs which
would be added to the resource-use information, and staff unit cost information is presented in the next
table (Table 21). The resource-use and unit cost information are combined and presented in Table 22,
which reports the cost of a monitoring review performed by community optometrists.
More specifically, Table 16 shows the mean numbers of equipment items which the community
optometrists stated that they already had in their practices when they completed the online resource
questionnaire. Although most practices had a CF camera, fewer than half had a projector which includes
an ETDRS (Early Treatment of Diabetic Retinopathy Study) chart or a retro-illuminated light box.
In terms of floor space, the respondents said that the average floor space was 173m2 and the average
number of rooms in the practice was 3.5 (SD 2.20 rooms). Of the 39 community optometrists who replied
to the question about the need to make modifications to their premises in order to assess nAMD patients,
just over 50% said that they would need to do so (mean 0.54, SD 0.505).
TABLE 16 Optometrist capital (equipment and building) resources
Resource item Number of responses Mean number (SD)
Building
Approximate size (floor space, m2) 27 173.10 (266.37)
Approximate size (number of rooms) 40 3.5 (2.20)
Equipment for monitoring review
Number of items of
equipment
Mean number per
practice (SD)
ETDRS visual acuity charts (e.g. Lighthouse Inc.):
4-m viewing distance required (with/without mirrors)
40 0.575 (0.984)
Projector that includes ETDRS chart 39 0.46 (0.756)
Retro-illuminated light box 39 0.49 (1.022)
Trial frame 40 2.225 (1.230)
Lens set 40 2 (0.905)
Light meter to measure luminance (e.g. Sper Scientific) 40 0.1 (0.304)
Slit lamp 40 1.75 (0.776)
CF camera 39 0.72 (0.456)
OCT acquisition system 37 0.22 (0.417)
OCT acquisition system with fundus photography
included as a component
38 0.342 (0.481)
Computer 39 4.92 (3.382)
Computer networka 40 0.63 (0.490)
Printer 40 2.73 (1.66)
ETDRS, Early Treatment of Diabetic Retinopathy Study.
a Maximum of one network included per practice.
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In terms of staffing resources, Table 17 presents a breakdown of activities for the monitoring review, the
staff members who would perform the various tasks and the average predicted time for the tasks. The
optometrists said that they would always take a patient history, carry out a clinical examination and make
the final assessment, and that they would be largely responsible for other activities such as undertaking
OCTs; pre-registration optometrists and other support staff could help in some of these other activities.
The optometrists stated that they expected to book appointments for patients only rarely, as this activity
was mainly done by clerical/administrative staff.
TABLE 17 Staff performing each task and average duration of each task
Role in monitoring
review
Main member of staff
performing task (%)
Other staff performing
task (%)
Mean durationa
in minutes (SD)
Number of
responses
Taking patient history Optometrist (100) Pre-registration optometristb 4 (1.50) 40
Clinical examination: slit
lamp biomicroscopy,
anterior segment and
macula
Optometrist (100) Pre-registration optometristb 4 (1.50) 40
Visual acuity assessment Optometrist (95) Pre-registration optometrist,
optical assistant (5%)
8 (2.98) 38
Administration of 1%
tropicamide drops
Optometrist (92.5) Pre-registration optometrist,
optical assistant (7.5%)
1 (0.37) 37
CF photography (or
equivalent CF image)
Optometrist (67.5) Pre-registration optometrist,
optical assistant, clerical/retailer
staff, practice manager other
administrative staff (32.5%)
4 (1.38) 27
Spectral domain OCT Optometrist (67.5) Pre-registration optometrist,
optical assistant, clerical/retailer
staff, practice manager other
administrative staff (32.5%)
4 (1.35) 27
Final assessment Optometrist (100) Not applicable 5 (1.88) 40
Update Optometrist (77.5) Pre-registration optometrist,
optical assistant, clerical/retailer
staff, practice manager other
administrative staff (22.5%)
2 (0.73) 31
Booking appointments Optometrist (2.5) Pre-registration optometrist,
optical assistant, clerical/retailer
staff, practice manager other
administrative staff (97.5%)
1 (not applicable) 1
a Based on optometrist report of duration of the whole monitoring consultation and expert advice on the percentage of
time devoted to each task.
b Pre-registration optometrist could replace main optometrist in this task.
TABLE 18 Time spent by optometrists on revisiting webinars and consulting other resources
Time spent
Number of optometrists revisiting
webinars (% of observations)
Number of optometrists consulting
other resources (% of observations)
Up to 30 minutes 4 (8) 4 (11)
30 minutes to 1 hour 16 (30) 13 (34)
1–2 hours 21 (40) 10 (26)
2–4 hours 9 (17) 8 (21)
> 4 hours 3 (6) 3 (8)
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TABLE 19 Time spent by ophthalmologists on revisiting webinars and consulting other resources
Time spent
Number of ophthalmologists revisiting
webinars (% of observations)
Number of ophthalmologists consulting
other resources (% of observations)
Up to 30 minutes 13 (57) 3 (38)
30 minutes to 1 hour 5 (22) n/a
1–2 hours 4 (17) 4 (50)
2–4 hours n/a n/a
> 4 hours 1 (4) 1 (12)
Number of observations 23 8
n/a, not applicable.
TABLE 20 The ECHoES trial unit costs (2013/14 prices unless otherwise stated)
Unit cost (£)
Item
Unit
cost (£) Source Notes
ETDRS visual acuity
charts – 4-m viewing
distance required
83.00 Expert’s opinion,a recommended website:
http://sussexvision.co.uk/index.php/
distance-tests/logmar-charts/4-metre-
viewing/logmar-4m-etdrs-chart-r-original.
html (accessed 30 September 2014)
Sussex Vision item. The ECHoES trial
protocol requires three of them: one for
doing the refraction, one for the right
eye and one for the left eye
Projector that includes
ETDRS chart
2850.00 Personal communication with Topcon
(2014)b
Model: 1240263 CC-100XP LED with
remote control
Retro-illuminated light
box
878.00 Expert’s opinion,a recommended website:
http://sussexvision.co.uk/index.php/
distance-tests/logmar-test-types/
precision-vision-logmar-cabinet.html
(accessed 30 September 2014)
Sussex Vision item
Bulb for retro-
illuminated light box
15.00 Expert’s opinion,a recommended website:
http://sussexvision.co.uk/index.php/
distance-tests/logmar-test-types/tube-for-
sdt-396-lpv-cabinet-without-diffuser.html
(accessed 30 September 2014)
Sussex Vision item. Two bulbs: bulb
needs to be replaced every 2 years for
each chart
Trial frame 375.00 Expert’s opinion,a recommended website:
www.opticalmarketplace.co.uk/new-
equipment/optical-equipment/trial-
frames/omp1559/oculus-ub4-trial-frame/
(accessed 30 September 2014)
Optical Marketplace item
Lens set 475.00 Expert’s opinion,a recommended website:
www.opticalmarketplace.co.uk/new-
equipment/optical-equipment/trial-lens-
sets/omp1464/quality-trial-lens-set/
(accessed 30 September 2014)
Optical Marketplace item
Light meter to
measure luminance
(e.g. Sper Scientific)
120.00 Expert’s opinion,a recommended
website: www.coleparmer.co.uk/Product/
Sper_Scientific_840006_Light_Meter_
with_Analog_Output/UY-01588-24?
referred_id=3482&gclid=
CKX6m8PjiMECFUn3wgodxJYA6Q
(accessed 30 September 2014)
Cole Parmer item
continued
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TABLE 20 The ECHoES trial unit costs (2013/14 prices unless otherwise stated) (continued )
Unit cost (£)
Item
Unit
cost (£) Source Notes
Slit lamp 4000.00 Expert’s opiniona Estimate
Computer 549.00 www.dell.com/uk/business/p/desktops-n-
workstations.aspx?c=uk&l=en&s=bsd&
∼ck=mn (accessed 1 October 2014)
Dell desktop OptiPlex 9020
Computer network 1000.00 Expert’s opinionc confirming estimates
at www.itdonut.co.uk/it/communications/
networking (accessed 29 September 2014)
Guide price to build a simple network of
up to 10 computers
Printer 155.00 http://accessories.euro.dell.com/sna/sna.
aspx?c=uk&cs=ukdhs1&l=en&s=dhs&
∼topic=printer_shopall_lasers (accessed
1 October 2014)
Dell C1660w colour printer
Eye drops,
tropicamide 1%
0.50 British National Formulary28 Single use – net price 20 × 0.5 ml
= £10.00
Consultant 139.00 Unit Costs of Health and Social Care
201329
PSSRU table 15.5; consultant: medical.
Cost including qualifications
Ranibizumab (dose of
0.5 mg)
742.00 British National Formulary28 –
Aflibercept 816.00 British National Formulary28 –
Bevacizumab (dose of
1.25 mg)
49.00 Dakin et al. (2014)25 Price typically charged by the not-for-
profit NHS provider used in the IVAN trial
(£49/prefilled syringe)
Ratio
Type of ratio Ratio Source Notes
Ratio ‘salary oncost/
salary’
0.234 Unit Costs of Health and Social Care
201329
PSSRU table 9.1; community
physiotherapist. Ratio applied to salary as
reported by participant to the Health
Economics Questionnaire
Ratio ‘qualification/
salary’
0.237 Unit Costs of Health and Social Care
201329
PSSRU table 9.1; community
physiotherapist. Ratio applied to salary as
reported by participant to the Health
Economics Questionnaire
Ratio ‘overheads/
salary’
0.756 Unit Costs of Health and Social Care
201329
PSSRU table 9.1; community
physiotherapist. Ratio applied to salary as
reported by participant to the Health
Economics Questionnaire
Ratio ‘capital
overheads/salary’
0.093 Unit Costs of Health and Social Care
201329
PSSRU table 9.1; community
physiotherapist. Ratio applied to salary as
reported by participant to the Health
Economics Questionnaire
ETDRS, Early Treatment of Diabetic Retinopathy Study; PSSRU, Personal Social Services Research Unit.
a Expert’s opinion from personal communication (Dr Ruth Hogg, Institute of Clinical Science, Queen’s University
Belfast, 2014).
b Personal communication with Topcon (sales manager, Topcon Europe BV T/A Topcon Ireland, 2014).
c Expert’s opinion from personal communication (university IT officer, University of Oxford, 2014).
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Tables 18 and 19 present information on the number of times that optometrists and ophthalmologists
revisited the webinars and consulted other resources. As already described (see Chapter 3, Participants’
views on ECHoES trial training), the ophthalmologists were less likely to revisit the webinars or seek out
other sources of information, which might be predicted given that they have more experience than
optometrists in caring for nAMD patients.
The medical retina experts spent 30 hours preparing and delivering the webinar training for the
ECHoES trial (i.e. 15 hours for preparing the webinars, 5 hours for agreeing on the content of webinars
and 10 hours for delivering the webinars to the participants).
Table 20 provides a summary of the unit costs which were attached to the resource-use information above.
In terms of unit cost information on salaries for staff working in community optometrist practice, Table 21
provides a breakdown of the salary bands for different types of staff.
TABLE 22 Cost of a monitoring review performed by community optometrists
Cost items Mean cost, £ (SD)
Equipment 22.99a (5.552)
Refurbishment/building/rent 0.05 (0.147)
Staff labour 27.26 (7.317)
Preparation and delivery of webinar training 0.13 (0.101)
Optometrist’s time on training 0.89 (1.080)
Eye drops, tropicamide 1% 0.50 (n/a)
Total cost per monitoring review 51.82 (8.153)
n/a, not applicable.
a The figure for ophthalmologist cost of purchasing and setting up equipment and facilities was £2 per patient, with much
of the remaining costs making up the £75.60 attributed to staff labour.
TABLE 21 Salaries of staff employed in optometrist practices
Salary band Optometrist
Pre-registration
optometrist
Optical
assistant
Clerical/retailer
staff
Practice
manager
Other
administrative
staff
Less than £20,000 4 5 24 14 3 10
£20,000–29,999 2 n/a 4 2 5 2
£30,000–39,999 9 n/a n/a n/a 6 n/a
£40,000–49,999 9 n/a n/a n/a n/a n/a
£50,000–59,999 10 n/a n/a n/a n/a n/a
£60,000–69,999 4 n/a n/a n/a n/a n/a
£70,000–79,999 1 n/a n/a n/a n/a n/a
£80,000 per year or
more
1 n/a n/a n/a n/a n/a
Observations 40 5 28 16 14 12
n/a, not applicable.
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Table 22 shows the combination of resource-use and unit cost information which produces the cost for
each of the cost categories. The table also shows the sum of these categories, which leads to the total
average cost per optometrist monitoring review equal to £51.82 per review (SD £8.153 per review). This
sum compares to the average cost of £75.60 (SD £44.31) for ophthalmologists performing a monitory
review, as costed in the IVAN trial. The cost of purchasing and setting up equipment and facilities
accounted for £2 per patient, with staff labour accounting for much of the rest of the remaining cost
of ophthalmologist-based monitoring reviews.
Cost-effectiveness of monitoring by optometrists compared
with ophthalmologists
The care pathway cost table (see Table 23) shows the cost and effect information combined, highlighting
the impact that incorrect assessments could have on costs. The pathway includes the cost of a monitoring
consultation itself and also downstream costs (e.g. ranibizumab injections and follow-up visits based on
the care cost pathway decision tree).
Table 23 shows that, of the vignettes that experts rated as reactivated, the optometrists made more
correct decisions than the ophthalmologists (39.43% compared with 36.51%) and were less likely to
misclassify reactivated lesions as suspicious or quiescent. When optometrists correctly judge the lesion as
reactivated, the patient needs to be referred for another monitoring review at the hospital eye clinic before
actually receiving treatment (anti-VEGF injection). There were 795 vignettes assessed in this category for
the optometrists (39.43%) and only 736 (36.51%) for the ophthalmologists. There are two points to note
here. First, if the optometrist is correct in his or her diagnosis in the model of care delineated in this study,
the additional cost for an ophthalmologist-led monitoring review will represent an unnecessary cost.
However, if the optometrist is incorrect then the further ophthalmologist-led monitoring review will
represent a cost saving because in our model of care we assume that the ophthalmologists are able to
detect the mistake and, therefore, the patient will not undergo the unnecessary treatment. Second,
and inversely to the optometrist case, when an ophthalmologist says that a patient requires treatment
there is not a second monitoring review; the patient simply continues to have their treatment, thereby
directly incurring costs. This represents a cost saving with respect to the optometrist care model if the
ophthalmologist’s diagnosis is correct (cost of a second monitoring review avoided), but will instead
represent an additional unnecessary cost in the event that the patient undergoes unnecessary treatment.
Of the vignettes that experts rated as suspicious, 10 (0.50%) were incorrectly classed as reactivated
observations in this category for the optometrists, compared with only one (0.05%) in the ophthalmology
group. In this case, the second monitoring review in the optometrists’ pathway is actually helpful, as it
can prevent unnecessary treatment. However, if we assume that this ophthalmologist would go on to
provide treatment when the patient did not need it, this would cost £877 compared with only £118 for
an optometrist making an incorrect decision here (this figure is the cost of optometrist review, plus the
cost of an ophthalmologist review).
For the truly quiescent vignettes that the health professional incorrectly assesses as reactivated, the
ophthalmologists go ahead with treatment, whereas the optometrists will refer a patient to the HES where
the mistake will be identified before treatment is given. However, although the cost consequences of
incorrectly rating quiescent eyes as reactivated are much smaller for optometrists than for ophthalmologists,
optometrists are three times more likely to make this error. For cases where participants correctly rate the
vignette as suspicious, only the routine monitoring review is considered here, as both optometrists and
ophthalmologists will recommend a subsequent routine check, so options will be cheaper for optometrists
than ophthalmologists in this case, reflecting the differential in cost between the two professionals. A similar
pathway is implemented in ‘suspicious’ cases incorrectly rated as ‘quiescent’.
Table 24 presents the base-case analysis of the cost-effectiveness of optometrists compared with
ophthalmologists in performing monitoring reviews. The cost of a monitoring review is based on an average
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TABLE 23 Care pathways costs: base-case analysis
Lesion status assessment Observations (% of total) Pathways cost (£),a mean (SD)
Experts (true) Optometrists’ decision
Reactivated Reactivated 795 (39.43) 935.40 (45.50)
Reactivated Suspicious 142 (7.04) 103.61 (18.51)
Reactivated Quiescent 57 (2.83) 51.29 (9.08)
Suspicious Reactivated 10 (0.50) 118.12 (16.39)
Suspicious Suspicious 11 (0.55) 57.04 (9.10)
Suspicious Quiescent 14 (0.69) 52.96 (9.37)
Quiescent Reactivated 105 (5.21) 117.14 (32.61)
Quiescent Suspicious 234 (11.61) 78.31 (11.53)
Quiescent Quiescent 648 (32.14) 51.98 (8.23)
Total – 2016 (100) –
Experts (true) Ophthalmologists’ decision
Reactivated Reactivated 736 (36.51) 882.67 (46.41)
Reactivated Suspicious 196 (9.72) 153.18 (92.25)
Reactivated Quiescent 62 (3.08) 77.01 (45.49)
Suspicious Reactivated 1 (0.05) 877.38 (n/a)
Suspicious Suspicious 17 (0.84) 68.84 (31.00)a
Suspicious Quiescent 17 (0.84) 60.57 (17.16)a
Quiescent Reactivated 35 (1.73) 882.29 (38.00)
Quiescent Suspicious 146 (7.24) 150.34 (95.19)
Quiescent Quiescent 806 (39.98) 75.28 (44.72)
Total – 2016 (100) –
a Pathways cost includes the cost of a monitoring consultation and downstream costs (e.g. injections and follow-up visits).
The single consultation figures are not equal to the cost of one monitoring review for the IVAN trial, which was £71
because of the random assignment of costs, as described in Chapter 2, Economic evaluation methods.
Reproduced open access from Violato et al.16 under the terms of the Creative Commons Attribution (CC BY 4.0) licence.
TABLE 24 Base-case analysis of cost-effectiveness of monitoring review performed by optometrists versus cost of a
monitoring review performed by ophthalmologists
Costs and effects
Optometrists
(observations, n= 2016)
Ophthalmologists
(observations, n= 2016)
Cost of a monitoring review (£), mean pathway cost (SD) 410.78 (424.92) 397.33 (387.46)
Mean proportion of correct assessments (SD) 0.844 (0.363) 0.854 (0.353)
Incremental cost (£) (95% CI) 13.45 (–17.96 to 44.85)
Incremental benefit, proportion of correct assessments
(95% CI)
–0.0099 (–0.045 to 0.025)
ICER, incremental cost per correct assessmenta Dominated
a The 95% CI around the ICER could not be defined.
Reproduced open access from Violato et al.16 under the terms of the Creative Commons Attribution (CC BY 4.0) licence.
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of the patient cost pathways in the previous table (unweighted according to the most likely pathways).
The table shows that the mean care pathway cost for each assessment is quite similar between groups,
at £410.78 for optometrists and £397.33 for ophthalmologists, producing an incremental cost difference
of £13.45 (95% CI £17.96 to £44.85). The higher cost for optometrists than for ophthalmologists may
reflect the fact that optometrists were more likely to incorrectly classify vignettes as reactivated, thereby
incurring higher unnecessary costs for the health service.
In terms of effectiveness information, the proportion of correct treatment decisions is also quite similar,
with around 85% of optometrists and ophthalmologists making correct decisions; ophthalmologists
made marginally more correct decisions, but this difference was not statistically significant. With higher
mean costs (albeit not statistically significant) and a lower proportion of correct treatment decisions
(albeit not statistically significant) differences between the groups, Figure 10 shows that the strategy
of optometrists performing monitoring reviews is dominated by ophthalmologist-led reviews, with
optometrist-led monitoring reviews being more costly and less effective. However, the differences are
extremely small: optometrist-led reviews increase the total costs by only £13 per review (3% of the total
cost of the care pathway) and result in only one more incorrect decision per 101 monitoring reviews
conducted. Furthermore, there is substantial uncertainty around this finding. The CEAC shown in Figure 11
shows that the probability that it is cost-effective for optometrists to perform monitoring reviews is below
30% regardless of how much we are willing to pay per correct decision. In fact, if the NHS is willing
to pay less than £600 per correct decision, which is likely to be the case, the probability that it is
cost-effective to conduct monitoring by community optometrists is 14% for willingness to pay equal
to £200 and 8% for willingness to pay equal to £600.
Thus, it appears that there is no willingness-to-pay level for which we can be 95% confident that the two
ways of performing a monitoring review differ in value; that is, they differ in terms of cost-effectiveness.
The CEAC in Figure 11 shows the probability that the optometrists are cost-effective compared with
ophthalmologists for a range of willingness-to-pay thresholds. If a decision-maker is willing to pay
£200 for an extra correct retreatment decision, then the probability of optometrists being cost-effective is
around 14%. The probability that optometrists are cost-effective changes little across a broad range of
willingness-to-pay thresholds, indicating that this probability is invariant to the willingness-to-pay threshold.
Figure 10 presents the cost-effectiveness plane and graphs the point estimate of the ICER and two
confidence ellipses, with the outer ellipse representing the 95% CI and the inner being the 85% confidence
ellipse for our base-case analysis. The figure shows that the 95% CI is not definable and there is no
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FIGURE 10 Optometrists vs. ophthalmologists cost-effectiveness plane.
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willingness-to-pay threshold for which we can be 95% confident that the optometrist-led and the
ophthalmologist-led monitoring reviews differ in value from each other. The widest definable Fieller
interval is 85% and the green line shows the tangent to the 85% confidence ellipse.
Sensitivity analyses
One-way sensitivity analyses investigated the impact of varying the way of delivering treatment for lesions
assessed as reactivated, which is one of the main cost drivers in our analysis. In the base-case analysis it
was assumed that treatment for an active lesion consisted of one ranibizumab injection given during an
injection consultation. In three of our sensitivity analyses, one ranibizumab injection was replaced with
alternative treatments to reflect new emerging practices across eye hospitals (sensitivity analyses 1 and 2)
and to make a comparison with a much cheaper drug assessed in the IVAN trial (sensitivity analysis 3):
l Sensitivity analysis 1: all patients in whom treatment for a reactivated lesion was initiated were
assumed to receive a course of three injections of ranibizumab at three injection consultations, with no
additional monitoring reviews. The ‘mandatory’ three injections, at monthly intervals, matched the
discontinuous treatment regimen administered in the IVAN trial (although in the IVAN trial monitoring
continued thereafter).
l Sensitivity analysis 2: treatment was assumed to be given in the form of one aflibercept injection during
an injection consultation.
l Sensitivity analysis 3: treatment consisted of one bevacizumab injection given during an
injection consultation.
l Sensitivity analysis 4: only considered the cost of a monitoring review rather than considering the cost
of the whole pathway.
Sensitivity analysis 1 (three ranibizumab injections and consultations) increases the costs of lesion care at the
eye hospital because more treatment and consultations are required and, once combined with data on the
consequences of retreatment decisions in our care pathways model, optometrists remained dominated,
although there remained very little difference in costs or effects between optometrists and ophthalmologists.
Akin to our base-case analysis, there was also no acceptable willingness-to-pay threshold for which we
can be 95% confident that the two alternative ways of performing a monitoring review differ in value.
A similar result was found for the sensitivity analysis that used aflibercept rather than ranibizumab for
treatment, which was predictable given that aflibercept is more expensive than ranibizumab. When
switching to the much cheaper bevacizumab (in place of ranibizumab), with a reduced cost of treatment,
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FIGURE 11 Cost-effectiveness acceptability curve. Reproduced open access from Violato et al.16 under the terms of
the Creative Commons Attribution (CC BY 4.0) licence.
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again very little difference was found in costs and effects difference across the two groups, with
optometrist-led reviews again being more costly and less effective than ophthalmologists-led monitoring
reviews. However, the fourth sensitivity analysis, which considered only the cost of the monitoring review,
rather than the total care pathway information, found that community optometrist-led care cost £23.70
less per consultation than ophthalmologist-led care (the difference between the crude consultation
costs, p < 0.001). As a result, optometrist-led care was less effective and significantly less costly than
ophthalmologist-led care. Ophthalmologist-led care cost an additional £2389 per additional correct
treatment decision compared with optometrist-led care. Although the maximum the NHS is willing to pay
for a correct retreatment decision is unknown, it is unlikely to be this high (since this figure is higher than
the cost of simply treating all patients without assessing whether or not the eye is quiescent). At ceiling
ratios of £600 or lower, we can be > 95% confident that optometrists are a cost-effective option compared
with ophthalmologists in this fourth sensitivity analysis. This final sensitivity analysis highlights how important
it was to have built a simple decision model to explore the consequences after the initial monitoring review
and not just use the information from the initial review. However, it also suggests that the conclusions may
be sensitive to the assumptions within the decision tree. The economic evaluation section in Appendix 3
presents the results of the sensitivity analysis in respect to the cost care pathways, cost-effectiveness analysis
and the respective cost-effectiveness planes for the four sensitivity analyses.
Budget impact
Data on the prevalence and incidence of nAMD (Table 25) were used to calculate that around 219,000
patients currently attend VEGF clinics in England in any given month, of which 52,000 (19%) have bilateral
disease (Table 26). In our budget impact calculations, we assumed that patients would be referred from
the HES to community optometrists for monitoring if they did not meet the IVAN retreatment criteria
1 month after finishing a course of anti-VEGF treatment. We assumed that patients with bilateral disease
would not be referred from the HES to community optometrists for monitoring if they met retreatment
criteria in either eye in the same month; the probability of meeting retreatment criteria was assumed to be
independent in the two eyes.
In the IVAN trial, 18% of study eyes in the discontinuous treatment arms completed a 3-month cycle of
treatment each month, of which 38% still met retreatment criteria at the next visit. The probability of
meeting retreatment criteria and the duration of quiescence were constant over the trial period; therefore,
no distinction was made between the first and subsequent years of treatment. Applying these figures
to the national patient numbers and allowing for patients with bilateral disease suggests that around
21,949 of the total of 219,514 patients currently attending clinics may be eligible for referral to community
optometry review each month (see Table 26), assuming that such referrals would occur in all patients who
are quiescent according to the IVAN trial criteria 1 month after their last anti-VEGF injection. In the IVAN
trial, quiescence lasted a median of 61 days; allowing for this duration and extrapolating monthly figures to
12 months suggests that 535,548 monitoring reviews could be done by community optometrists in England
(see Table 26) each year.
Applying the results of the ECHoES trial costing analysis suggests that the initial monitoring consultation is
£23.70 cheaper if performed by community optometrists rather than by hospital ophthalmologist-led
teams. Scaling this up across the 535,548 visits that could be transferred to community optometrists
suggests that initial savings of £12.7M could be made for the NHS in England. However, this figure takes
no account of the increased numbers of second monitoring reviews or additional intravitreal injections
that result from optometrist judgements. If we allow for the costs accrued from the entire pathway
(see Table 24), optometrist care is £13.45 more costly and therefore referring patients to community
optometry review will cost an additional £7.2M across England.
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TABLE 25 Data inputs for budget impact calculations
Data Value Source
Population of adults aged 50 years and over in
England
19,323,400 Population of England aged 50 years and over –
Office for National Statistics30
Prevalence of diagnosed nAMD among
over-50-year-olds
1.2% The estimated prevalence and incidence of late
stage age-related macular degeneration in the UK –
Owen et al.31
Percentage of diagnosed prevalent nAMD cases
starting anti-VEGF treatment
100% Assumption
Incidence of diagnosed nAMD among
over-50-year-olds
0.11% NICE TA294 macular degeneration (wet age-related) –
aflibercept: costing template32
Percentage of people eligible for treatment 80% NICE TA294 macular degeneration (wet age-related) –
aflibercept: costing template32
Percentage of prevalent cases with bilateral
nAMD
19% NICE TA294 macular degeneration (wet age-related) –
aflibercept: costing template32
Percentage of patients seen in clinic who finish a
course of treatment in month n
18% In the IVAN trial, proportion of months in which
patients in the discontinuous arm completed a
3-month cycle
Of those eyes completing a cycle of treatment at
visit n, what percentage remain quiescent at visit
n+ 1 (the month after the end of treatment)
62% In the IVAN trial, proportion of study eyes in the
discontinuous group becoming quiescent at visit
n+ 1 after completing a 3-month cycle of treatment
at visit n, by month stratum: weighted average of
months 3–24
Median duration (in months) of quiescence for
those eyes achieving quiescence after the end of
treatment, i.e. the number of months for which
we expect a quiescent eye to remain quiescent
2.0 Based on median time to retreatment in the IVAN
trial from each time a patient becomes treatment
free. Medians were calculated for each 3-month
period and the median of the 3-month periods was
used. Converted from days to months assuming each
month has 30 days
Mean cost of monitoring consultation conducted
by community optometrist
£51.90 The ECHoES trial costing analysis (see Table 22)
Mean cost of monitoring consultation conducted
by hospital ophthalmologist
£75.60 The IVAN trial costing analysis
Total cost of monitoring consultation and
downstream costs (e.g. injections and follow-up
visits): community optometrist
£410.78 The ECHoES trial economic evaluation (see Table 24)
Total cost of monitoring consultation and
downstream costs (e.g. injections and follow-up
visits): hospital ophthalmologist
£397.33 The ECHoES trial economic evaluation (see Table 24)
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TABLE 26 Results of budget impact calculations
Estimated patient numbers in England per year
Total number of patients attending clinic
All patients 219,514
Unilateral nAMD 167,263
Bilateral nAMD 52,250
Total number of patients quiescent in both eyes who become eligible for community optometry in any
given month
All patients 21,949
Unilateral nAMD 18,366
Bilateral nAMD 3583
Total number of monitoring visits that could be transferred from hospital to community per year
All patients 535,548
Unilateral nAMD 448,128
Bilateral nAMD 87,420
Budget impact – initial consultations only
Total cost of community optometrist monitoring consultations in England £27,794,931
Total cost of hospital ophthalmologist monitoring consultations in England £40,487,414
Budget impact (i.e. incremental cost of using community optometry rather than hospital monitoring) –£12,692,483
Budget impact – including downstream costs
Total cost of community optometrist monitoring consultations and downstream costs (e.g. injections and
follow-up visits) in England
£219,992,329
Total cost of hospital ophthalmologist monitoring consultations and downstream costs (e.g. injections and
follow-up visits) in England
£212,789,211
Budget impact (i.e. incremental cost of using community optometry rather than hospital monitoring) £7,203,118
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Chapter 5 Results: views of patients and health
professionals about the shared care model
(objective 5)
Participants in focus groups and interviews
Health professionals
The focus groups lasted a mean of 110 minutes, ranging from 99 to 121 minutes. The interviews lasted
a mean of 48 minutes, ranging from 31 to 61 minutes. In total, 24 health professionals were recruited.
This comprised eight optometrists, six ophthalmologists, two public health representatives, six NHS
commissioners and two clinical eye care advisors to their local CCGs. Of these, 12 were women and
12 were men. Participants had a mean age of 39 years (range 31–64 years) and stated that they had been
in their profession for a mean of 21 years (range 4–40 years). Although none had participated in shared
care for nAMD, 11 participants had experience of shared care schemes for other conditions such as
diabetic retinopathy screening and ocular hypertension monitoring. Table 27 shows participants’
professional background. Years in profession and location are not presented for the ‘other’ health
professionals (i.e. those other than ophthalmologists and optometrists) to protect their anonymity given
their unique roles. However, these participants’ locations were distributed evenly throughout England and
they had been in their profession for an average of 20 years (range 8–37 years).
Service users
The focus groups lasted a mean of 71 minutes, ranging from 65 to 90 minutes. Three focus groups were
conducted with 23 participants in total, with seven or eight participants in each group. The sample
consisted of 15 women (65%) and eight men (35%) who described themselves as white British. The
sampling strategy intended to recruit individuals from a mix of ethnicities, but all those at the supporting
groups who were willing to be contacted were white British. They had a mean age of 82 years (range
72–93 years). All had nAMD and attended the same eye hospital in a major city and were diagnosed an
average of 5.9 years ago (range 6 months to 20 years). Nine participants had active nAMD in one eye
(39%), nine were stable in one eye (39%), four people had active disease in both eyes (18%), and
one person was stable in both eyes (4%). Eight participants had dry AMD in their other eye (35%). The
partners of two participants (who were also their carers) joined the focus group but spoke very little;
their comments were not included in the final analysis. Table 28 provides participants’ demographic and
health-related details.
Results of focus groups and interviews
Overall, the majority of participants were extremely enthusiastic about the possibility of a shared care
model being implemented for nAMD care. Thematic analysis of the focus group and interview data
produced six key themes: ‘Current clinic capacity: Pushed to the limit’, ‘Potential for a more patient-centred
model’, ‘Perceptions of optometrists’ competency’, ‘(Lack of) communication between optometrists and
ophthalmologists’, ‘The cost of shared care’ and ‘The importance of specialist training’. The interpretation
of themes and subthemes is supported by illustrative quotes. The codes used for the quotation sources can
be found in Tables 27 and 28.
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Current clinic capacity: pushed to the limit
Many health professionals stated that the number of repeat visits for patients was rising exponentially,
which was attributed to an increase in the number of patients who were being diagnosed with nAMD
and to new government guidelines for treatment.
The numbers going through the system are higher, and they need treatment for longer.
Comm3
TABLE 27 Health professional participants’ background
Participanta Role(s) Years in professionb Location
Focus group 1
Optom1 Optometrist 37 South West England
Optom2 Optometrist 28 South East England
Optom3 Optometrist 29 North West England
Optom4 Optometrist 37 West Midlands
Optom5 Optometrist 15 South West England
Optom6 Optometrist 20 South West England
Optom7 Optometrist 36 South West England
Optom8 Optometrist 40 West Midlands
Focus group 2
Ophthalm1 Ophthalmologist 20 North West England
Ophthalm2 Ophthalmologist 20 London
Ophthalm3 Ophthalmologist 4 Dundee
Ophthalm4 Ophthalmologist 7 East Midlands
Ophthalm5 Ophthalmologist 17 North West England
Ophthalm6 Ophthalmologist 3 South West England
Interviews
CA1 Optometrist, clinical advisor to local CCG – –
CA2 Optometrist, clinical advisor to local CCG – –
Comm1 Commissioner, pharmacist – –
Comm2 Commissioner, GP – –
Comm3 Commissioner, GP – –
Comm4 Commissioner, GP – –
Comm5 Commissioner, pharmacist – –
Comm6 Commissioner, optometrist – –
PH1 Member of eye health local professional
network, optometrist
– –
PH2 Optical advisor for eye charity, optometrist – –
CA, clinical advisor; Comm, commissioner; Ophthalm, ophthalmologist; Optom, optometrist; PH, public health representative.
a Health professionals are identified by their professional role and their individual participant number.
b Owing to their unique roles, the other health professionals’ years in profession and location have been removed to
protect anonymity.
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Hospital clinics were felt to be ‘pushed to their limit’ [Optom7, Ophthalm3] and the ophthalmologists felt
frustrated that their time was mostly spent on stable patients who did not require treatment.
You are taking the potential time from the ones that actually need the care. There is a limit of work
that you can do. I mean you can’t go home at 8 every day.
Ophthalm2
Both the health professionals and service users described how patients would often have to wait for long
periods of time for their appointment because of how busy the eye hospital clinics were:
TABLE 28 Service user participants’ demographic and health-related details
Participanta Gender
Age
(years)
Location of
support group Information about condition
Time since
diagnosis
Focus group 3
Arthur Male 80 City Advanced active nAMD in one eye 20 years
Edith Female 83 City Inactive nAMD in one eye 7 years
Edward Male 78 City Active wet in one eye, dry in other 10 years
Elizabeth Female 81 City Inactive wet in one eye, dry in other 12 years
Harriett Female 86 City Inactive nAMD in one eye, dry in other 2.5 years
Kath Female 77 City Inactive in nAMD in both eyes 15 years
Ruth Female 87 City Active nAMD in one eye 10 months
Tom Male 79 City Inactive wet in one eye, dry in other 13 years
Focus group 4
Alice Female 79 Large town Inactive nAMD in one eye 5 years
Debbie Female 84 Large town Advanced active nAMD in one eye, dry
in other
4 years
Julie Female 86 Large town Active nAMD in one eye, dry in other 6 months
Mandy Female 93 Large town Active nAMD in one eye 6 months
Maria Female 93 Large town Inactive nAMD in one eye 20 years
Pam Female 83 Large town Active nAMD in one eye, dry in other 4 years
Ralph Male 79 Large town Active nAMD in one eye 7 years
Robert Male 78 Large town Active nAMD in both eyes 10 years
Focus group 5
George Male 85 Rural village Active nAMD in both eyes 6 years
Harry Male 72 Rural village Inactive nAMD in one eye 1 year
Henry Male 82 Rural village Active nAMD in one eye, dry in other 4 years
Olivia Female 84 Rural village Active nAMD in both eyes 8 years
Pat Female 78 Rural village Active nAMD in both eyes 7 years
Tracey Female 77 Rural village Inactive nAMD in one eye 11 years
Yvonne Female 76 Rural village Inactive nAMD in one eye 1 year
a Pseudonyms were assigned to participants.
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Well, quite honestly when you go to the eye hospital, it always seems to be packed out left, right
and centre.
Harry
Sometimes we have to wait a long time, but you know it can’t be helped.
Henry
It’s just generally the issue of they have had to wait a long time [. . .] You’ve got to think also there are
diabetics among there that have to regulate their meals, and they have their set routine in terms of
their meals and health. It’s the same with everybody, but perhaps diabetics most, because it affects
them straight away. I’ve known diabetics that have gone into a hypo [hypoglycaemia] because they
were waiting around. Because they had a 9 ‘clock appointment and it got to 11. It’s just a real shame.
PH2
There was a sense that the current model would inevitably need to adapt to cope with this demand and
agreement that optometrists monitoring in the community had the potential to reduce clinical workload.
It will help shift a lot of the workload out of the hospital environment where they are overrun with this
and putting it into a more capable environment with local optometrists.
Optom6
[Monitoring in the community] will make less queues at the hospital. At the moment they’re choc à
bloc with people.
Ruth
The optometrists, clinical advisors and commissioners also described how a shared care scheme
represented a great opportunity to enhance optometrists’ professional roles by developing their skills.
It’s fantastic for the optometry profession, because it must give them much more exciting and
interesting careers, and career progression, and variety within their work.
Comm3
Potential for a more patient-centred model
Most health professionals also felt that the current model of care was not appropriate for older patients
with limited vision who had to regularly travel to the hospital.
The problem is that all the patients have got to go to the eye hospital all the time, which isn’t very
patient-centric . . . It’s not very easy for people to get in once a month – which is obviously what
Lucentis is about – for their assessment. Given that they are, almost by definition, elderly and with
poor vision, it’s not an ideal centre for it.
Comm2
The service users found it stressful travelling to and from the hospital for care. Many stated that they were
unable to drive because of their nAMD, which was described as a ‘massive blow’ to their independence
(Pat). These service users reported difficulty seeing the bus numbers, and most needed to get multiple
buses each way as there were no direct buses. Others were driven by family or friends, but described
parking as ‘awful’ (Arthur).
It’s not just getting to the hospital. It’s all that time afterwards, if you’ve got to get the bus, it’s – in
the winter, it’s even worse.
Ralph
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One of the things that’s come out here is that everyone is, obviously, getting older. They’re stressed
when they have to go out of the town because getting home when you’ve got . . .
Robert
Oh, it’s terrible.
Mandy
So if they have someone in the town who is an optician and deals with us, it’s only a short distance
from home.
Robert
Monitoring in the community was described as a ‘wonderful’ idea (Elizabeth), particularly for those who
lived further away from the hospital or older participants who had severe vision loss.
For me, living out of town in [small town], to get to an optician on the bus is easy, whereas it’s a day’s
expedition to come into [city].
Tracey
Many rarely saw the same consultant or nurse at the hospital, and felt that staff were often impersonal as
they were ‘so busy’. This was likened to ‘being on a conveyer belt’ (Pam).
If a doctor said, ‘Well, that’s alright’, that’s it. It’s reassurance. I think they’re trying to speed up time,
and I know they’re very busy and they obviously look at the photographs and they can see everything,
but for patients’ feel-good interest, I always like a doctor or someone to say, ‘That’s alright. You’re not
doing too badly. Well, you’re in your eighties now.’ Just to talk to you properly.
George
I think one of the greatest things wrong in the eye hospital is they . . . they kick you out the door.
Arthur
In addition, most others felt that they did not receive enough information about the status of their condition.
Just be told what’s happening –
Harriett
The only criticism I would have is to try to find out how you’re doing and whether you’re getting
worse or getting better, or stable, because they’re all so busy.
Ruth
These participants were therefore enthusiastic about the potential for continuity of care, which they hoped
would enable them to build up a relationship with their optometrist.
I think one of the things, I think you’ll agree, has come to light this morning, is basically that many
aspects of the eye hospital, it’s so impersonal. I think that probably a system like you’re suggesting
would probably add a personal touch to it and a more one-on-one situation . . . That’s the big thing,
seeing the same person. Like I said, the personal touch . . . The relationship would build up.
Edward
Perceptions of optometrists’ competency
The optometrists in the focus groups, who acknowledged that they had a special interest in nAMD, were
very positive about the possibility of shared care and felt that their profession was more than capable of
monitoring in the community. This was also echoed by the commissioners, clinical advisors and public
health representatives.
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They’re [optometrists] really incredible, impressive professionals, with just a huge amount of experience
at looking at eyes.
Comm3
However, several health professionals (from mixed professions) commented that ophthalmologists would
resist shared care as they were not convinced of optometrists’ competence.
I think it’s the misconception that optometrists won’t do as good a job as secondary care. So I think
that’ll be the biggest barrier.
Comm4
This was considered to be problematic for shared care as there was uncertainty whether or not
ophthalmologists would ever truly relinquish responsibility for patients.
I would not want to close the door on them, ever. I’d still want them to contact me if they noticed
any change.
Ophthalm1
Honestly, I think that clinicians aren’t always very good at letting go [. . .] It will be an issue.
Comm3
There was hesitation among ophthalmologists about whether or not optometrists were capable of
monitoring nAMD. The ophthalmologists referred to how they frequently received incorrect referrals from
optometrists. Furthermore, they highlighted the ways in which nAMD differed to other eye diseases where
shared care schemes existed.
When you work in ophthalmology for quite some time you see just the amount of work that comes to
you from inappropriate referrals. Really they’re just doubling work up.
Ophthalm3
This is not like glaucoma where you notice pressure or you don’t feel OK and refer back to the
hospital. This is something . . . it’s based on the scan and each patient is different. There’s only a few
parameters for glaucoma, whereas here there are . . . it’s complex [. . .] So we can’t expect an
optometrist to . . . [laughter].
Ophthalm5
The ophthalmologists felt that the hospital provided an environment where they had access to all previous
scans and other colleagues’ expertise, which enabled them to confidently make a clinical judgement. They
expressed uncertainty about whether or not optometrists would have these resources. Ultimately, owing to
this perceived complexity of assessing the need for retreatment and the support and resources available in
the hospital, the ophthalmologists felt that monitoring patients in the community would be a compromise.
So what we are trying to say is hospital care is the best [laughter].
Ophthalm6
Several ophthalmologists felt that patients would prefer to remain being monitored by a consultant at the
hospital, whom they would inherently trust. In line with this, service users with active nAMD also tended
to be apprehensive about the level of optometrist competence in the community, and commented that
lengthy waiting times were secondary to receiving the best care for their condition.
If we put ourselves in their position what would we prefer to have? I’ll prefer to be seen by a doctor in
a hospital.
Ophthalm1
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So, you’ve got to have confidence in the person that is monitoring you [. . .] I feel that to rely on
somebody that has been trained up to identify problems can’t really be as efficient as seeing an actual
doctor who specialises in that subject, and because of that, I wouldn’t be happy going to an optician.
It might take you longer. We have sat up there for hours, but the end result is well worth it.
Henry
The majority of service users described needing to be able to ‘have faith’ in their optometrist if they were
to participate in shared care. Those whose optometrist had diagnosed their nAMD commented that this
gave them a sense of confidence in their optometrist’s abilities.
I would trust my optician. He really seems to care. I would trust him. If my wet macular was stable, I’d
be very happy to go to my optician because I’ve got confidence in him, because he detected it in
the beginning.
Harriett
However, a few service users were apprehensive about shared care and did not wholly trust the idea of
monitoring by an optometrist. Those who expressed this sentiment did not have faith in their optometrist
because the optometrist had not recognised the condition initially
Personally I wouldn’t have faith in the optometrist. I would much prefer to stay with the hospital.
Henry
(Lack of) communication between optometrists and ophthalmologists
Overall, the health professionals described the relationship between optometry and ophthalmology as poor.
Collaboration optometry and ophthalmology? No way. It’s absolutely dreadful!’ [laughter]
Optom8
These participants described how ‘systems-based’ issues made communication between the two professions
poor. This was described by all professions except the ophthalmologists. For instance, most of the optometrists
described how it could be extremely difficult to relay information to ophthalmologists because of incompatible
computer e-mail systems and variation in technology.
Our problem is we’ve got NHS.net in optometry and because everyone else, they’re all NHS.co.uk. So
their end isn’t secure. We can do NHS.net to NHS.net, but we can’t do NHS.net to NHS.co.uk, which
is what all hospitals give their consultants. It’s absolutely crazy.
Optom8
They’ve not embraced NHS.net at all.
Optom5
Some optometric practices don’t even have computers. Particularly in the [city] area where many of
them are way behind. We actually had to buy them fax machines when this started to make it work.
You’d expect most people had that sort of facility, but they didn’t. To make it work, we would do
that. So I think standardisation of forms across our units, across the country, and making those forms
readily available, and everybody knows that they’ve got to look for the red-topped form in the practice
or whatever, could possibly aid this model of shared care.
Optom2
The other big issue is transfer. If you’re actually going to transfer the data, they are massive, massive,
massive files. I was talking to an optometrist who has an OCT and sends scans to an ophthalmologist,
and he literally has to do it overnight. Just for one patient, it takes so long.
Optom1
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All of the optometrists also commented that technology had caused issues with their referrals to
ophthalmologists in the past, in that they often got lost between the two professions. As a result, the
optometrists stated that they would follow up each referral by calling the consultant to ensure it had
been received or they sent referrals via multiple technology methods to ensure that one would reach
the consultant.
It does happen that patients will wander back in 2 weeks later and say, ‘Oh, you told me I’d be seen
within a couple of weeks. I haven’t heard a thing.’ Then we contact the hospital and we think, ‘OK,
what’s happening?’.
Optom2
However, many participants (both health professionals and service users) explained that one of the key
concerns of nAMD was the rapid progression of the disease if the condition became active. In particular,
several service users described the devastating consequences of their vision deteriorating within days.
Last week I was all-seeing and driving and everything, and on Thursday I thought, ‘There’s something
missing on that signpost’, and the glare was terrible. So then I couldn’t read the paper at lunchtime . . .
To me, it’s been a disastrous week. I can no longer drive. I can no longer read. This is a week! To me,
that’s a disaster. It’s very frightening.
Pat
Participants, particularly the ophthalmologists and service users, therefore expressed concerns about a
potential delay between primary and secondary care if retreatment was required.
The problem is that the more steps you have in the system, the longer it takes. We don’t have
the time.
Edward
The nature of the disease is such that it needs urgent attention. So it’s better if we see the patient
[. . .] I can’t imagine going to the optometrist and him making a decision to refer the patient back,
all that delay.
Ophthalm1
The health professionals emphasised that, in order for shared care to be delivered successfully, it would
be essential that the two health-care professions were able to work collaboratively so that an efficient
pathway could be developed.
I think they would like to make sure that there’s a seamless process between community and hospital,
and that nothing drops through the cracks. So I think they would need to make sure that there’s a
robust recall service, and that if there is an issue, that there’s a pathway back for the patient into
secondary care. So those kinds of things, I think, would need to be ironed out before it goes ahead.
Comm2
The cost of shared care
A theme unique to the health professionals was the financial implications of implementing a shared care
model. Both the optometrists and the ophthalmologists believed that financial considerations should be
secondary to the care of the patients, although the other health professionals described how a harsh
reality of health care meant that shared care would not be commissioned unless it ‘got the most out of
the NHS pound’ (PH2).
I think you have to possibly take out the finance issues. How you buy something should be secondary
to what the patient needs.
Optom4
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You’ve got to show the CCGs that you’re saving money over sending them into the hospital. Because
otherwise, they’re just not going to commission it.
PH1
The commissioner participants undertook several roles professionally and were often optometrists or GPs
alongside this position. The multiple perspectives from a commissioning and clinical point of view appeared
to conflict in terms of patient outcomes and financial efficiency when contemplating nAMD care.
Patients would like it [being monitored in the community] because it’s much closer to home, they
don’t have to go to hospital. They don’t have to sit and queue and wait in pain, park and all that sort
of stuff that patients usually tell you . . . From a commissioner’s perspective. . . in terms of saving and
shifting costs across the health system for eye care services, it certainly doesn’t achieve that.
Comm4
The health professionals were divided about whether or not monitoring in the community would represent
a more cost-efficient model. For instance, some perceived that NHS costs of managing sight loss could
ultimately decrease.
So if you could use the monitoring to stop the wet AMD getting worse, so that it’s kind of preventative,
then you would be addressing the public health indicator of dropping those numbers of people
registered with AMD sight loss. [. . .] Yes, that would be the biggest advantage that I would see of it.
PH2
Many also considered that there may be an opportunity to save money with a differential fee for optometrists
and ophthalmologists. Conversely, the ophthalmologists stated that the money saved from following up with
patients with nAMD could be set towards resources to improve secondary care resources, rather than being
‘lost’ to the community (Ophthalm3).
It would be a cost-efficient option for the commissioners because we would be paying something like
£60 for an optometrist to measure the patient’s visual acuity, rather than £100 and whatever it is for a
consultant outpatient episode.
Comm4
If the optometrist where I am gets compensated, that pot of money comes from the resources from
the hospital and we’re struggling as it is. We’re diverting resources to somebody else who’s not doing
as much work as we are doing in the hospital, just doesn’t make sense.
Ophthalm3
The ophthalmologists stated that they took around 15 minutes to see a patient and determine the need
for retreatment, while the optometrists’ estimates varied at 20, 30 or 40 minutes. As the requirements to
determine reactivation were listed (including a clinical examination, administration of tropicamide drops
and use of an OCT), the optometrists concluded the estimate of up to 40 minutes was more realistic to
make a clinical decision and explain the results to the patient.
It has to be realistic so you can practise and sustain it.
Optom3
I’ll allow 30 and probably spend 40 [. . .] But once you’ve got an OCT sitting there and you start
looking at it, and you really want to explain it to the patient and they say, ‘Oh, thank you. No one
ever tells me anything like that at the hospital. It makes you feel so good at the end. You’ve actually
told the patient what’s really wrong and, ‘Rest assured my dear, it’s not getting any worse, so we
don’t need to send you back’. ‘Oh, thank you!’ It probably would take me 40 minutes.
Optom8
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Several commissioners and one clinical advisor therefore highlighted a potential conflict between practices’
clinical and commercial interests and stated that optometrists would need to be paid a sufficient amount
to ensure that shared care was economically possible.
If the current business model for eye care is that funding comes from selling glasses, then if you fill
your clinic appointments up with OCTs which will be a lovely service for patients, but if the only thing
that’s happening is that you are breaking even with doing an OCT, your practice isn’t going to survive.
Comm1
There was also agreement that an OCT, although considered essential for monitoring nAMD, is an expensive
piece of kit that not all practices can invest in. The clinical advisors and public health representatives felt that
CCGs should provide OCTs, although most of the commissioners and the ophthalmologists felt it should be
self-funded to demonstrate a level of commitment to monitoring in the community or that those practices
which already had an OCT would represent a more enthusiastic, clinically orientated team.
Well, it’s on the optometrists, really. Whether they’ve got the kit or whether they will want to invest in
one. I think what it will be is that you’ve have a small group of practices within a particular area, who
will show keenness. [. . .] They will be the more cutting edge practices.
Comm6
I think CCGs should pay for that [an OCT], the NHS. I don’t think it should be the optometrist.
PH2
A further financial issue was whether or not ophthalmologists would repeat tests, owing to difficulty
relinquishing responsibility or not trusting an optometrist’s judgement.
If you’re doing injecting from a message that you’ve got from the community, then actually if
something was to go wrong, you can’t just say, ‘I did it because the optician outside told me to do it.’
Do you know what I mean? [. . .] For their peace of mind.
CA1
You’d have to attend another OCT in the hospital, look at the scans and then we have to take
everything, yes, you may need another angiogram, just to be certain.
Ophthalm1
Consequently, a main concern of the commissioners was that the CCGs might be charged for
repeated testing.
‘From a commissioner’s point of view, we would want to make sure then we would only be being
charged for that element of it, and they wouldn’t go on and repeat all the tests again.
Comm1
The importance of specialist training
The health professionals spent a considerable amount of time addressing how they felt training should be
delivered, in terms of which method was most effective for learning and ensuring training was delivered in
a way to reassure ophthalmologists that optometrists were being trained to a high standard.
I think the training needs to be very carefully designed.
PH2
The ophthalmologists have to believe in the competence of the optometrist. It’s important that they
have belief in the quality of the accreditation.
Optom4
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Virtual training was deemed appropriate for providing a ‘foundation’ level of knowledge, although most
felt that this alone would not be sufficient to train the optometrists. In particular, the ophthalmologists
were unconvinced by the applicability of a virtual trial.
I think it complements training, but I don’t think it should be the sole course of training. I think you
still need a bit of hands-on.
Comm1
I’m sure in your studies you will find 100% virtual case studies that you give, that you will find good
correlation between what the ophthalmologist would say and what the optician would say in a
virtual case. You can’t just say ‘Yes, the optom [optometrist] has 100% exactly the same as the
ophthalmologist, which says that now they are just as good’.
Ophthalm3
Clinical experience, whereby optometrists would gain experience of monitoring nAMD patients in a
hospital setting, was viewed as an ‘essential’ component of training.
I think they need to come and see the real patient. There’s no point on sitting on the MediSoft or
whatever and clicking boxes and thinking they know it all. Real life is not like that. I mean there are the
OCT scans like that, sometimes they can be very devious and very challenging and very confusing . . .
Ophthalm2
The majority of participants felt that having ophthalmologists supervising this training would provide
assurance of optometrists’ competence and enable greater collaboration between the two professions.
However, they acknowledged that this would be time-consuming.
I would suggest that they [optometrists] would spend a certain amount of time in a consultant clinic.
Most services will have a specialist clinic for macular degeneration, so they would maybe spend a
session a week, or something, in such a clinic for 6 months, just getting familiar with the treatments
and the monitoring, etc. Also that will help the consultants’ gain a bit of confidence in the optom
[optometrist] as well. So it’s a working partnership going on there.
Comm2
I think they would be involved if they had an element of control over it. If they’d done the training and
if they knew who they were sending the patients out to and they knew what protocols were being
followed, the service spec. You don’t get these things to work unless you’ve got clinical buy in. You
just don’t. You can set up all you want, but you’ve got to get the clinicians involved.
Optom5
The hospital departments are caving in and creaking under the weight . . . so getting a consultant to
be doing local training can be difficult.
CA2
Trial participants’ opinions on shared care
Feedback questionnaires were completed by 47 ophthalmologists and 55 optometrists, most of whom
had completed the study and were included in the analysis population (see Chapter 3, Participants’ views
on ECHoES trial training). Findings from the ECHoES trial participants’ questionnaire survey in relation
to perspectives of shared care mirrored those from the focus groups and interviews described above,
and they therefore act as a method of triangulation to increase the plausibility and dependability of the
main qualitative research.33 The vast majority commented in the questionnaire that monitoring in the
community represented an excellent opportunity to reduce current clinical capacity and a more efficient
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use of consultants’ time, which would enable them to focus on active patients who required retreatment.
In addition, many noted that shared care was a more accessible option for patients and provided a
welcome opportunity for the professional development of optometrists.
I think it is an excellent idea.
Ophthalm105
Makes perfect sense.
Optom270
However, a major concern of 18 optometrists was that ophthalmologists would resist the shared care
scheme as they were not convinced of optometrists’ competence. In line with this, several ophthalmologists
stated that there was interprofessional distrust and acknowledged that a buy-in from their profession
would be difficult.
Ophthalmologist fear in delegating care to optometrists if patient care is compromised.
Optom278
Ophthalmology departments do not want to let go of their patients.
Optom202
Similar to the findings from the focus groups and interview data, most respondents emphasised the need
for appropriate training which should include supervision by ophthalmologists. However, several
commented that training would be a time-consuming process for both disciplines.
Good-quality training with HES involvement from the start.
Ophthalm222
The local ophthalmologists would have to be prepared to give time to hands-on training to those
optometrists participating.
Optom207
In addition, both groups felt that these interprofessional barriers had the potential to be problematic with
regard to poor communication between primary and secondary care sectors, which could cause a delay
for patients who required retreatment.
Need to create a good system of communication between optometrists and ophthalmologists.
Optom242
Work collaboratively and build partnership keeping patients at the centre.
Ophthalm138
Furthermore, respondents also expressed uncertainty as to how shared care should be funded. Twenty-one
optometrists and 11 ophthalmologists highlighted that most practices did not own an OCT and would
struggle to afford such an expensive piece of kit. Several optometrists also felt that, if practices were not
compensated sufficiently for the enhanced role, the practice’s business would ultimately suffer.
Each practitioner will need an OCT, which the majority of optometry practices do not have at the moment.
Optom201
There needs to be sufficient funding for the outlay on the OCT equipment and the professional time
on the high street to make this a viable investment in order to not lose money.
Optom216
RESULTS: VIEWS OF PATIENTS AND HEALTH PROFESSIONALS ABOUT THE SHARED CARE MODEL (OBJECTIVE 5)
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Chapter 6 Discussion
Main findings: study conduct
Recruitment
The staged nature of the trial and the risk of withdrawals (most, but not all, participants progressing from
training to the main trial or withdrawing for other reasons) combined with the priority of maintaining the
balanced incomplete blocks design made recruitment challenging, particularly given the short duration of
the trial. The balanced incomplete blocks design meant that each participant had to be assigned a specified
set of vignettes for the main trial assessment on completion of webinar training. This constraint prevented
an extra participant from being recruited until an existing participant had definitively withdrawn. As
participants could not all be recruited at the same time and progressed at different speeds, we did not know
until a considerable time had elapsed whether or not additional participants would be needed. In order to
expedite completion of the trial, we reopened recruitment at a later stage and deliberately over-recruited
participants to the webinar training, some of whom did not progress into the main trial because the target
sample size had been reached. Close to the end of the main trial, in order to increase the likelihood of
completing the main trial in accordance with our revised schedule, we also assigned two participants to one
set of vignettes in order to be more confident that at least one would complete the assessments promptly.
The need to over-recruit also had financial consequences for the trial budget. Participants who chose
to withdraw during their participation in the trial were paid only for the time spent on webinar training
and not for any training or main vignette assessments that had been carried out up to the time of
withdrawal. However, those participants who were withdrawn by the trial team, either because of failure
at the training stage or because the trial had reached its target, were reimbursed fully up to the point
of withdrawal, as if they had completed the study.
Images used to create vignettes and constraints on viewing images
Despite the overall size of the IVAN trial image repository, the number of suitable baseline and index
images available to create vignettes was much smaller than anticipated. This limitation required us to
identify a different combination of (1) number of participants, (2) number of vignettes per participant and
(3) number of times each vignette was assessed. The final design recruited 96 participants (48 in each
professional group), each of whom assessed 42 vignettes, with each vignette being assessed seven times
(by each group), requiring a total of 288 vignettes and 4032 assessments. This total was considerably
smaller compared with our original plan for 96 participants each to assess 48 vignettes, with each vignette
being assessed four times, which would have required 1152 vignettes and 4608 assessments.
The smaller number of available vignettes also forced us to sample sets of training vignettes from among
the 288 vignettes used for the main trial assessments. This constraint meant that extra participants
(recruited when recruitment reopened) could not start their training assessments until an earlier participant
had withdrawn and freed up a specified set of vignettes for the main trial assessment.
All images used to create vignettes were reviewed by a senior grader from NetwORC UK (AM) and a retina
specialist (UC) to identify appropriate pairs of sufficient quality. Almost all of the CF photographs in the
IVAN trial repository that were potentially suitable for inclusion were considered to be of sufficient clarity
and focus for constructing the vignettes. However, OCT images were subject to several limitations:
l We made the decision that vignettes could only be constructed with OCT images captured by spectral
domain tomographic equipment. Spectral domain OCT systems provide images of greater clarity,
resolution and definition and represent systems to which clinicians and optometrists are currently
exposed. These spectral domain systems came into widespread use in 2008. When the IVAN study
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started in 2007/8, the standard for clinical trials was time domain OCT because the data import and
export protocols and grading methods had been established and validated only for these acquisition
systems. Therefore, the majority of sites in the IVAN trial used time domain systems to capture OCT
images. Nonetheless, as the old time domain systems began to fail, most IVAN trial clinical sites replaced
these with spectral domain systems. Validation of the spectral domain systems for trials was undertaken
and, therefore, spectral domain OCT images were permitted in the IVAN trial protocol. Approximately
one-third of all IVAN trial participants had OCT images acquired on one of the three types of commonly
used spectral domain systems (Heidelberg Spectralis®; Zeiss; Optovue). All the spectral domain systems
yielded high-quality images. However, the lower aspect ratios of the Zeiss and Optovue made it more
difficult to interpret images than with the Spectralis. This is because the appearance of the Spectralis
images is more similar to that observed on a standard retinal histological preparation. The Spectralis is
also in more widespread use in the UK. Both experts and participants commented that OCT images from
the Zeiss and Optovue spectral domain systems were unfamiliar and, therefore, that the images were
more difficult to interpret and that they were less certain about their assessments.
l Baseline and index OCT images consisted of six radial line scans which passed through the fovea.
Ideally, scan lines at the same clock-face orientations should be captured at every visit and be displayed
in the same order so that an assessor can compare the appearance of the retina at specific locations.
For some of the scans, the orientations did not match exactly for baseline and index images.
l The web application presented ‘thumbnail’ images of all six OCT images and an assessor could ‘click’
on an image to enlarge it and to toggle backwards and forwards between the six enlarged images.
(The website www.echoestrial.org/demo shows how assessors carried out assessments in the trial.)
However, it was not possible to view baseline and index images for corresponding orientations
simultaneously because of the limitation of providing the application on a single monitor. Paired
viewing of OCT images is a desirable feature and it is usual practice for clinicians to use a paired display
which allows the viewer to scroll through the different scan orientations from two visits on a single
screen. One participant (Optom268, see Chapter 3, Participants’ views on ECHoES trial training)
achieved this by having one set of images on a tablet and one set on a conventional computer display.
Reference standard
The original plan (described in the grant application) was for the reference standard to be derived
directly from grading data collected during the IVAN trial. For various reasons, this was not considered
acceptable once we started to set up the study: there are occasional errors in the grading data and
the list of features/questions drawn up for the web assessment (see Table 2) did not completely match the
table in the protocol or the grading data available. There were two key differences, namely (1) the
distinction between presence of a feature in the index OCT and whether or not an increase in the feature
had occurred from the baseline to the index OCT, and (2) the inclusion of DRT as a feature. Grading data
were used to select baseline and index OCT pairs that were likely to suitable, based on the features
described in the table in the protocol, but it was decided that the reference standard should be assigned
by expert ophthalmologists (reading centre leads, UC, TP and SPH).
This decision was taken when the first draft of the assessment part of the website was available, in late
June 2013. We accepted that training could begin while vignettes were being assessed by experts.
However, there was still insufficient time for the three experts to assess each vignette by the time
participants’ responses to the training vignettes had to be scored. Instead, we aimed for two experts to
assess each vignette (one-third of the total number of vignettes by each pair of expert ophthalmologists),
but only had one assessment for each vignette at the time that participants’ responses were scored.
These assessments were carried out by two of the three experts.
As participants’ assessments on the training vignettes accrued, it became clear that there were some
vignettes that participants were getting consistently wrong. Consequently, the two experts who had
provided the expert assessments reviewed about 30 vignettes. Some of these were believed to be mistakes
(mainly key-stroke errors when completing the web data entry) by an expert and the overall assessment was
changed for 10 vignettes. These new gradings were later used in the derivation of the reference standard.
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Main findings: study results
Classification of lesion activation status and lesion components
Optometrists were non-inferior to ophthalmologists with respect to their overall ability to classify lesions
correctly: that is, the primary outcome. Neither group attained the level of performance expected at the
outset (on which the target sample size was calculated). However, optometrists made different kinds
of errors. Compared with ophthalmologists, it was less likely that they would classify a reactivated lesion
as quiescent or suspicious (false-negative misclassifications) and more likely that they would classify a
quiescent or suspicious as reactivated (false-positive misclassifications); better sensitivity, worse specificity.
It is probable that this finding arises because optometrists tended to adopt a more cautious decision
criterion, which would be consistent with their obligations under the General Optical Service contract
(to refer any suspected pathology). The finding may also reflect the fact that optometrists had more
difficulty in interpreting the diversity of appearance of quiescent lesions, that is, eyes with an abnormal
appearance but not needing treatment, which are normally managed in the HES.
The poorer than expected overall performance may have arisen because the quality of the images was
suboptimal. In a real-life scenario, any monitoring review (carried out by either an ophthalmologist or an
optometrist) is likely to include examination of the patient, for example slit-lamp biomicroscopy, as well as
review of CF and OCT images. Some components, such as blood and exudates, might be identified more
reliably from this examination than from images. If this were the case, the combination of the vignette
information with direct examination would increase the performance.
No harms could arise in the trial itself because all of the decisions being made were for anonymised
vignettes. However, the health economic evaluation carefully considered the costs and consequences of
the different types of error predominantly made by each group. In the context of community optometry,
it seems desirable that optometrists should use a cautious decision criterion for referral, although this
limits the potential benefit of the shared care model in terms of both the impact on workload in the HES
(because of false-positive referrals) and its potential cost-effectiveness.
Optometrists were also non-inferior to ophthalmologists with respect to the frequency of false-negative
sight-threatening errors (i.e. failure to identify a lesion as reactivated). In fact, optometrists were slightly
less likely than ophthalmologists to make such errors because of their tendency to adopt a more cautious
decision criterion. Conversely, optometrists made more non-sight-threatening errors (false-positive errors,
i.e. failure to identify a lesion as quiescent or suspicious) than ophthalmologists.
Except for PED (which did not inform the classification of lesion activity), lesion components were identified
as present more often by optometrists than by ophthalmologists, again consistent with optometrists
adopting a more cautious decision criterion. This tendency was particularly evident for DRT and exudates.
Ophthalmologists were much more confident in their classifications than optometrists. However, there
was no association between confidence and the odds of classifying a lesion correctly. For all grades
of confidence in the classification, optometrists had slightly better odds of classifying a lesion correctly.
As hypothesised, other items of information included in a vignette did not influence participants’
lesion classifications.
The sensitivity analysis found a statistically significant difference, but not clinically important one, with
respect to the prespecified non-inferiority margin, in favour of ophthalmologists. The alternative definition
of the primary outcome used in this analysis involved reassigning four cells from Table 3. Participants’
classifications changed from incorrect to correct for two cells (suspicious reference lesions classified as
reactivated by participants and reactivated reference lesions classified as suspicious by participants) and
from correct to incorrect for two cells (suspicious reference lesions classified as quiescent by participants
and quiescent reference lesions classified as suspicious by participants). Of these, the latter were both
the most numerous (380 out of 4032 participants’ classifications) and showed the greatest difference in
frequency between ophthalmologists and optometrists (88 more such classifications by optometrists
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considered incorrect in the sensitivity analysis; see Table 7). Reactivated reference lesions classified as
suspicious by participants were second most numerous (338 out of 4032), with the difference in frequency
going in the opposite direction (54 more such classifications by ophthalmologists considered correct in the
sensitivity analysis). Both of these changes favoured the performance of the ophthalmologists. The large
number of quiescent reference lesions classified as suspicious by optometrists almost certainly arises from
their tendency to adopt a more cautious decision criterion. It is not obviously the case that it would be
desirable to encourage optometrists to shift their criterion to a less cautious position, that is to ‘trade’ an
improvement in specificity for a reduction in sensitivity, given the potential sight-threatening consequences
of false-negative errors. The desirability of shifting the criterion would depend on the likelihoods of
(1) reactivation being identified by the optometrist at the next monitoring review (when relevant lesion
components are likely to have increased) and (2) irrecoverable sight loss from deterioration of the lesion.
The time taken to assess vignettes decreased as participants worked through their assessments for the
main trial, and this finding was particularly marked for the optometrists. Interestingly, the time taken by
optometrists more than halved and approached that taken by ophthalmologists by the time they reached
their final assessment (2 minutes 31 seconds compared with 1 minute 55 seconds). This information gives
some indication of how quickly optometrists can become proficient in assessing CF photographs and OCT
images. We also investigated whether or not the time taken was associated with the odds of a correct
assessment and found, in both professional groups, that a correct lesion assessment was more likely with a
shorter assessment duration. This finding suggests that duration of assessment may have been a proxy for
difficult assessments.
Data about the agreement between expert medical retina consultants represent a bonus from the study,
as such data have not previously been reported. (These experts are responsible for the three sites that
together make up the UK Network of Ophthalmic Reading Centres.) All three experts assigned congruent
lesion classifications to over three-quarters of vignettes and disagreed completely (all three experts
classified a lesion differently) for only seven vignettes. The level of agreement judged on the basis of
kappa values (see Table 14) varied by lesion component; it was excellent for SRF, IRC and blood but poor
for exudates and DRT. (Experts agreed about the presence or absence of exudates of > 90% of vignettes
but the kappa value was low because exudates were rarely present.) These data emphasise several
important points. First, the assessment task was difficult and was sometimes compromised by the images
that were available (see Images used to create vignettes and constraints on viewing images). Second, signs
of reactivation inevitably spanned a continuum and hence there was a need to assign a reference
classification of suspicious for some vignettes. Third, the vignettes created from the IVAN trial repository
represented a real-world spectrum of reactivation that was appropriate for the ECHoES trial.
There are no similar studies with which to compare our data and, consequently, no meta-analysis
combining our findings with previous findings.
It is difficult to assess the extent to which the performance of participants is representative of the
performance of the two professions and, hence, the applicability of the findings. Models of shared care for
other eye conditions have been voluntary. Indeed, it is difficult to conceive a model in which optometrists,
who are private practitioners, might be required to provide shared care. Our recruitment methods sought
volunteer optometrists, presumably who were interested in shared care, albeit in the context of a research
project. We cannot be sure that our recruitment methods for optometrists were generally applicable but can
imagine that similar methods might be used, for example by clinical commissioners seeking to commission
shared care in a particular geographic region. The motivations of the volunteer ophthalmologists were less
clear, but a similar interest in the feasibility of shared care for nAMD is a possibility. The key question is
whether or not volunteer ophthalmologists might have been less than averagely expert/experienced – or
optometrists more than averagely expert/experienced – compared with the kinds of people who might
volunteer for shared care. We think that this is unlikely but have no evidence to substantiate this.
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For the findings to be applicable, the vignettes used for the study also needed to be representative of the
clinical circumstances that community-based optometrists would be likely to encounter. In this respect, we
are more confident that the study findings are applicable. The IVAN trial was pragmatic and had broad
eligibility criteria. It recruited participants on presentation and followed their progress in the trial. Although
their treatment was specified by their experimental allocation, all treatment regimens had similar effects on
vision and morphology which were consistent with clinical experience and other trials of anti-VEGF drugs.
Decisions about the need for retreatment had to be made in the IVAN trial just as in usual care. The
availability of spectral domain tomographic equipment was limited by hospitals and clinic scheduling.
Health economics
The results of the economic evaluation show that, when we take account of downstream costs
(e.g. follow-up consultations and injections), the optometrists had slightly higher costs and made slightly
fewer correct retreatment decisions compared with ophthalmologists when performing the virtual
monitoring review for the ECHoES trial. However, the differences were very small (an incremental cost of
£13/consultation and one additional incorrect decision per 101 reviews conducted) and the differences
were not significantly different.
Views of patients and health professionals about the shared care model
Overall, the findings show there was consensus that optometrists monitoring quiescent nAMD in the
community have the potential to reduce clinical workload and could represent a more patient-centred option
for patients. However, a number of potential barriers were identified which could limit the feasibility of a
shared care scheme, including ophthalmologists’ perceptions of optometrists’ competence, the need for
clinical training, whether or not optometry and ophthalmology could work more collaboratively and whether
or not shared care was a financially efficient option for CCGs.
Participants felt that hospital eye clinics were pushed to the maximum capacity with the volume of patients
who required care for nAMD. Research has found an insufficiency of resources to deliver nAMD secondary
care from the burden of follow-up visits required in patients with inactive nAMD.12 Therefore, the health
professionals agreed that shared care would relieve the ophthalmology workload. Shared care schemes are
also attractive to patients who would find it more convenient to be monitored closer to their home.34,35 In line
with previous research, the service users described how they were frustrated at the lack of support and
information that they had received about their condition.36,37 Consequently, they felt that being monitored in
the community would enable them to build up a relationship with one optometrist, with whom there would
be more of an opportunity to receive better support and information.
While most participants felt that motivated optometrists would be capable of monitoring patients, several
ophthalmologists and service users were unsure whether or not the expertise of an optometrist in
detecting reactivation of nAMD would be equal to that of an ophthalmologist. Previous research exploring
perceptions of shared care for glaucoma has found that specialists are not convinced of optometrists’
expertise, even when they have received additional training.38 Furthermore, interviews with service users
who had declined to take part in a shared care scheme for a range of eye diseases (including nAMD) did
so because of their familiarity with, and the reputation of, the HES.35
Overall, the health professionals described poor collaboration between community optometrists and
ophthalmologists working in the HES. Many participants, particularly the ophthalmologists and service
users, voiced concerns about a potential delay between primary and secondary care if retreatment was
required. This is a new finding, as previous research exploring patient perceptions of shared care for a range
of eye conditions has not found this to be an issue.34,35,39,40 Long-term research has demonstrated that
recurrence of neovascular activity is common,15 and any delay beyond the recommended interval may cause
patients to unnecessarily lose vision permanently.12 Given that vision can deteriorate in a short time if nAMD
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is not treated and the potential impact this could have on independence and quality of life for patients, it is
perhaps not surprising that receiving prompt treatment is an important priority for nAMD care.
The health professionals felt that, although virtual training could provide a foundation level of knowledge,
clinical experience under the supervision of an ophthalmologist would be a more effective method of
training. Shared care research for a variety of eye conditions has reported that, although web-based
training is a convenient and effective option, it is not representative of clinical practice and may not be
appropriate for teaching practical clinical skills which need to be developed through attendance at a
training course.35,41 Health professionals in the current study also highlighted that face-to-face training of
this kind would provide reassurance to the ophthalmologists that optometrists were being trained to a
high standard and further encourage interprofessional collaboration.
The health professionals considered the financial implications of moving to a shared care model, although
commissioners appeared to experience conflict between what was best for the patient and what was
financially efficient. There was also agreement that optometry practices may struggle to obtain appropriate
equipment, but there was uncertainty as to how funding for OCTs would be provided. In line with this
research, studies exploring optometrists’ perspectives of extending or enhancing their roles has highlighted
a conflict between the retail and clinical sides of the optometric practice.41,42 Amoaku et al.12 points out
that the technology involved in monitoring nAMD, particularly an OCT, is expensive and optometrists
would be unlikely to receive any grants for their purchase. An additional financial consideration was that
there could an opportunity to save money with a reduced fee for optometrist rather than ophthalmologist
monitoring, although commissioners expressed concerns about the possibility – and subsequent cost – of
repeat testing by ophthalmologists who doubted optometrists’ judgements when a patient was deemed to
require retreatment.
In summary, the qualitative research demonstrates enthusiasm for shared care for nAMD. However,
ophthalmologists and patients would need reassurance that greater convenience would not compromise
the quality of care, in terms of both optometrist competence and the speed of the referral pathways
back into secondary care if retreatment was deemed to be necessary. The research highlighted poor
communication and trust between ophthalmologists and optometrists, and there was agreement that,
if shared care were to be implemented, it would be essential that the two professions work more
collaboratively. Training for optometrists under the supervision of ophthalmologists was deemed to
be the most effective method of training and could improve the communication and trust between
the disciplines.
Patient and public involvement
Patient and public involvement (PPI) impacted on the trial in two main ways. Firstly, review of the grant
application highlighted the need for the study to explore the views of patients and health professionals
about the shared care model. Secondly, we ensured that a patient perspective was represented on the
Trial Steering Committee (TSC).
The first impact of PPI led to inclusion of substantial qualitative research (interviews and focus groups) with
patients with nAMD, ophthalmologists, optometrists and clinical commissioners. This research highlighted
that implementation of shared care for nAMD is likely to be challenging. The second impact of PPI led to
the nomination and appointment of Cathy Yelf as the patient representative on the TSC. Cathy Yelf is the
Head of External Relations for the Macular Society.
Owing to the virtual nature of the trial, there was no need for PPI to inform recruitment and aspects of the
conduct of the trial.
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Strengths and limitations
Classification of lesion activation status and lesion components
The virtual nature of the trial element of the ECHoES study made it feasible to address the research
question when a conventional trial may not have been feasible, either because of reluctance by patients or
the professions to participate or because of the high cost of a conventional trial.19 We were able to carry
out the trial within a relatively short period of time and at low cost compared with a conventional trial of
the research question, and the study design did not require any compromise with respect to the risk
of bias. Participants engaged extremely well with the tasks that they were set, evidenced by the trial
having complete data for the analysis population and the level of participation in additional tasks not
communicated to participants at the outset, for example questionnaires about training and the likely
resources needed to provide shared care in community optometric practices.
There are two limitations that may be perceived to be critical, namely the virtual nature of the trial itself
and the adequacy of training. A critic might argue that decision-making on the basis of a vignette
bears no resemblance to face-to-face decision-making in a HES clinic. However, decision-making on the
basis of investigations made previously, in the absence of the patient, reflects quite well how some
hospitals are managing their workload by implementing a two-step process. Patients are first recalled
for a monitoring appointment to capture BCVA and retinal images (usually staffed by non-medical
personnel); the information is then reviewed in an ‘offline’ assessment by an ophthalmologist or other
trained member of staff, and the patient is rapidly recalled for treatment if required. In our view, the task
of vignette assessment in the ECHoES study closely parallels this offline assessment in the HES.
The importance of training was highlighted by identification of concern about the competence of optometrists
as a potential barrier to implementation (see Chapter 5, Perceptions of optometrists’ competency). The quality
of the training was perceived to be good, very good or excellent by over 90% of ophthalmologists but by only
about 70% of optometrists; 70% of ophthalmologists considered that the training was sufficient, compared
with only 20% of optometrists; and almost all optometrists, but only half of the ophthalmologists, revisited
the webinars (see Chapter 3, Participants’ views of ECHoES trial training). These simple responses to the
questionnaire items eliciting feedback about training were supported by free-text comments. These differences
in perception about training are likely to have arisen for various reasons: some ophthalmologists may have
considered themselves to be already trained; the training was inevitably conceived by ophthalmologists from a
HES perspective; and the relative unfamiliarity of the task for optometrists may have made them less confident
about the competence that the training had in fact conferred. Both the feedback questionnaire and the
qualitative research suggest that a bigger investment in training would be required if shared care were to be
implemented. The nature of further training that would address the need voiced by optometrists is unclear.
The nature of some of the images available to create the vignettes and the method for viewing OCT
images were also potential limitations of the study (see Images used to create vignettes and constraints on
viewing images). These limitations may explain in part why the performance of ophthalmologists was
worse than expected (about 85% correct compared with the expected 95%). Consequently, the
performance levels observed in the trial should, perhaps, be considered to be the minimum achievable.
It is possible that ophthalmologists (most of whom were already familiar with OCT images) could have
been selectively disadvantaged, in that they were used to seeing images captured on spectral domain
systems and displayed on very high-resolution monitors. Alternatively, they may have had the advantage of
having seen older images in the HES, which optometrists may not have done. Therefore, it is unknown
whether or not vignettes created from more recent information may have favoured the performance of
one professional group over the other. The important point is that the trial design ensured a ‘level playing
field’ in terms of the assessments that both groups, and the experts, carried out.
Finally, the final reference standard was not available by the time that participants’ training performance
had to be assessed (see Reference standard). This could have been a serious limitation if the information
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used to assess participants’ performance at the time misclassified participants with respect to their
performance and their ability to progress in the trial. However, as previously stated (see Chapter 2, Reference
standard), when all experts had classified all vignettes, we checked the performance of all applicants
for their training vignettes using the final reference standard classifications. No applicant was refused
admission to the main trial on the basis of the interim expert classifications who would have progressed to
the main trial on the basis of the final reference classifications.
Health economics
The cost-effectiveness results should be considered in the light of some limitations of the study. Because
the ECHoES trial was virtual, participants were asked questions about a service not implemented yet,
which posed challenges for optometrists in identifying appropriate costing information for their potential
nAMD monitoring review provision. The health economics questionnaire was not a compulsory part of the
trial and we wanted to avoid overburdening participants with lots of questions. Therefore, we used expert
opinion to inform the economic evaluation about the types and models of different pieces of equipment,
the average volume of patients using some of the equipment items and the expected working life of
equipment. Furthermore, the costs used in the economic evaluation rely on the assumptions inherent
within the decision trees shown in Figures 1 and 2.
Expert opinion was also used to help to map the pathways for the care cost model with respect to the likely
courses of action arising from various decisions being made by optometrists and ophthalmologists. In particular,
the optometrist pathway assumes that all patients classed as reactivated receive a second monitoring review in
hospital (at the more expensive ophthalmologist cost, rather than the cheaper optometrist review cost), which
increases costs for correct judgements of lesion reactivation in the optometrist pathway but also enables a
second opportunity for any errors to be corrected before costly ranibizumab injections are given. In real-world
implementations of shared care, other pathways may be devised or pathways may improve with time after they
have been implemented. For example, the optometrist pathway is likely to include direct clinical examination,
as well as review of CF and OCT images, and an integrated shared care pathway could allow the HES to review
information obtained by community optometrists following rapid referral (as envisaged by the last item of the
economic question, see Appendix 3, Q8), rather than repeating monitoring tests. Alternatively, shared care
pathways may also improve with time after they have been implemented.
Views of patients and health professionals about the shared care model
A purposeful sampling approach was adopted within and across the research to ensure that the feasibility and
acceptability of the proposed shared model of care for nAMD was captured from a range of perspectives.
However, ophthalmologists and optometrists were recruited from specialist conferences, which may limit the
extent to which their perspectives are representative of optometrists and ophthalmologists in the UK.
Furthermore, service users were recruited from Macular Society support meetings and such individuals may
be more proactive and informed about their condition than non-members.37 Service users at the support
groups who were willing to be contacted were white British, possibly because white people may be more
susceptible to developing nAMD43 or because people from ethnic minority groups are less likely to access eye
care services.44,45 It should also be acknowledged that all service users attended the same eye hospital for their
nAMD care and some aspects of their care may differ to other hospitals throughout the UK, although the
themes relating to current experiences of hospital care have also been highlighted by previous research.34,36,37
Focus groups were used to explore and understand key issues when considering barriers and facilitators to
implementation. Separate rather than mixed focus groups were undertaken to capture any potential
interprofessional trust issues which emerged from previous research.35 One-to-one interviews were
conducted with other health professionals because it was not possible to ascertain a convenient location,
date and time to organise a third focus group. These interviews provided a rich account of the perceived
feasibility and acceptability of a shared care scheme and allowed the findings from the focus groups to
be followed up further and explored in-depth.
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None of the participants had experience of shared care for nAMD. Research has questioned whether or
not evaluations of hypothetical scenarios accurately relate to judgements in real-life situations.46,47
However, participants gave negative as well as positive views of the shared care model, which suggests
that they carefully considered the practicalities of implementation. In addition, focus groups provided
an opportunity to prompt a range of issues about shared care to be discussed which participants may not
have otherwise considered individually in one-to-one interviews.48 Furthermore, the issues identified
in this study about a hypothetical shared care scheme mirror many of the findings from studies in which
participants gave feedback after direct experience of shared care.35,41
Lessons for the future
Lessons for a future shared care approach to the management of
neovascular age-related macular degeneration
It is clear that, given foreseeable health technologies for treating nAMD (including potential emerging therapies
combining anti-VEGF drugs with stereotactic radiotherapy), the need for efficient methods of long-term review
will remain an urgent priority. Some form of shared care with community-based optometrists is one approach
for achieving this, notwithstanding the findings of the economic evaluation (see Future research). The ECHoES
study has demonstrated that community-based optometrists can develop competency in decision-making
about lesion reactivation that is equivalent to the competency of ophthalmologists working the HES. Although
it was not straightforward to conduct the study in a short period of time, we were able to apply the methods
we planned at the time of the grant application with few modifications. We would recommend further trials of
this nature to address research questions where appropriate data repositories can be identified.
Lessons for a future economic evaluation alongside a virtual trial
The virtual trial imposed the limitation of asking participating optometrists to identify the resources and
likely costs for providing a service that had not yet been implemented. This is not an intrinsic feature
of virtual trials but is a likely feature, since the attraction of a virtual trial is greatest when there are
obstacles to provide a service. The absence of an existing shared care pathway also contributed to
uncertainty about the cost-effectiveness estimates. This was highlighted by the economic evaluation
sensitivity analyses, notably the analysis which excluded rereview in the HES of a patient rapidly referred by
a community-based optometrist.
Lessons for qualitative research alongside a virtual trial
This study highlights the importance of exploring the views of relevant stakeholders about the acceptability
of shared care for nAMD and barriers to its implementation alongside a virtual trial. The qualitative
research identified key concerns that would need to be addressed in formulating a concrete shared care
model. Had the study proceeded as originally proposed by the applicants, the headline non-inferiority
findings might have led to unreasonable optimism about the feasibility of shared care for nAMD.
Future research
The ECHoES trial platform remains in place and could be used either for further research or future training.
It proved to be robust for carrying out the trial and the medical retina experts see no reason to alter its
main features, including the rules for classifying lesion activity based on assessing lesion components.
It would be interesting to assess the performance of other professional groups using the ECHoES trial
training and assessment protocols, for example hospital optometrists and ophthalmologists in training who
did not meet the qualifications/experience criteria specified for this study.
Further research is required to investigate whether lesion components can be defined more precisely,
especially where there was less than good agreement between experts. DRT is a good example of this and
as, like SRF, this component may be a key sign of reactivation, a clearer definition may be important.
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Improvements in technology, and the expertise of OCT technicians in capturing OCT images, may make
the vignettes based on the IVAN trial image repository increasingly irrelevant. Replacing these images
with images for patients currently being managed in the HES would be easy to do, in principle, but would
require investment (primarily, the time of experts to assess the new images to provide the reference
classifications and the necessary approvals to use patients’ data).
A further, desirable information technology feature to add to the web application would be an interface
with modern CF and OCT equipment, allowing images to be imported automatically for assessment, for
example within a local network operating in an optometry practice (potentially across multiple sites).
Wider network integration with the HES could allow for a telemedicine-style shared care, with optometrists
having responsibility for capturing the images required and having discussions with HES ophthalmologists
in scheduled ‘virtual’ clinics to review them. Such an arrangement could allow trust between professions
to evolve over time, with subsequent handover of decision-making to specified optometrists, without the
need for formal face-to-face training in hospitals.
A key attraction of a shared care model for nAMD is the ability to relieve the HES of some its workload.
However, this benefit is not formally included in a conventional health economic evaluation (such as the
one reported here), which provides a direct comparison of two or more interventions in terms or their
cost-effectiveness. It would be useful for follow-up work to explore the process of freeing up HES
resources through implementation of shared care for nAMD. One potential approach for doing this would
be to use the simple framework of programme budgeting and marginal analysis, which can explicitly
explore the resource implications of moving resources around within a given health service area.49
Although the final results of the research exploring the health professionals’ views on shared care for
nAMD were formulated from a combination of focus groups and interviews, the constant comparative
method provided an opportunity to highlight similarities and differences between the disciplines. Future
research could conduct a mixed focus group to enable the range of health professionals to engage in a
discussion to address the differences of opinion that were identified in this study.
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Chapter 7 Conclusion
The ECHoES study has demonstrated that community-based optometrists can develop competency indecision-making about lesion reactivation that is equivalent to the competency of ophthalmologists
working in the HES. Overall, optometrists were as good as ophthalmologists in classifying the activity status
of a lesion but tended to make different types of error. The tendency of optometrists to adopt a more
cautious decision criterion than ophthalmologists, making them less likely to misclassify reactivated lesions,
may be a desirable attribute.
Our cost-effectiveness analysis showed that there was little difference in costs and effects between
optometrists and ophthalmologists in cost per correct retreatment decisions for patients with nAMD in the
ECHoES trial. As optometrists have less training and experience compared with ophthalmologists, once
they become more familiar with undertaking monitoring reviews, a shared care model such as this has the
potential to represent a cost-effective way of managing patients with nAMD and the freeing up of
resources in hospital eye clinics, especially as the cost for the review itself was cheaper in the community.
The findings of the economic evaluation should be used carefully to guide further planning of shared care
models, as the hypothetical nature of shared service provision in the ECHoES study gave rise to important
uncertainties. Indeed, the economic model should be useful for exploring concrete shared care pathways.
Patients and professionals were enthusiastic about the opportunities afforded by a shared care model for
nAMD, which has the potential to reduce clinic capacity and represent a more patient-centric model of
care. However, ophthalmologists and service users need reassurance that the convenience of community
monitoring would not compromise the standard of care. Training for optometrists, under the supervision
of ophthalmologists, was deemed to be the most effective method to ensure competency; it might also
improve communication and trust between the professions.
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Appendix 1 ECHoES Trial Steering Committee
Independent members
l Chairperson: Professor Jon Gibson, Professor of Ophthalmology at Aston University, Birmingham.
l Patient representative/service user: Cathy Yelf, Macular Society, Andover.
l Hospital optometrist: Dr Robert Harper, Manchester Royal Eye Hospital, Manchester.
l Community optometrist: Mr Timothy Young, McDowell Opticians, Belfast.
l Ophthalmologist: Professor Yit Yang, New Cross Hospital, Wolverhampton.
l Statistician/researcher: Professor Nicholas Freemantle, University College London Medical
School, London.
Non-independent members
l Trial representatives: Professor Usha Chakravarthy, Professor Barney Reeves and Dr Jodi Taylor.
l A representative of the sponsor institution.
l A representative of the funding body.
Given the virtual nature of the trial, which did not impact on the care of any actual patients, we did not
convene a Data Monitoring and Safety Committee.
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Appendix 2 Screenshots from the web application
FIGURE 12 Information collected from ophthalmologists on registration.
DOI: 10.3310/hta20800 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 80
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Reeves et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
77
FIGURE 13 Information collected from optometrists on registration.
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FIGURE 14 Participant data collected from ophthalmologists.
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FIGURE 15 Participant data collected from optometrists.
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FIGURE 16 Example of an ECHoES vignette.
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FIGURE 17 Vignette assessment questions.
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FIGURE 18 Example of a web application validation message to the assessor.
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Appendix 3 Additional health economic
evaluation information
Copy of ECHoES Resource use and cost questionnaire
for optometrists
 
RESOURCE USE AND COST QUESTIONNAIRE FOR OPTOMETRISTS 
Date..............................(please fill in) 
 
Thank you for taking time to complete this questionnaire.  Your answers will be kept 
confidential and used only for the ECHoES study. 
 
One component of the ECHoES study is to provide the NHS with information on how cost-
effective it is for optometrists to perform retreatment assessments for patients with quiescent 
neovascular age-related macular degeneration (nAMD).   
 
In order to do this we would like you to answer, to the best of your knowledge, the following 
questions about any resources and costs that would be associated with providing this new 
service in optometric practices.  
 
Notes on questionnaire completion: 
• If you do not know the answer to any given question, please give your best guess 
wherever possible and otherwise leave it blank and complete the rest of the 
questionnaire.  
• Please write “0” in response to any questions to which the answer is zero.  
• All costs should include VAT whenever applicable. 
• 
 
 
If you have any questions regarding this questionnaire please contact:
Dr Mara Violato (XXXX; Tel XXXXX XXXXXX) or 
Dr Sarah Wordsworth (XXXX Tel XXXXX XXXXXX) 
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****************************** 
Set up/ Capital and operative costs 
****************************** 
Imagine that the community optometric practice where you work is going to be involved in 
shared care-management for monitoring the need for retreatment of patients with nAMD 
whose disease has been rendered quiescent by anti-VEGF drugs, such as Avastin or 
Lucentis. We would like to know which facilities the practice already has and which facilities 
need to be set up in order to be able to offer this new monitoring service.  
 
When answering, please keep in mind that the appointment for monitoring will typically 
consist of the components and skills summarised in Table a:  
 
Table a 
Component Description Skills required 
History 
 
Discussion of patient-reported 
vision status in each eye and 
comparison to status at previous 
visit. 
 
Clinical examination 
Slit lamp biomicroscopy: 
Anterior segment and 
macula 
Clinical exam to ensure absence of 
VEGF-related adverse events 
and/or incidental other disease. 
Slit lamp and 
ophthalmoscopy 
skills 
Visual acuity assessment 
 
Visual acuity recorded as letters 
read on an ETDRS chart at 4 
metres (with/without mirrors) using 
previously recorded refraction.  
 
The results will then be recorded in 
the patient medical record. 
Test and interpret 
visual acuity  
Administration of 1% 
tropicamide drops 
 
Pupil dilation. Drops will need to be 
administered 20 minutes before CF 
photography and spectral domain 
coherence tomography. 
Instillation of eye 
drops 
CF photography (or 
equivalent CF image) 
One good quality photograph 
centred on the centre of the macula 
of each eye. 
 
Spectral domain OCT 
 
Cube scan of the posterior pole for 
each eye. Images will be acquired 
using a standardised protocol, 
which is pre-set on the OCT 
machine.  
 
Final assessment 
 
 
A retreatment decision will be made 
on the basis of the visual acuity 
data and interpretation of images 
obtained.  
 
The decision and rationale will need 
to be entered in the patient record.    
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Q1. Given the above description, how long do you think each monitoring review will take? 
Please include in your estimate the 20 minutes that the patient will have to wait for the 
dilating drops to work. 
..minutes 
 
As optometric practices are very heterogeneous, we would first like to have a sense of such 
diversity in order to plan a shared-care programme that accounts for the needs of all 
practices. We would therefore like you to describe your practice by replying to the following 
questions.  
N.B. If you own/work in more than one practice, please reply to the whole questionnaire 
referring only to the practice where you spend most of your time. 
  
Q2. What is the approximate size of the practice you work in? 
 (Please answer ONLY ONE of the alternative options) 
 
 
 
 
Q3. How many rooms are there in your practice? 
 rooms 
 
Q4. What facilities are available in the practice you work in that could be used to assess 
visual function and/or perform optometric monitoring on patients with nAMD?  
N.B. If the practice does not have a specific piece of equipment please type “0” in the 
corresponding line. Go to page 2 to see again Table a describing a typical 
monitoring review. 
 
Equipment Quantity currently in the practice 
ETDRS visual acuity charts - 4 metres viewing 
distance required (with/without mirrors) 
 
Projector that includes ETDRS chart  
Retro-illuminated light box  
Trial frame  
Lens set   
Light meter to measure luminance. e.g.  SPER 
Scientific 
 
Slit-lamp  
Colour fundus camera   
OCT acquisition system  
OCT acquisition system with fundus photography 
included as a component 
 
Computer   
Do you have a computer network (allowing images 
to be viewed at more than one workstation)? 
 YES/NO 
Colour fundus camera software   
OCT software   
Printer  
Other (please specify)  
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Approximately when was the latest colour fundus camera acquired? 
What model is the colour fundus camera that you most recently acquired? 
 
. 
 
 
 
 
 
. 
. 
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. 
. 
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Q5. We would like now to know about the staff (including yourself) in your practice, their 
role, working hours, average salary and how long they would potentially spend on each 
monitoring review to perform retreatment assessments for patients with quiescent 
nAMD. Please complete the table below to the best of your knowledge. If a staff type 
indicated in the table is not employed at your practice, then leave the corresponding row 
blank. If there is more than one staff for each type, please fill in a row for each (e.g. 
Optometrist 1, Optometrist 2, etc ). Go to page 2 to see again Table a describing a 
typical monitoring review. If you need additional space, please give further details 
on a separate piece of paper and label it as “Q5”. 
 
For replies in columns 2 and 5, please use one of the categories indicated below 
the table. 
 
Table Q5 
Staff type Role that they would have 
during the consultation 
(please choose one or 
more from the list belowa) 
Time that they 
would spend 
on patient-
related 
activities per 
monitoring 
review 
(minutes) 
Please refer back to 
the total consultation 
length  that you 
reported in your reply 
Q1 
Hours 
worked 
per 
week 
 
Annual salary 
(gross) bandb 
Optometrist 1: 
yourself 
 
 
 
   
  
 
 
   
  
 
 
   
  
 
 
   
Pre-registration 
optometrist 1 
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Staff type Role that they would have 
during the consultation 
(please choose one or 
more from the list belowa) 
Time that they 
would spend 
on patient-
related 
activities per 
monitoring 
review 
(minutes) 
Please refer back to 
the total consultation 
length  that you 
reported in your reply 
Q1 
Hours 
worked 
per 
week 
 
Annual salary 
(gross) bandb 
 
 
  
 
 
   
Optical assistant 
1 
 
 
 
   
  
 
 
   
  
 
 
   
  
 
 
   
Clerical/retailer 
staff 1 
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Staff type Role that they would have 
during the consultation 
(please choose one or 
more from the list belowa) 
Time that they 
would spend 
on patient-
related 
activities per 
monitoring 
review 
(minutes) 
Please refer back to 
the total consultation 
length  that you 
reported in your reply 
Q1 
Hours 
worked 
per 
week 
 
Annual salary 
(gross) bandb 
 
Practice 
manager 
 
 
 
   
  
 
 
   
  
 
 
   
  
 
 
   
Other 
administrative 
staff 1 
    
  
 
   
  
 
 
   
  
 
 
   
Other (specify)  
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Staff type Role that they would have 
during the consultation 
(please choose one or 
more from the list belowa) 
Time that they 
would spend 
on patient-
related 
activities per 
monitoring 
review 
(minutes) 
Please refer back to 
the total consultation 
length  that you 
reported in your reply 
Q1 
Hours 
worked 
per 
week 
 
Annual salary 
(gross) bandb 
  
 
 
 
   
     
  
 
 
 
   
7. Assessment of need for retreatment
1. History
4. Administration of eye drops
9. Booking appointments
2. Clinical examination
5. Colour fundus photography
10. None of the above
3. Visual acuity assessment
6. OCT
11. Other (please specify)
8. Updating patient  
and next follow-up records 
b Please give the salary in one of the following bands: Less than £20,000; £20,000 to £29,999; 
£30,000 to £39,999; £40,000 to £49,999; £50,000 to £59,999; £60,000 to £69,999; £70,000 to 
£79,999; £80,000 per year or more. 
 
We anticipate that for any given monitoring visit, each individual task will be conducted by 
one individual optometrist. If that is not the case could you, please give details of which tasks 
would be done jointly by two or more people working on the same patient visit?  
. 
. 
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Q6. Given the CURRENT size and structure of your practice would it be necessary to set up 
or modify any room(s) to offer the additional monitoring service?  
 
 
(Please tick as many options as appropriate) 
 
 
 
 
 
(Please tick as many options as appropriate) 
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If you expect your practice would incur “building/construction work” or “refurbishment 
/conversion work” or would need to “rent an additional room”, how much would that cost 
(excluding cost for specialist equipment, office equipment and furniture/furnishing)? Please 
include VAT in your replies if applicable. 
 
Q6.d “Refurbishment /conversion” 
 
 
 
 
 
 
 
 
Q6.f “Additional rent” 
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************** 
Final questions 
************** 
 
Q9. What would motivate you to join a shared-care scheme? Please choose as many 
options as applicable. 
 (Please tick as many options as appropriate) 
 
 
 
 
 
 
 
Q10. Are there any other costs or resources that your practice would need to incur in order 
to provide monitoring reviews for nAMD patients that are not mentioned in the 
questionnaire? 
 
 
 
Please provide details below 
 
 
Q11. If you have any comments on the questionnaire (such as difficulties that you 
encountered interpreting or finding the information for any specific sections), please record 
them here. 
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Components of a typical monitoring review
TABLE 29 Components of a typical monitoring review and skills required
Component Description Skills required
History Discussion of patient-reported vision status in each
eye and comparison with status at previous visit
Communication skills
Clinical examination: slit lamp
biomicroscopy; anterior
segment and macula
Clinical examination to ensure absence of
VEGF-related adverse events and/or incidental
other disease
Slit lamp and ophthalmoscopy skills
Visual acuity assessment Visual acuity recorded as letters read on an ETDRS
chart at 4 m (with/without mirrors) using previously
recorded refraction. The results will then be
recorded in the patient medical record
Test and interpret visual acuity
Administration of 1%
tropicamide drops
Pupil dilatation. Drops will need to be administered
20 minutes before CF photography and spectral
domain coherence tomography
Instillation of eye drops
CF photography (or
equivalent CF image)
One good-quality photograph centred on the
centre of the macula of each eye
Taking and interpreting retinal
images
Spectral domain OCT Cube scan of the posterior pole for each eye.
Images will be acquired using a standardised
protocol, which is pre-set on the OCT machine
Taking and interpreting OCT
images
Final assessment A retreatment decision will be made on the basis
of the visual acuity data and interpretation of
images obtained. The decision and rationale will
need to be entered in the patient record
Ability to assess the need for
retreatment and arrange necessary
follow-up
Resource use and costs associated with training
The cost of each of the three training activities was calculated by multiplying the time spent on each
activity by the unit cost of optometrist time. The average cost per hour of optometrist time was £62.13
(SD £34.62) and its calculation was based on participants’ reports on salary and hours worked (through
the health economics questionnaire). Given that our objective was to estimate the cost of optometrist
training per monitoring review, each of the three components of costs in the table below was divided by
the annual number of patients (after the changes in the practice would take place, as reported by each
optometrist in reply to question Q7 in the health economics questionnaire), to obtain the cost of
optometrist training per monitoring review, that is £0.89 (SD £1.080).
TABLE 30 Resource use and costs of training
Training type Optometrist’s time (minutes), mean (SD) Optometrist’s cost (£), mean (SD)
Attending webinars 120 (0) 124 (69.26)
Revisiting webinars 90 (68.74) 96 (111.58)
Consulting other resources 64 (76.21) 66 (112.35)
Observations 48 48
DOI: 10.3310/hta20800 HEALTH TECHNOLOGY ASSESSMENT 2016 VOL. 20 NO. 80
© Queen’s Printer and Controller of HMSO 2016. This work was produced by Reeves et al. under the terms of a commissioning contract issued by the Secretary of State for
Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science
Park, Southampton SO16 7NS, UK.
101
Sensitivity analysis 1: three ranibizumab injections and
consultations instead of one
TABLE 31 Care cost pathways for sensitivity analysis 1
Lesion status assessment Observationsa (%) Pathways cost (£),b mean (SD)
Experts Optometrists
Reactivated Reactivated 795 (39.43) 2548.83 (67.90)
Reactivated Suspicious 142 (7.04) 103.61 (18.51)
Reactivated Quiescent 57 (2.83) 51.29 (9.08)
Suspicious Reactivated 10 (0.50) 118.12 (16.39)
Suspicious Suspicious 11 (0.55) 57.04 (9.10)
Suspicious Quiescent 14 (0.69) 52.96 (9.37)
Quiescent Reactivated 105 (5.21) 117.14 (32.61)
Quiescent Suspicious 234 (11.61) 78.31 (11.53)
Quiescent Quiescent 648 (32.14) 51.98 (8.23)
Experts Ophthalmologists
Reactivated Reactivated 736 (36.51) 2495.81 (70.01)
Reactivated Suspicious 196 (9.72) 153.18 (92.25)
Reactivated Quiescent 62 (3.08) 77.01 (45.49)
Suspicious Reactivated 1 (0.05) 2452.74 (n/a)
Suspicious Suspicious 17 (0.84) 68.84 (31.004)
Suspicious Quiescent 17 (0.84) 60.57 (17.16)
Quiescent Reactivated 35 (1.73) 2493.45 (65.87)
Quiescent Suspicious 146 (7.24) 150.34 (95.19)
Quiescent Quiescent 806 (39.98) 75.28 (44.72)
n/a, not applicable.
a The number of observations (i.e. vignettes) is 4032, namely 2016 referring to optometrists and 2016 referring
to ophthalmologists.
b Pathway cost includes the cost of a monitoring consultation and downstream costs (e.g. injections and follow-up visits).
TABLE 32 Impact on cost-effectiveness of sensitivity analysis 1
Costs and effects
Optometrists
(observations, n= 2016)
Ophthalmologists
(observations, n= 2016)
Cost of a monitoring review (£), mean (SD) 1047.03 (1213.05) 1015.01 (1168.80)
Proportion of correct assessments (SD) 0.844 (0.363) 0.854 (0.353)
Incremental cost (£) (95% CI) 32.02 (–60.87032 to 124.9)
Incremental benefit, proportion of correct assessments (95% CI) –0.0099 (–0.045 to 0.025)
ICER, incremental cost per correct assessmenta Dominated
a The 95% CI around the ICER could not be defined.
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FIGURE 20 Cost-effectiveness acceptability curve for sensitivity analysis 1.
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Sensitivity analysis 2: one aflibercept injection instead of
one ranibizumab
TABLE 33 Care cost pathways for sensitivity analysis 2
Lesion status assessment Observationsa (%) Pathways cost (£),b mean (SD)
Experts Optometrists
Reactivated Reactivated 795 (39.43) 1009.24 (45.50)
Reactivated Suspicious 142 (7.04) 103.61 (18.51)
Reactivated Quiescent 57 (2.83) 51.29 (9.08)
Suspicious Reactivated 10 (0.50) 118.12 (16.39)
Suspicious Suspicious 11 (0.55) 57.04 (9.10)
Suspicious Quiescent 14 (0.69) 52.96 (9.37)
Quiescent Reactivated 105 (5.21) 117.14 (32.61)
Quiescent Suspicious 234 (11.61) 78.31 (11.53)
Quiescent Quiescent 648 (32.14) 51.98 (8.23)
Experts Ophthalmologists
Reactivated Reactivated 736 (36.51) 956.50 (46.41)
Reactivated Suspicious 196 (9.72) 153.18 (92.25)
Reactivated Quiescent 62 (3.08) 77.01 (45.49)
Suspicious Reactivated 1 (0.05) 2452.74 (n/a)
Suspicious Suspicious 17 (0.84) 68.84 (31.004)
Suspicious Quiescent 17 (0.84) 60.57 (17.16)
Quiescent Reactivated 35 (1.73) 2493.45 (65.87)
Quiescent Suspicious 146 (7.24) 150.34 (95.19)
Quiescent Quiescent 806 (39.98) 75.28 (44.72)
n/a, not applicable.
a The number of observations (i.e. vignettes) is 4032, namely 2016 referring to optometrists and 2016 referring
to ophthalmologists.
b Pathway cost includes the cost of a monitoring consultation and downstream costs (e.g. injections and follow-up visits).
TABLE 34 Impact on cost-effectiveness of sensitivity analysis 2
Costs and effects
Optometrists
(n= 2016)
Ophthalmologists
(n= 2016)
Cost of a monitoring review (£), mean SD 439.90 (460.90) 425.61 (422.93)
Proportion of correct assessments (SD) 0.844 (0.363) 0.854 (0.353)
Incremental cost (£) (95% CI) 14.29 (–19.91 to 48.49)
Incremental benefit, proportion of correct assessments (95% CI) –0.0099 (–0.045 to 0.025)
ICER, incremental cost per correct assessmenta Dominated
a The 95% CI around the ICER could not be defined.
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Sensitivity analysis 3: one bevacizumab injection instead of
one ranibizumab
TABLE 35 Care cost pathways for sensitivity analysis 3
Lesion status assessment Observationsa (%) Pathways cost (£),b mean (SD)
Experts Optometrists
Reactivated Reactivated 795 (39.43) 242.23 (45.50)
Reactivated Suspicious 142 (7.04) 103.61 (18.51)
Reactivated Quiescent 57 (2.83) 51.29 (9.08)
Suspicious Reactivated 10 (0.50) 118.12 (16.39)
Suspicious Suspicious 11 (0.55) 57.04 (9.10)
Suspicious Quiescent 14 (0.69) 52.96 (9.37)
Quiescent Reactivated 105 (5.21) 117.14 (32.61)
Quiescent Suspicious 234 (11.61) 78.31 (11.53)
Quiescent Quiescent 648 (32.14) 51.98 (8.23)
Experts Ophthalmologists
Reactivated Reactivated 736 (36.51) 189.50 (46.41)
Reactivated Suspicious 196 (9.72) 153.18 (92.25)
Reactivated Quiescent 62 (3.08) 77.01 (45.49)
Suspicious Reactivated 1 (0.05) 184.21 (n/a)
Suspicious Suspicious 17 (0.84) 68.84 (31.004)
Suspicious Quiescent 17 (0.84) 60.57 (17.16)
Quiescent Reactivated 35 (1.73) 189.12 (38.002)
Quiescent Suspicious 146 (7.24) 150.34 (95.19)
Quiescent Quiescent 806 (39.98) 75.28 (44.72)
n/a, not applicable.
a The number of observations (i.e. vignettes) is 4032, namely 2016 referring to optometrists and 2016 referring
to ophthalmologists.
b Pathway cost includes the cost of a monitoring consultation and downstream costs (e.g. injections and follow-up visits).
TABLE 36 Impact on cost-effectiveness of sensitivity analysis 3
Costs and effects Optometrists Ophthalmologists
Cost of a monitoring review (£), mean (SD) 137.43 (91.78) 131.89 (77.12)
Proportion of correct assessments (SD) 0.844 (0.363) 0.854 (0.353)
Incremental cost (£) (95% CI) 5.54 (–0.834 to 11.916)
Incremental benefit, proportion of correct assessments (95% CI) –0.0099 (–0.045 to 0.025)
ICER, incremental cost per correct assessmenta Dominated
a The 95% CI around the ICER could not be defined.
APPENDIX 3
NIHR Journals Library www.journalslibrary.nihr.ac.uk
106
D
if
fe
re
n
ce
 in
 c
o
st
 (
£)
– 0.0480492 – 0.0289849 – 0.0099206 0.0091437 0.028208
Difference in effect
14.00
9.75
5.50
1.25
– 3.00
FIGURE 23 Cost-effectiveness plane for sensitivity analysis 3 (inner ellipse: 50%; outer ellipse: 95%).
0.00
0.25
0.50
0.75
1.00
Pr
o
b
ab
ili
ty
 c
o
st
-e
ff
ec
ti
ve
0 10,000 20,000 30,000 40,000 50,000
Willingness to pay (£)
FIGURE 24 Cost-effectiveness acceptability curve for sensitivity analysis 3.
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Sensitivity analysis 4: only monitoring review cost,
no pathway cost
TABLE 37 Care cost pathways for sensitivity analysis 4
Lesion status assessment Observationsa (%) Pathways cost (£),b mean (SD)
Experts Optometrists
Reactivated Reactivated 795 (39.43) 51.79 (8.49)
Reactivated Suspicious 142 (7.04) 51.81 (9.26)
Reactivated Quiescent 57 (2.83) 51.29 (9.08)
Suspicious Reactivated 10 (0.50) 50.64 (7.12)
Suspicious Suspicious 11 (0.55) 57.04 (9.10)
Suspicious Quiescent 14 (0.69) 52.96 (9.37)
Quiescent Reactivated 105 (5.21) 51.49 (8.01)
Quiescent Suspicious 234 (11.61) 52.21 (7.69)
Quiescent Quiescent 648 (32.14) 51.98 (8.23)
Experts Ophthalmologists
Reactivated Reactivated 736 (36.51) 76.09 (43.66)
Reactivated Suspicious 196 (9.72) 76.59 (46.13)
Reactivated Quiescent 62 (3.08) 77.01 (45.49)
Suspicious Reactivated 1 (0.05) 89.70 (n/a)
Suspicious Suspicious 17 (0.84) 68.84 (31.004)
Suspicious Quiescent 17 (0.84) 60.57 (17.16)
Quiescent Reactivated 35 (1.73) 76.71 (38.22)
Quiescent Suspicious 146 (7.24) 75.17 (47.59)
Quiescent Quiescent 806 (39.98) 75.28 (44.72)
n/a, not applicable.
a The number of observations (i.e. vignettes) is 4032, namely 2016 referring to optometrists and 2016 referring
to ophthalmologists.
b Pathway cost includes the cost of a monitoring consultation and downstream costs (e.g. injections and follow-up visits).
TABLE 38 Impact on cost-effectiveness of sensitivity analysis 4
Costs and effects
Optometrists
(observations, n= 2016)
Ophthalmologists
(observations, n= 2016)
Cost of a monitoring review (£), mean (SD) 51.90 (8.36) 75.60 (44.31)
Proportion of correct assessments (SD) 0.844 (0.363) 0.854 (0.353)
Incremental cost (£) (95% CI) –23.70 (–26.09 to –21.31)
Incremental benefit, proportion of correct
assessments (95% CI)
–0.0099 (–0.045 to 0.025)
ICER, incremental cost per correct assessment
(95% CI) (£) Fieller’s methoda
2389.07; lower limit: 535, upper limit: –943b
a We can be 95% confident that the way of performing a monitoring review with the larger point estimate for effect
(i.e. monitoring review performed by ophthalmologists) represents bad value compared with the alternative.
b The lower confidence limit for the ICER is positive, and the upper limit is negative, because the ICER point estimate
(see Figure 25) is in the south-west quadrant of the cost-effectiveness plane, hence positive, but the CI spans both the
south-west (positive ICER) and south-east quadrants (negative ICER). The upper confidence limit of –943 lies in the
south-east quadrant, which is represents a win-win situation (monitoring by optometrists is less costly and more effective).
In contrast to the previous analyses, this sensitivity analysis shows a clear difference in costs and uncertainty in the effects.
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FIGURE 26 Cost-effectiveness acceptability curve for sensitivity analysis 4.
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Appendix 4 Additional figures
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FIGURE 27 Ophthalmologist years of experience against number of correct responses.
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FIGURE 28 Comparison of participant scores for each set of vignettes. Values above the dashed line are vignettes
sets for which ophthalmologists correctly assessed more vignettes than their optometrist counterparts, and values
below the dashed line are vignette sets for which optometrists scored higher. For example, the value with a score
difference of 16 and mean score of 32 is a set of vignettes for which the ophthalmologist scored 40/42 and the
optometrist scored 24/42.
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Appendix 5 Statistical analysis plan
1. Introduction to SAP
1.1 Scope
This statistical analysis plan (SAP) details information regarding the statistical analysis of the completed
ECHoES trial and covers analyses of trial data outlined in the study protocol. It does not include the health
economic evaluation or analysis of the focus group discussions.
1.2 Editorial changes
Any changes made to this SAP after approval must be clearly justified and documented as an amendment
at the end of this document. The SAP should then be re-approved.
1.3 SAP document approval
The trial statistician should authorise this document.
2. Study background and objectives
2.1 Study background
Wet, or neovascular, age-related macular degeneration (nAMD) is a condition which causes severe sight
loss in older people. There is currently no evidence about the effectiveness of community follow-up by
optometrists for nAMD. However, there is evidence about the acceptability of further training to
optometrists, and their effectiveness in providing ‘shared care’ with the Hospital eye clinic setting (HES), for
other eye diseases. Community optometrists already participate successfully in shared care management
schemes for patients with glaucoma and diabetic eye disease, and evaluations comparing agreement
between management by optometrists and ophthalmologists has been shown to be acceptable in the
context of glaucoma and accident and emergency services.
The question of interest to the NHS is whether community optometrists can be trained to make decisions
about the need for retreatment in patients with nAMD whose disease has been rendered quiescent
by treatment with anti-vascular endothelial growth factor (VEGF) drugs with the same accuracy as
ophthalmologists working in the HES.
2.2 Study objectives
The aim of the trial is to test the hypothesis that, compared to conventional hospital eye clinic follow-up,
community follow-up by optometrists (after appropriate training) is not inferior for patients with nAMD with
stable vision. This hypothesis will be tested by comparing decisions made by samples of ophthalmologists
working in the HES and optometrists working in the community about the need for retreatment, following
a period in which patients have not required treatment. Rather than carrying out a new (prospective) trial,
optometrists and ophthalmologists participating in the trial will make decisions about vignettes composed
of clinical information and colour fundus (CF) and ocular coherence tomography (OCT) images collected in
the course of the IVAN trial (HTA ref: 07/36/01). Retreatment decisions made by participants in both groups
will be validated against a reference standard based on the opinions of three medical retinal experts
(see Appendix 5, section 4.1).
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The trial has five specific objectives:
i. To compare the proportion of retreatment decisions (based on lesion classifications, see Appendix 5,
section 2.3) classified as ‘correct’ (against the reference standard, ‘reactivated’ vs. ‘suspicious’ or
‘inactive lesion’, see Appendix 5, section 4.1) made by optometrists and ophthalmologists.
ii. To estimate the agreement, and nature of disagreements, between retreatment decisions made by
optometrists and ophthalmologists.
iii. To estimate the influence of vignette clinical and demographic information on retreatment decisions.
iv. To estimate the cost-effectiveness of follow-up in the community by optometrists compared to
follow-up by ophthalmologists in the HES. This is not covered in this SAP.
v. To ascertain the views of patient representatives, optometrists, ophthalmologists and clinical
commissioners on the proposed shared care model. This is not covered in this SAP.
2.3 Terminology
Throughout the protocol and this SAP, the terms lesion classification, retreatment decision and referral
decision are used interchangeably. Unless otherwise stated, the analyses will use the lesion classification
question, for which participants must classify the vignette as reactivated, suspicious or quiescent. The logic
behind this is that the identification of key vignette features and the resultant classification of lesions is
the difficult part; retreatment/ referral decisions can be defined by rules based on these classifications.
2.4 Primary outcome
The primary outcome is a participant’s judgement of lesion classification (“Reactivated lesion” vs. “Inactive
lesion” or “Suspicious lesion”) against the reference standard (see section 4.1). The number of ‘correct’
assessments will be compared between the two participant groups (see section 4.2 for details).
2.5 Secondary outcomes
(a) The secondary outcomes are:
(b) The frequency of “serious” errors judged likely to be sight-threatening. This classification will be
assigned to a participant’s classification of a vignette when the participant’s decision is “lesion
quiescent” and the reference standard classification is “lesion reactivation”, i.e. a definitive false
negative classification by the participant. Definitive false positive decisions will not be considered
serious but will be tabulated separately. Misclassifications involving classifications of “suspicious
lesion”, whether assigned as the reference standard or by a participant, will also not be
considered serious.
(c) Judgements about the presence or absence of lesion components, e.g. blood, exudates and sub retinal
fluid (SRF) in the fundus colour images; SRF, intra-retinal fluid/cysts and pigment epithelial detachment
(PED) in the OCT images.
(d) Participant-rated confidence in their decisions about the lesion classification, on a 5-point scale.
3. Study population
The study population consists of fully qualified optometrists registered with the General Optical Council
(GOC) for at least 3 years, and ophthalmologists with 3 years post-registration experience in Ophthalmology.
The planned number of participants to be included in the study is 96, with a 1:1 ratio of optometrists and
ophthalmologists. On the basis that some participants will be unable to attend the webinars, will not
complete the training vignettes or will not correctly assess an adequate number of training vignettes,
more than 96 participants will be recruited to attend the webinars. The first 48 ophthalmologists and
48 optometrists enrolled in the study will be assigned their training vignettes and the additional participants
will be assigned vignettes on an as needed basis.
The initial sample size calculation was based on the number of vignettes required to be assessed, and the
number of participants was then decided based on this calculation.
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3.1 Trial design
The participants are not randomised into the trial as by training they are either an optometrist or an
ophthalmologist. However, randomisation, using a randomised block design, was used in assigning
vignettes to each participant. The ‘main study’ vignettes (i.e. excluding training vignettes) were assigned to
participants in a random order such that each vignette is seen seven times by an ophthalmologist and
seven times by an optometrist, and each of the 48 participants in each group sees 42 vignettes. There are
therefore a total of 288 (48 × 42 / 7) vignettes included in the trial. The selection of vignettes and the order
they are viewed is matched for the two groups in a 1:1 ratio in order to reduce any bias that may be
introduced by different assessors viewing different vignettes in different orders. Each participant is also
assigned a random 24 training vignettes (and a further 24 training vignettes if they fail their first set) such
that none of the vignettes in their training set(s) appear in their main study set. Again, this is matched
across groups.
3.2 Flow of participants
Participants who are consented into the study must first complete two webinar training sessions. Once
these have been complete they are allocated a training set of 24 vignettes, of which they must correctly
assess at least 18 (75%) to pass their training. If they pass, they will then be allocated their 42 ‘main study’
vignettes. If they fail their first training vignettes, they are allocated a second training set of a further
24 vignettes. If they pass this second training set they will be allocated their 42 main study vignettes;
if they fail their second set of training they will be withdrawn from the study. Only participants who assess
all of their 42 main study vignettes will be included in the analysis population (see Appendix 5, section 3.5).
Participants are followed up until they have assessed all of their main study vignettes or until they withdraw
or are withdrawn from the study. The planned study time is approximately six months from registration until
study completion.
The participant flow will be described via the flowchart.
3.3 Protocol deviations
There is no protocol deviations defined for this study.
3.4 Withdrawals
Participants can withdraw from the study at any time after registration. They may also be withdrawn by
the study team if they do not correctly assess an adequate number of vignettes in their training sets
(see Appendix 5, section 3.1 for details).
3.5 Analysis population
The analysis population will consist of the 48 ophthalmologists and 48 optometrists who complete their
42 main study vignettes. Participants who withdraw or are withdrawn before completion of their main
study vignettes will not be included in the analysis population but their progression in the trial will be
described in the flowchart.
4. Derivations
4.1 Reference standard
All vignettes will be assessed by three experts; it is expected that for most vignettes the classification
decisions of all experts will agree. For those where there is disagreement, the three experts will collectively
make a final consensus decision. The agreed assessment decision for each vignette (“reactivated”,
“suspicious” or “quiescent” lesion) will be known as the reference standard and will be used to calculate
‘correct’ assessment decisions of all participants.
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4.2 Primary outcome
For the primary outcome, a binary ‘active lesion’ variable will be derived for both the reference standard
and the participant responses, as follows:
l If a vignette is classified as “lesion reactivated” then active lesion= Yes
l If a vignette is classified as “lesion quiescent” or “lesion suspicious” then active lesion=No
l Else missing (by design there should not be any missing data)
An indicator of whether participants have made the correct classification for each vignette will then be
derived as follows:
l If the reference standard and a participant have both classified a vignette as an active lesion or have
both classified a vignette as not an active lesion, then classification status= correct
l If the reference standard have classified a vignette as an active lesion and a participant has not
classified it as an active lesion, or vice versa, then classification status= incorrect
l Else missing (by design there should not be any missing data)
An overall count of the number of vignettes that each participant correctly classified (out of a possible 42)
will also be derived.
4.3 Other variables
New variable Rules
Secondary outcome (a): ‘Serious’ errors judged
to be sight threatening
If reference standard= lesion reactivated and participant opinion= lesion
quiescent, then= Yes
If reference standard = lesion reactivated and participant opinion= lesion
suspicious or lesion reactivated, then=No
Else missing
Years since qualification for optometrists Year since qualification=Date of consent – date of registration with the
General Optical Council
Years since qualification for ophthalmologists First, a date of qualification was calculated:
Dateofqual= Royal college date if available, else MRCOphth date if
available, else FRCOphth date if available, else diploma date, else other
appropriate date.
Years of experience=Date of consent – dateofqual
5. Statistical analyses
5.1 Participant characteristics
Participant characteristics will be described by group for participants in the analysis population.
Continuous variables will be summarised using the mean and standard deviation (SD) (or median and inter
quartile range (IQR) if the distribution is skewed), and categorical data will be summarised as a number
and percentage. The summary statistic headings given are those we expect to use based on a-priori
knowledge of the measurements but may change.
Characteristics of the participants will be described and compared formally using t-tests, Mann-Whitney
tests, chi-squared tests or Fishers exact tests as appropriate.
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5.2 Primary and secondary outcome data
5.2.1 Adjustment in models
The intention is to adjust all primary and secondary outcome models for participant and vignette number
as random effects, and the order that the vignettes were viewed in as a fixed effect (modelled as tertiles:
1–14, 15–28 and 29–42).
5.2.2 Analysis models
All outcomes listed in the study protocol will be presented as follows. For all formal group comparisons,
the ophthalmologists will be the reference group.
5.2.3 The primary outcome
The number and percentage of correct active lesion decisions will be presented by group, and formally
compared using logistic regression. The sensitivity and specificity for each of the professional groups, as
well as a summary of individual participants, will also be presented; a more detailed descriptive breakdown
of vignette classifications will be presented separately.
The adjusted odds ratio (OR) and corresponding 95% confidence interval (CI) for the group effect
(generated from the logistic regression model) will be presented. Using this OR and 95% CI, we will
address the non-inferiority limit stated in the protocol: less than 10% absolute difference between the
groups assuming the ophthalmologist group would correctly assess 95% of their vignettes. To test this it is
necessary to convert this 10% difference to the odds scale as follows:
Using the values in the below table, the OR of a correct response is calculated by (c/d) / (a/b). The
non-inferiority limit on the odds scale is therefore ((0.85/0.15) / (0.95/0.05) = 0.298.
Ophthalmologist Optometrist Overall
Correct a c a+ c
Incorrect b d b+ d
Overall a+ b c + d a+ b+ c+ d
In addition to the analysis described above, the influence of key vignette features on correct lesion
decisions will be investigated using Poisson regression, and presented as incidence rate ratios (IRR) and
95% CIs. Key features include baseline VA, index VA, age and sex of patients, smoking status and past
history of angina or heart disease. All features will be retained in the model regardless of statistical
significance. The reference standard and group will also be fitted as fixed effects. Interactions between
the vignette features and group will also be tested and if significant at the 5% level, estimates will be
presented separately for the two groups.
Note: The protocol states that the primary outcome would be analysed using Poisson regression. However,
after further consideration we are proposing to fit a logistic rather than Poisson model in order to fully
account for the incomplete block design in the analysis. Fitting a Poisson model would not allow us to
include both participant and vignette in the model.
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5.2.4 Secondary outcome (a) – serious errors
The numbers and percentages of serious errors judged to be sight threatening will be presented by group.
Additionally, the frequencies of such errors will be presented at participant level. The groups will be
compared using logistic regression, applied to the subset of vignettes with a reference standard
classification of reactivated (other vignettes by definition cannot result in a serious error).
5.2.5 Secondary outcome (b) – lesion characteristics
Participants’ judgements about presence (or absence) of each of the lesion components (e.g. SRF, PED and
bloods) will be summarised by numbers and percentages in each group and formal comparisons between
the groups will be made using logistic regression. There is no agreed reference standard for the lesion
components so participant’s classifications will only be compared to each other, not to a ‘correct’ response.
5.2.6 Secondary outcome (c) – confidence in decision making
Participants’ confidence in each of their lesion classification decisions, on a five point scale, will be
summarised for each group. Logistic regression will be used to formally compare confidence (5 vs. 1 to 4)
between the two groups. Additionally, the number of correct reactivation decisions will be tabulated by
confidence level for each group.
5.2.7 Statistical significance
For hypothesis tests, two-tailed p-values < 0.05 are considered statistically significant. Likelihood ratio tests
will be used in preference to Wald tests for hypothesis testing.
5.2.8 Model assumptions
Underlying assumptions will be checked using standard methods, e.g. graphical plots etc. If assumptions
are not valid then alternative methods of analysis will be sought. If outlying observations are found and
the models do not fit the data adequately, such observations will be excluded from the main analyses.
Sensitivity analyses may be performed to examine the effect on the study’s conclusions of excluding
outlying observations.
5.2.9 Subgroup analyses
There are no subgroup analyses planned for this study.
5.2.10 Sensitivity analyses
A sensitivity analysis of the primary outcome, reclassifying vignettes graded as suspicious as ‘active lesion’
group, rather than ‘no active lesion’ group will be undertaken, to assess the sensitivity of the conclusions
to the classification of the vignettes graded as suspicious.
5.2.11 Additional analysis
Lesion classification decisions will be tabulated against referral decisions for ophthalmologists
and optometrists.
A descriptive analysis of the time taken to complete each vignette, and how this time changes with
experience in the trial (learning curve), will be performed. The relationship between this time and
participants ‘success’ in correctly classifying vignettes will also be explored.
Cross tabulations and Kappa statistics will be used to compare experts’ initial classifications with the final
reference standard. Similarly, cross tabulations and Kappa statistics will be used to compare lesion
component classifications between the three experts.
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5.2.12 Missing data
By design there should be no missing data in this study apart from time taken to complete vignettes. The
time that user “saved” the assessment decision was recorded for each vignette and therefore the time
between saving one vignette and the next can be calculated. However, the time taken for the first vignette
(of each session) cannot be calculated as the time of the start of the session was not captured. Similarly,
if a participant takes a break within a session this cannot be identified (expect that the time between
saving the decisions on two consecutive vignettes may be excessively long). As time taken to complete
vignettes is not an outcome specified in the protocol, and the only vignette where the time will be missing
is the first of a session and the vignettes were randomised these times will be assumed to be missing at
random and a complete case analysis will be performed.
5.2.13 Multiple testing
No formal adjustment will be made for multiple testing.
5.3 Safety data
There is no safety data in this study as there are no risks to participants and therefore it is not possible for
clinical adverse events to be attributed to study specific procedures.
6. AMENDMENTS TO THE SAP
Previous version Previous date New version New date Brief summary of changes
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